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SUMMARY
Two separate cancer topics are included in our studies of the synthesis 
and biological evaluation of novel anticancer agents. These topics are synthesis 
of antimelanoma agents to combat malignant melanoma and synthesis of MAP 
kinase inhibitors designed to interfere with cell signalling pathways.
In the chemotherapeutic approach towards malignant melanoma 
treatment a selective approach can be adopted in drug design. Melanin is 
synthesised within specialised cells called melanocytes and malignant 
melanoma results when the control of melanocytic cell division is disturbed 
leading to excessive melanin production. The target strategy behind malignant 
melanoma drug design exploits specifically Tyrosinase, an enzyme crucial to 
melanin synthesis and unique to the melanocyte. Tyrosinase catalyses the 
conversion of L-tyrosine (i) into dopaquinone (ii).
C°2 H TYROSINASE COoH
NH NHHO
(ii)
Design strategies concentrate on phenolic prodrugs modelled on the 
natural substrate (i) of the oxidase enzyme. Tyrosinase catalyses the 
conversion of the phenolic prodrug into the corresponding o-quinone. These o  
quinones are the mediators of cytotoxicity believed to impair the melanocytes' 
metabolism by combining with sulfhydryl-containing entities crucial to the cell 
cycle such as DNA polymerase. Alternatively the o-quinones may participate in 
a cyclic redox process resulting in the production of active oxygen species. The 
parent drug in the antimelanoma field, (iii), has been found to possess 
significant activity. An extensive programme of research was performed by Neil 
Lant at the University of Glasgow into the structure activity relationships of 
related compounds.
ix
Our programme of research involved the synthesis of three sets of target 
compounds modelled on the lead compound designed as substrates for 
Tyrosinase. These tertiary amides (iv), amidine salts (v) and tyrphostins (vi) 
were successfully prepared and biologically evaluated for in vitro antimelanoma 
activity and relative substrate activity for Tyrosinase.
0  H m H C | G
IJ I^ R  rf^YNY NTC0H
r1  h o 'A ^ J r(iv) (v)
Ft = Me, Ph, cyc/oCgHn n = 1, 2
R1 = Me, Et, Bn R = Me, Et
V ~ r -rR x=H' °H’ °Me
L J  CN R = CN, C 02Et, CONH2, 
(vi, C(NH2)=C(CN)2
The lipophilic tertiary amides (iv) proved to be the most successful as 
potential antimelanoma agents with the A/-benzyl methyl analogue in particular 
exhibiting good levels of cytotoxicity and selectivity for Tyrosinase-containing 
melanoma cell lines with GI50  values in the range 5-30 |iM. Furthermore this 
compound was a Tyrosinase substrate. Although the amidine salts indicated 
some levels of cytotoxicity and selectivity their cytotoxicity is believed to be the 
result of a non-Tyrosinase mediated mechanism of action. In general this 
biological behaviour exhibited by the amidines (v) was mirrored by the 
tyrphostins (vi). In conclusion we believe that the combination of the lipophilic 
nature of the tertiary amides and the close structural resemblance to the parent 
compound (iii) provided the series (iv) with better antimelanoma activity than 
the other two series (v) and (vi).
The second area of cancer chemotherapy research investigated is 
concerned with cell signalling pathways and inhibition of mitogen-activated 
protein (MAP) kinases which will prevent division of cancer cells. In our studies
x
into MAP kinase inhibitors we employed 2-iminolactone derivative (vii) as our 
lead which had been identified from a preliminary screen within the Robins 
research group. This compound is modelled on serine, an amino acid residue 
phosphorylated by the MAP kinase enzyme.
NH
MeO CN
(vii)
Our programme of research first investigated the optimum position of the 
methoxy substituent on the benzene ring of the lead compound with the series 
(viii) prepared. The corresponding open chain derivatives (ix ) and the 
coumarins (x) were also prepared.
OMeNH
MeO-f- MeO-hMeO-b
(viii)
R = CN, CONH
The in vitro inhibitory assay results for the 2-iminolactones (v iii) and 
tyrphostins (ix) indicated worthwhile candidates for a more detailed study into 
MAP kinase inhibitory behaviour. However, the coumarins (x) did not exhibit 
inhibitory behaviour. In response to the biological study results the preparation 
of thiophene bioisosteric replacements (xi) and (xii) of the 2-iminolactone (viii) 
and tyrphostins (ix) was proposed. Only the thiophene tyrphostins (xii) were 
successfully prepared and the MAPK inhibitory activity shown by the thiophene 
tyrphostins appeared to support the strategy behind their design.
OMe
CN
NH
(xi) (xii)
R = CN, CONH
xi
CHAPTER 1 
CANCER - A GENERAL OVERVIEW
1.1 CANCER - AN EPIDEMIC
The World Health Organisation reported that an estimated 10 million 
cases of cancer occurred world-wide in 1998. Furthermore they predicted a 
continuation of this onslaught with numbers rising to 14.7 million over the next 
20 years.1 The current situation is that the proportion of fatalities from cancer in 
the population is increasing simply because fewer people are dying from other 
illnesses.2
Many factors combine to ensure the prevalence of this epidemic which is 
especially high in the industrialised nations. Among the causative factors are 
increased life expectancy, growing urbanisation, industrialisation and changes 
in lifestyle. Although the incidence in the number of cancer cases (and deaths) 
could be significantly lowered through changes in factors such as lifestyle and 
diet, preventative measures for many cancers remain either unknown or not 
applicable.2
In these cancer-stricken times, comfort must be taken from the 
technological advances and scientific progress which continue to be made by 
the present science community. These developments in turn enable a greater 
understanding of epidemiological diseases such as cancer and ultimately 
should facilitate the progress towards prevention, treatment and cure for most, if 
not all, cancers by sometime in the 21st century.
1.2 THE AETIOLOGY OF CANCER
The term carcinogen is a very loosely used one and by definition 
encompasses any agent which confers an increase in cancer risk. This is a vast 
topic and under this heading of aetiology of cancer some of the main causative 
factors of cancer will be presented.
1.2.1 CHEMICALS
1
The cancer-causing potential of chemicals was first recognised over 200 
years ago by the English physician Pott who linked soot to the incidence of 
scrotal cancer in chimney sweeps.3 The carcinogen involved, a polycyclic 
aromatic hydrocarbon, was not identified until much later. This exemplifies the 
workplace as one source of chemical carcinogens, with other sources including 
pollutants in air and water, foodstuffs and natural products.4 A monograph 
series published by the International Agency for Research on Cancer (IARC)5 is 
one of many publications that details chemicals with carcinogenic potential for 
employers, workers and the public in general to consult.
The polycyclic aromatic hydrocarbons like those found in the chimney 
soot are far more abundant today as air pollutants. With the onset of 
industrialisation these chemicals are prevalent in exhaust fumes and factory 
emissions.4 A very well publicised chemical carcinogen of modern times is 
asbestos,6 with pneumoconiosis or asbestosis affecting workers in that area. 
Furthermore, it is believed that exposure to this chemical increases the 
individual's risk of lung cancer and mesothelioma.6
These are just a few representatives of the vast number of chemical 
carcinogens known. However, many chemical cancer causing agents found in 
some sources are present in very low levels such that the attributable risk is 
considered to be negligible, e.g. some food colourants.
1.2.2 RADIATION
Following Roentgen's discovery of X-rays in 1895 the first reports of 
radiation carcinogenesis emerged. The cancer appeared on the hands of 
pioneering radiologists and later cases of leukaemia were to emerge.7 The 
carcinogenic nature of ionising and ultraviolet (UV) radiation has been well 
documented since these early reports. Radiation cancer risk studies were 
carried out on individuals including patients irradiated for medical treatment and 
the Hiroshima and Nagasaki atomic bomb survivors.8 These studies confirmed 
the radiation exposure/cancer risk correlation. Some of the cancers reported 
with an increased risk of development following exposure include leukaemia 
and cancer of the breast, lung and stomach.9
UV light radiation is a well known carcinogen.10 The correlation between 
malignant melanoma and UV light is an established phenomenon with 
overexposure to this form of radiation thought to increase the cancer risk.11 The
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use of UV artificial light sources such as sun lamps and beds confirms these 
findings.12 The UV light/melanoma topic is discussed in greater detail in 
Chapter 2.
1.2.3 LIFESTYLE
Of all the causative factors in cancer the one responsible for the most 
cancer deaths is cigarette smoking.13 So great are the number of deaths linked 
to smoking that cigarette companies are legally bound to advertise the fatal 
implications of this habit on their packaging. As well as lung cancer, other 
tobacco-related cancers include cancer of the oral cavity, pharynx, urinary 
bladder and pancreas.13
The American Institute for Cancer Research is devoted to cahcer 
prevention through changes in diet and nutrition. This research body reports 
reductions in some cancers of 60 to 70% by changes in lifestyle such as diet, 
weight and physical activity.1 The pioneering work in this area by 
Tannenbaum14 demonstrated correlations between animal diets and risk of 
breast cancer with increased carcinogenicity found in animals consuming a diet 
high in fat and calories compared to those adhering to normal diets.
1.2.4 VIRUSES
Cancer-causing viruses can be divided according to their genetic 
makeup such that DNA- and RNA-containing tumour viruses exist.15 
Retroviruses are the oncogenic viruses with an RNA genome exclusively. The 
first reported human retrovirus, human T-lymphotropic virus-type 1 (HTLV-1) 
infects mature T-lymphocytes which results in adult T-cell leukaemia-lymphoma 
(ATL). ATL incurs high mortality rates and is geographically restricted with the 
highest incidence found in Japan and the Caribbean.16 Consider the second 
group of oncogenic viruses. Examples of these DNA-containing tumour viruses 
are more plentiful, e.g. the Epstein-Barr virus (EBV). This infects B lymphoma 
cells producing lymphoproliferative diseases including Burkitt's lymphoma and 
infectious mononucleosis.17 Other DNA-containing tumour viruses such as 
human papilloma virus (HPV) and herpes simplex virus-type 2 (HSV-2) both 
produce cervical cancer.
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1.2.5 CANCER-CAUSING GENES
Genes are well established as a causative factor of many cancers. The 
two main types of these genes are oncogenes and tumour suppressor genes.
1.2.5.1 Oncogenes (and proto-oncogenes)18
Oncogenes are the main cancer-causing genes. When expressed these 
genes encode protein products which bring about changes to a normal cell 
characteristic of malignancy. Proto-oncogenes are genes found in every cell in 
the human body which can be converted into oncogenes, e.g. by mutation or 
deletion which then enables them to assume an oncogenic function. In normal 
cells proto-oncogenes encode proteins which play important roles in cellular 
processes such as proliferation and growth.19 Therefore the net effect of the 
proto-oncogene/oncogene transformation is that proteins are encoded with 
aberrant cellullar functions and the transformed cell proliferates in an 
uncontrolled manner, characteristic of a cancer cell.20 Proto-oncogenes and 
their role in malignant transformations of normal cell are discussed in greater 
detail in section 3.4.
1.2.5.2 Tumour suppressor genes
Tumour suppressor genes play a regulatory role in normal cell growth. 
These genes are activated on demand to halt the cell growth process. However, 
when these genes are lost or inactivated, their inhibitory regulation of cell 
growth is thus removed whereupon malignancy results.21 Wilms' tumour gene 
is a common suppressor gene. Deletions or mutations to this gene on the short 
arm of chromosome 11 are attributed to Wilms' tumour, the most prevalent 
childhood kidney cancer.22 The CDKN2 tumour suppressor gene is the most 
important familial malignant melanoma gene.23 This gene and its relationship 
with malignant melanoma is discussed further in section 2.4.3
1.3 THE CELL CYCLE24
Cell division plays a role of immeasurable importance in the life 
processes of various organisms. Just consider for example the unicellular 
organism Amoeba which reproduces by cell division or that multicellular 
organisms require cell division for growth and repair.25
4
The cell cycle comprises of an ordered sequence of definitive events 
within the dividing cell. This cycle is made up of the mitotic (M) phase and 
interphase with 90% of cycle time devoted to interphase. In G-|, G2 and S, the 
three sub phases of interphase, the cell grows (G1 and G2 sub phases) and 
chromosomes are copied (only in S subphase). On reaching the mitotic phase 
of the cycle the cell is divided whereupon two identical daughter cells are 
produced.26
The crucial point for the cell cycle occurs within G1 phase at the 
restriction point. A trigger at this point is required for procession into the S 
phase. However, the cell can depart from the cycle at this point into the Go 
phase, the phase in which most human cells are found. The proliferative nature 
of cells vary such that some cells, for example marrow cells rapidly divide, 
whereas other cells like those of the nerves or muscle, never divide. However, 
certain cells including lung and liver cells, have the potential to enter the cell 
cycle when required which is usually only for repair purposes.26
1.3.1 CANCER CELL DIVISION
Cancer cell proliferation is uncontrolled with the transformed cell failing to 
respond to the regulatory mechanisms for normal growth control.27 The 
malignant transformation of normal cells to cancer cells is under genetic control 
with the genes which are controlling cell proliferation being active beyond 
control and apparently unable to be switched off. The mechanism which 
maintains the genes in this active state holds the key to fully understanding 
cancerous cell production and the genetics behind its control.27
1.4 THE TREATMENT OF CANCER
1.4.1 SURGERY AND RADIOTHERAPY
Cancer in its many forms can be treated with a variety of therapeutic 
agents which include surgery, radiotherapy, chemotherapy and immunotherapy.
The use of surgery in cancer treatment is relatively diverse and very 
much dependent on the nature of the cancer, e.g. surgery is fundamental for 
use in biopsies and localised excisions but limited in the successful treatment of 
many advanced neoplastic cancers.28 Common to most cancer therapies, 
surgery is regularly supplemented with other approaches.
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Radiotherapy is a potentially very effective treatment of cancer, 
hampered only by its ability to damage normal cells. Irradiation sources include 
X-rays, y-rays and radioactive isotopes of elements such as radium and 
cobalt.29 This therapeutic agent is common in adjuvant treatment for post- 
surgical patients to limit the risk of recurrence. In the treatment of Hodgkin's 
disease, radiotherapy and chemotherapy (see section 1.4.2) in combination or 
as single agents provide one of the most successful treatments of a cancer 
regardless of the stage of the disease.30 Computerised tomography31 and NMR 
imaging32 advances have enabled improvements in surgery and radiotherapy 
by providing a more defined image of the cancer. These imaging modems 
enable a precise treatment of infected tissues with normal tissues affected as 
little as possible.
1.4.2 CHEMOTHERAPY33- 3*
The vast range and number of cancer chemotherapeutic agents in 
clinical use today alone means that this topic cannot be discussed here in great 
detail. However, a representative discussion of the major classes of anticancer 
drugs will follow describing alkylating agents, antimetabolites, topoisomerase II 
inhibitors and antimitotic agents.
1.4.2.1 Alkylating agents
This class of chemotherapeutic agents react chemically with the cancer 
cells' own DNA. On rendering the DNA structurally and functionally redundant, 
cell death occurs. The alkylating agents can be classified into nitrogen 
mustards, platinum complexes and nitrosoureas.
1.4.2.1.1 Nitrogen mustards35
The tertiary amine methyl bis(2-chloroethyl)amine (mechlorethamine) 1 
was the first clinical cancer chemotherapeutic agent used and still finds 
employment today as part of a drug combination regimen to treat Hodgkin's 
disease.36 Chlorambucil 2 and melphalan 3, both structural analogues of 
mechlorethamine are widely used antitumour agents in combination or as single 
agents. Notably melphalan is used as an adjuvant to surgery in primary breast 
cancer treatment.37
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The mechanism of cytotoxicity for these three nitrogen mustards is the 
same with the bis(2-chloroethyl)amino moiety providing the structural feature 
required.35 The nitrogen mustards function as alkylating agents by crosslinking 
the double strands of DNA. Cell death ensues as a crosslinked DNA species 
cannot unwind and replicate to complete the cell cycle. A simplified illustration 
for this cytotoxic mechanism of the action of nitrogen mustards using 
mechlorethamine 1 is shown in Scheme 1.
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Scheme 138
On forming the aziridine species 4, the nitrogen mustard is set up for 
nucleophilic attack. For cytotoxicity leading to cell death DNA provides the 
source of nucleophilicity. Nucleotide bases on the DNA, e.g. guanine provide 
the nucleophilic site (N-7 position) for attack of the aziridine. The monoadduct 
product 5 can result in the mispairing of bases or strand breakage of the DNA; 
however the cell can invariably repair this damage. On the other hand, the 
monoadduct can be further involved in a repeat crosslinking process with a final
7
adduct 6 linking either the same DNA strand (intrastrand crosslink) or as is 
more commonly found linking complementary DNA strands (interstrand 
crosslink).35
The leading alkylating agent, cyclophosphamide 7 is not itself active, 
requiring metabolic activation before it can exert cytotoxicity against the cancer. 
Amongst the cyclophosphamide metabolites produced are phosphoramide 
mustard 8 and acrolein 9 and these are believed to be the cytotoxic species 
with the phosphoramide mustard 8 behaving as a DNA crosslinking species. 
Cyclophosphamide exhibits broad spectrum anticancer activity which is 
reflected in its wide use in the treatment of cancers such as acute lymphocytic 
leukaemia, breast carcinoma and Hodgkin's disease.39
P-N
/ HO-fj>-N
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1.4.2.1.2 Platinum complexes
H3N p r CI 
H3N' 'Cl 
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Of the platinum complexes cisplatin 10 exhibits the best antitumour 
effects with activity against several human cancers when used alone or in 
combination drug therapy.40 Structure activity studies identified the cis- 
arrangement of ligands in cisplatin to be imperative for activity.40 The 
cytotoxicity of this platinum complex is believed to arise from DNA interactions 
whereby the main adducts form from intrastrand DNA crosslinks 41 Carboplatin, 
iproplatin and tetraplatin are among the most potent of 2000 or so analogues of 
cisplatin synthesised. However, they do not improve on cisplatin itself as they 
fail to reduce levels of toxicity or resistance of tumours found with repeated 
cisplatin drug use.40
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1.4.2.1.3 Nitrosoureas
Random screens performed by the National Cancer Institute in 1959 
prompted the first work into nitrosoureas as potential chemotherapeutic 
agents.42 Later 1,3-bis(2-chloroethyl)-1 -nitrosourea (BCNU) 11 emerged as one 
of the first nitrosoureas with anticancer potential, followed by lomustine (CCNU) 
12 and its 4-methyl homologue, semustine (MeCCNU) 13.43 The replacement 
of the chloroethyl moiety in BCNU 11 with a cyclohexyl ring in CCNU 12 and 
MeCCNU 13 was found to improve lipophilicity thus greatly assisting 
absorption. This enhanced lipophilicity enabled penetration of the blood-brain 
barrier with central nervous system tumours able to be reached.44 Although all 
three nitrosoureas are employed in drug combination chemotherapy, each of 
them are found to exhibit significant activity in the treatment of Hodgkin's 
disease44 and brain tumours. DNA is the major target of the nitrosoureas with 
evidence of interstrand crosslinking and single strand breaks reported.43
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1.4.2.2 Antimetabolites
Antimetabolites target the metabolic pathways of the cancer cells. These 
agents usually take the form of synthetic analogues of the normal metabolites 
with the prime objective being to halt the uncontrolled cell growth in the cancer 
patient.45 In effect, antimetabolites assume the role of an imposter in the 
metabolic pathways of cancer cells. The most successful antimetabolite drugs 
are found to affect the pathways leading to the production of DNA-related 
components.45 The main antimetabolites include flluoropyrimidines, thiopurines 
and antifolates.
1.4.2.2.1 Fluoropyrimidines
The lead fluoropyrimidine, 5-fluorouracil (5-FU) 14 was designed as a 
pyrimidine base mimic. The cytotoxicity of 5-FU' results from DNA-directed 
action of the drug due to incorporation of 5-FU into DNA. This fluoropyrimidine 
as a single chemotherapeutic agent is most commonly used in the treatment of
9
solid tumours, in particular breast and gastrointestinal tract carcinomas. 
However, it is employed to a greater extent in combination drug therapy.45 For 
example, 5-FU in a three-drug regimen with doxorubicin (see section 1.4.2.3) 
and cyclophosphamide is used to treat advanced breast cancer.46 
Derivatisation of fluoropyrimidines has been found to be biologically very useful. 
One such example is the prodrug ftorafur 15 which exhibits antitumour activity 
against a range of solid tumours.47
1.4.2.2.2 Thiopurines
Of the unnatural purines investigated for anticancer activity, 6- 
mercaptopurine 16 and 6-thioguanine 17 proved to be among the most 
promising.48 However, 6-mercaptopurine 16 proved to be the most potent of the 
two antimetabolites exhibiting activity against acute childhood leukaemia.49 The 
tumour response with 6-mercaptopurine 16 has been correlated with conversion 
of the drug into the corresponding ribonucleotide.48
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1.4.2.2.3 Antifolates
The folates are coenzymes involved in many biochemical 
transformations. Dihydrofolate reductase (DHFR) is among the many folate- 
utilising enzymes and plays a key role in pathways leading to the formation of 
nucleic acids.50 Methotrexate (MTX), 18 a classical antifolate, potently inhibits 
DHFR resulting in cytotoxicity. Used in the treatment of choriocarcinoma and
10
acute lymphocytic leukaemia,51 MTX 18 is also employed in various 
combination drug regimens. However major limitations in MTX drug use arise 
via toxic side effects and the development of resistance to the drug by tumour 
cells.51 These are problems commonly faced by many antitumour agents.
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1.4.2.3 Topoisomerase II inhibitors
DNA topoisomerase II is a homodimeric protein responsible for the 
control of double stranded DNA topology. When required these enzymes 
function by first breaking the paired DNA strands and then later reforming the 
breaks e.g. during transcription whereby the DNA returns to its original strand- 
paired state.52 This characteristic topoisomerase II action has seen these 
enzymes implicated in facilitating the cytotoxicity of intercalating drugs. These 
agents bind tightly to DNA but this alone does not correlate with the cytotoxicity 
observed.53 A complex mechanism is proposed whereby the intercalators 
inhibit the breakage-reunion reaction of the topoisomerase II.54 Cell death 
arises from lethal breaks in the double stranded DNA.54
The anthracycline antibiotics are DNA intercalating agents believed to 
target topoisomerase II enzymes to elicit their anticancer activity. Isolated from 
a Streptomyces species, the anthracyclines include Daunomycin (daunorubicin) 
19 and Adriamycin (doxorubicin) 20 which were the first anthracycline 
antibiotics to be used in tumour chemotherapy. Notably Daunomycin 1 9 
predominates in the treatment of acute leukaemia. However the side effects of 
toxicity and alopaecia are standard.55 The functional diversity of the 
anthracyclines is of particular interest because in addition to inhibiting 
topoisomerase II, these chemotherapeutic agents chelate transition metal ions 
and generate free radicals within the tumour cells.55
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The synthesis of anthracycline analogues has provided little 
improvement on anticancer activity. However, the synthetic anthraquinone 
mitoxantrone 21 although not strictly an anthracycline analogue is structurally 
quite similar. While it demonstrates similar cytotoxicity,56 mitoxantrone 21 
reduced overall toxicity suggesting perhaps that the toxicity in the 
anthracyclines may be attributable to the varied functionality they exhibit. 
Metastatic breast cancer, leukaemias and renal cell carcinoma are among the 
cancers with which mitoxantrone has produced responses.56
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1.4.2.4 Antimitotic agents
As the name infers this class of compounds act during the mitotic phase 
of the cell cycle. In normal cells spindle apparatus operates in this mitotic phase 
by controlling the division of chromosomal material, a process crucial to 
successful cell division. The spindle is constructed from microtubule proteins 
which co-exist in a balanced state with tubulin.57 Antimitotic agents disturb this 
delicate microtubule/tubulin balance and by preventing spindle formation halt 
cell growth.57
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1.4.2.4.1 Catharanthus (Vinca) alkaloids
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Vinblastine 22 and vincristine 23 isolated from the Madagasian 
periwinkle plant Catharanthus roseus are amongst the best known Vinca 
alkaloids.58 These antimitotic agents function by binding to dimeric tubulin 
which perturbs the balanced microtubule/tubulin state. Inhibition of spindle 
construction and function results, followed by cell death.59 Vinblastine 22 and 
vincristine 23 are used to treat rapidly growing cancers such as leukaemia but 
neurotoxic side effects are common.59 This toxicity along with multidrug 
resistance has hampered the rapid progression with further natural or synthetic 
Vinca alkaloids.58 However, vindesine 24 is a more recently identified 
antimitotic agent used to treat leukaemia.60
1.4.2.4.2 Paclitaxel (Taxol)
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Unlike the Vinca alkaloids, the antimitotic agent paclitaxel (Taxol) 25 
disturbs the delicate microtubule balance by catalysing microtubule formation.61 
The equilibrium becomes heavily unbalanced in favour of the microtubule
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protein and hence cell death ensues due to incompletion of the mitotic phase of 
the cell cycle. The isolation of Taxol from the stem bark of the Pacific yew 
Taxus brevifolia revealed an antimitotic agent with potent anticancer 
properties.62 This discovery prompted the quest for a synthetic source of this 
very scarce natural product. However, it was over 20 years before the first total 
synthesis emerged from the groups of Nicolaou63 and Holton64 closely followed 
by Danishefsky.65 From the endeavours of these workers and others, chemistry 
crucial for the semi-synthetic production of Taxol was revealed. Initially 
approved for ovarian cancer treatment,66 this potent drug exhibits significant 
activity against breast, lung and head and neck cancers.67 The literature 
continues to be saturated with reported uses of Taxol. Whether on its own or in 
combination chemotherapy, this exceptionally promising agent is employed in 
treatment of the advanced metastatic forms of many cancers.
1.4.3 IMMUNOTHERAPY66
The immune system removes any agent or agents it regards as foreign 
to the human body by eliciting a specific immunological response. The potential 
for an immunological role in cancer therapy requires tumour cells to have target 
molecules recognised by antibodies or cells involved in the immune process.69 
Current approaches to immunotherapy include monoclonal antibodies and 
biological response modifiers.
1.4.3.1 Monoclonal antibodies
The use of monoclonal antibodies in cancer treatment is very limited. 
These antibodies are employed to recognise antigens specifically associated 
with the tumour cells.70 Some antigenic tumours include melanoma ovarian and 
colon cancers. Problems which limit this form of immunotherapy can arise from 
immunological responses removing the antibodies from the system.70 However, 
monoclonal antibody-directed therapy enjoys a far greater potential in cancer 
therapy. In effect, this therapy links the antibody to a drug thus directing the 
drug to the tumour cell surface.71 Shortages of specific antibodies and 
insufficient quantities of drug delivered have produced problems 71 However, 
promising results with experimental leukaemias or ascites tumour have been 
observed.72
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1.4.3.2 Biological response modifiers73
The biological response modifiers which are mostly polypeptides elicit 
their anticancer behaviour through regulating the immunological responses of 
the cancer patient.73 The most promising biological response modifiers are the 
interferons. Interferons are usually produced by the body in response to viral 
infection and display inhibition of cell proliferation.73 Gene cloning techniques 
have been employed to produce these immunotherapeutic agents and among 
the most successful are the interferons IFN-a and interleukin-2 (IL-2). IFN-a is 
used to treat malignancies including advanced lymphoma and renal-cell 
cancers. Interleukin (IL-2) is particularly effective against melanoma and kidney 
cancer.74 However, the problem with these interferons and other biological 
response modifiers is that the mechanism of action remains unclear.
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CHAPTER 2
MALIGNANT MELANOMA 
AND ANTIMELANOMA AGENTS
2.1 SKIN CANCER - A MISUNDERSTOOD TERM
Skin cancer is a familiar term to the population in general, however, its 
true nature is not well understood. Unknown to many, skin cancer or cutaneous 
malignancy comprises three forms: basal cell carcinoma, squamous cell 
carcinoma and malignant melanoma.11 Despite its comparative rarity malignant 
melanoma is the potential killer of the three forms.11 However non-melanoma 
skin cancer (basal cell carcinoma and squamous cell carcinoma) is one of the 
most common cancers to affect men and women.2 With mortality rates very low 
and tumours only rarely known to metastasise, sufferers of non-malignant 
melanoma can be treated in a very low key manner in general practice or as 
hospital outpatients.
The skin cancer discussed in depth from this point on is the 
comparatively rare but potentially lethal form, namely malignant melanoma.
2.2 TYPES OF MALIGNANT MELANOMA
There are four main types of malignant melanoma, namely superficial 
spreading, nodular, lentigo and acral melanomas.75 The superficial spreading 
and nodular melanomas generally occur in younger people, whereas lentigo 
malignant melanoma is most likely to affect the faces of the elderly. The acral- 
lentiginous melanoma is a malignancy of the skin which affects the palms and 
soles.75
Of the four types, the superficial spreading and nodular melanomas are 
the most common and aggressive types. Between them they constitute 
approximately 90% of all malignant melanoma cases and most recent 
epidemiological studies concentrate only on these types.76
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2.3 MALIGNANT MELANOMA - AN EPIDEMIC
Considering that malignant melanoma is the cause of only 1% of all new 
cancer cases,77 why then is there so much concern associated with this 
particular cancer? With this in mind, consider the following very sobering 
aspects of the disease which should illustrate the reasoning behind such 
widespread concern.
• At present the incidence of malignant melanoma continues to escalate 
among the fair-skinned populations of the world.76
• The major aetiological factor attributed to the cancer is known, namely 
overexposure of skin to strong sunlight (ultraviolet light with wavelength 290- 
320 nm, UV-B).10-11
• This cancer can be cured but only if recognised in its early stages of 
development before the onset of metastasis.78 Otherwise no curative 
therapy for advanced forms exists.
• The age at onset is earlier than in most other cancers. Over the period 1986- 
1995 it was the third most common cancer in the 15-34 age group.79
So in summary, unlike most other cancers, melanoma is potentially 
curable and the major cause known. It would therefore appear that through early 
identification of the cancer and simple education with regard to sun exposure 
the incidence and early age onset of the disease could be reduced.
2.4 RISK FACTORS AND THE DEVELOPMENT OF MALIGNANT 
MELANOMA
As already mentioned the main aetiological factor associated with skin 
cancer is exposure to solar radiation.10-11 However, the risk of developing 
malignant melanoma can be further increased by a number of contributing 
factors or risk factors. These principal risk factors can be illustrated through 
discussion of skin type, naevi and genetics and family history.
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2.4.1 SKIN TYPE
Susceptibility to malignant melanoma is considered to be related to skin 
pigmentation,77 i.e. those phenotypes with naturally occurring brown or black 
skin are at a far lower risk of developing malignant melanoma than fair-skinned 
individuals who have a tendency to burn or freckle rather than tan. It has also 
been proposed that episodes of severe sunburn and general overexposure to 
the sun can cause malignant melanoma 80
2.4.2 NAEVI
Benign pigmented melanocytic naevi or "moles" as they are more 
commonly known, can be present from around birth (congenital naevi) or 
acquired later in life (common or acquired naevi). Both types of naevi are 
considered to be risk factors for malignant melanoma.81
Dysplastic naevi are acquired naevi. The risk of malignant melanoma has 
been reported as proportional to the number of these naevi80 with large 
numbers proving to increase the significance of the risk factor. However, as 
solar exposure increases the number of naevi it remains unclear whether UV 
radiation promotes conversion of naevi into melanoma or acts as some sort of 
initiator.77
The other type of mole, congenital naevi, have been used as a powerful 
tool in public awareness campaigns to promote self-recognition of the early 
signs of the cancer.82 Warning signs of malignant melanoma manifest 
themselves in featural changes of these moles, from changes in mole size, 
outline and colour to bleeding and itching.11
2.4.3 EARLY HISTORY AND GENETICS
Case studies identified the link between family history and melanoma risk 
with an individual's risk of developing malignant melanoma doubled if they have 
at least one first-degree relative with the cancer.83 Statistically this represents 
approximately 2% of melanoma sufferers.84 Furthermore, it would appear that 
genetic susceptibility and sun exposure are likely to act multiplicatively on 
melanoma risk.83
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The search for the hereditary genetic component of malignant melanoma 
is an ongoing one. While 5-10% of malignant melanoma cases occur in a 
hereditary form,85 a number of familial cancer genes have been cloned and 
characterised, most of which prove to be involved in sporadic cancers as well as 
hereditary cancers.86 The most important familial melanoma gene reported to 
date is the p16INK4(CD/CA/2) MTS1 gene found on chromosome 9p21.87 CDKN2 
possesses the hall marks of a tumour suppressor gene and is lost or mutated in 
many cell lines including melanoma.85*88 Such CDKN2 mutations have been 
reported in approximately 20-30% of all familial melanoma cases.89
2.5 BRESLOW THICKNESS AND THE STAGES OF MELANOMA
Malignant melanoma originates within the melanocyte where under 
conditions of uncontrolled melanocytic cell division excessive production of 
melanin occurs. This results in malignant melanoma appearing as dark naevi or 
lesions on the skin. However, the most feared aspect of melanoma is 
metastasis, the spread of the cancer, as metastasis can spread the cancer to 
distant sites within the body including the brain, lungs and gastrointestine.78 It is 
of no surprise then that chances of survival are far greater when the malignancy 
is treated in the early stages of development, before metastasis.78
Of paramount importance in prognosis is the vertical thickness of the 
tumour known as the Breslow thickness.90 Quite simply "the thinner the better" 
best describes tumour prognosis for recovery. Breslow thickness along with the 
anatomical level of local invasion are used to characterise malignant melanoma 
into four stages of development91 as detailed below.
STAGE I
• Tumour less than 1.5 mm thick and/or invades papillary-reticular dermal 
interface.
• No regional lymph node or distant metastasis.
STAGE II
• Tumour between I.5 and 4 mm thick and/or invades reticular dermis.
• No regional lymph node or distant metastasis.
STAGE III
• Tumour more than 4 mm thick with invasions as far as subcutaneous tissue.
• Metastasis in any regional node(s).
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• No distant metastasis.
STAGE IV
• Mestasis in regional lymph node(s) and distant metastasis in skin tissue, 
subcutaneous tissue or lymph node(s) beyond the regional lymph nodes.
Having detected the cancer's stage of development, the appropriate 
treatment can be selected. However, treatment choice is greatly diminished for 
advanced metastatic tumours in the later stages of advancing metastasis.
2.6 TREATMENT OF MALIGNANT MELANOMA
The therapeutic forms of malignant melanoma treatment include surgery, 
radiotherapy, chemotherapy and biological therapy. As already implied, the 
applicability of each treatment is very much dependent on the stage of 
development of the cancer. Each of the four treatments will be discussed in turn.
2.6.1 SURGERY
Surgery is the most effective treatment of the early stages of 
melanoma.92 Furthermore, studies reported that surgical margins need be no 
greater than 2 cm for the excision of melanomas of intermediate thickness (0.75 
to 4.0 mm).93 This significantly reduces the need for skin grafting with most 
patients treated on an outpatient basis. Surgery faces a far more limited role in 
the treatment of advanced melanoma. However, isolated metastases found in 
the lungs, gastrointestinal tract, bone or occasionally the brain, may be palliated 
by resection with some improvements in survival resulting.94
2.6.2 RADIOTHERAPY
Radiation therapy does not play a curative role in treatment of melanoma 
patients. However, this treatment is not redundant as radiotherapy provides 
symptomatic relief for sufferers with metastases including those affecting the 
central nervous system and bone.95
2.6.3 CHEMOTHERAPY
The chemotherapeutic approach to melanoma treatment can be divided 
into the use of drugs as single agents or as part of a combination regimen.
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2.6.3.1 Single agents
From the early 1970s dacarbazine (DTIC) 26 has remained the drug of 
choice for single agent treatment of metastatic melanoma. DTIC 26 displays 
response rates around 20%.96 Before the discovery of DTIC 26, some of the 
single agents in use included hydroxyurea, procarbazine and alkylating agents 
such as cyclophosphamide.97 Their use was discontinued due to low response 
rates. Later cisplastin98 and the Vinca alkaloid family (vindesine99 and 
vinblastin100) demonstrated antitumour activity; in particular response rates of 
10 to 15% were exhibited for cisplatin treatment.98 The potential of these single 
agents was recognised by incorporating these drugs in combination 
chemotherapy regimens. To date, the nitrosourea family continues to produce 
encouraging single agents for melanoma treatment. Earlier nitrosourea 
examples include carmustine (BCNU), lomustine (CCNU) and semustine 
(MeCCNU)96 which reported antitumour potency analogous to DTIC. However 
severe toxicological problems hampered further use of nitrosoureas such as 
CCNU.96
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Fotemustine 27 is a relatively new nitrosourea with response rates 
reported in the region of DTIC.101 Such was the antitumour potential of 
fotemustine 27, it was incorporated immediately into combination therapeutic 
regimens with DTIC 26 and further studies for it as a single agent should be 
imminent. Many of these chemotherapeutic agents, their uses and mechanisms 
of action are discussed in section 1.4.2.
2.6.3.2 Combination chemotherapy
In an attempt to improve on the antitumour activity of single agents, 
combination chemotherapy employs two and three combinations of drugs to 
treat metastatic melanoma. However, results have proven to be quite 
disappointing with the response rates observed for DTIC 26 never surpassed.
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Combination chemotherapy regimens involving DTIC and the nitrosoureas 
BCNU, CCNU and MeCCNU displayed some potential but not comparable to 
the results from DTIC alone.102 Similarly two and three drug combinations of 
vinblastine, vindesine and cisplatin with DTIC were to produce analogous 
observations in their results.103 Encouraging results were obtained very recently 
in a study using DTIC and fotemustine. Although response rates were mediocre 
(11%), minimal side effects and no lung toxicity were observed. This provides a 
palliative treatment for advanced metastic melanoma.104
To date however, DTIC maintains the lead single chemotherapeutic 
agent for malignant melanoma and as yet no conclusive evidence has been 
reported to demonstrate combination chemotherapy as a superior mode of drug 
treatment.
2.6.4 BIOLOGIC THERAPY
2.6.4.1 Interferons
The first evidence of effective adjuvant therapy for metastatic malignant 
melanoma treatment emerged recently using interferons.105 These 
immunotherapeutic agents provide a novel source of anticancer agents (see 
section 1.4.3.2). The Eastern Co-operative Oncology Group (ECOG) trial 1684 
reported using interferon alfa-2b (IFN-a2b) at maximally tolerated doses for one 
year.106 Overall survival was improved by approximately 1 year with estimated 
overall 5-year survival rates of 46% (compared to 37% for those who received 
no adjuvant therapy). Furthermore, the toxic side effects were tolerated by the 
majority of patients.106
2.6.4.2 Other immunotherapies
One target in the development of immunological cancer vaccines are the 
ganglioside antigens found expressed on the cell surface of human malignant 
melanoma.107 The ganglioside GM2 antigen vaccine (GM2 vaccine) induces 
antibody responses with a high percentage of patients and on combining the 
GM2 vaccine with Bacillus calmette-guerin (BCG), in the GM2/BCG vaccine, 
improvements in overall recovery and relapse times occurred.108 To investigate 
these findings further, GM2 vaccine and Interferon IFN combination trials are 
expected.
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Another approach in specific tumour immunotherapy arises from the 
discovery of T-cell recognised tumour associated antigens (TAA).109 This has 
enabled the development of T-cell antigens vaccines which have been used in 
clinical trials for the past few years.110
To summarise the treatments of malignant melanoma discussed: 
although surgery enables treatment of early stage melanoma with relative ease 
and minimal disruption to the patient, advanced metastatic melanoma remains 
resistant to most therapies. However the reported encouraging responses from 
some chemotherapy and especially the emerging immunotherapies can surely 
provide hope for sufferers and provide concrete foundations for further work in 
this cancer field.
2.7 PREVENTATIVE MEDICINE?
When we consider the overwhelming contribution sun exposure plays in 
the incidence of skin cancer, never has prevention been such an attractive 
therapy. In an attempt to change habits with regard to sun exposure public 
awareness campaigns have been implemented world-wide from Australia to the 
UK.111 These campaigns have a common theme whereby tanned skin is no 
longer to be considered a sign of beauty, wealth or status. Re-education tactics 
include promoting the use of sunscreens, avoidance of midday sun and special 
care of young children's skin whilst in the sun.112 To enable the earliest 
treatment of this cancer, prompt identification through self-examination of moles 
is also encouraged (see section 2.4.2).
Sadly however, on reflection, the white skinned individual's urge for the 
perfect tan has had alarming consequences on a scale which could never have 
been predicted. It can only be hoped then that in this trend-following world, 
styles will revert back in time to the Victorian era when white almost porcelain­
like skin was desired to portray the image of upper class status, wealth and 
social standing!
2.8 THE MELANIN PIGMENTARY SYSTEM
Malignant melanoma results from the aberration of melanocytic cell 
division which leads to excessive melanin production.113 To understand the 
biological process of pigmentation itself114 the functional components of the 
melanin pigmentary system should be examined. The more important
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components include Tyrosinase, the melanosome, keratinocytes, melanocytes 
and melanin itself.
2.8.1 MELANIN
This brown-black pigment of the skin is synthesised within the 
melanocyte on the melanosome (a sub-cellular organelle). The virtual 
insolubility of melanin made elucidation of the biosynthetic pathway very 
difficult.115 Scheme 2 depicts a very simplified version of this pathway. Two 
types of pigment, eumelanins 28 and phaeomelanins 29 (coloured brown-black 
and reddish respectively) are both seen to originate from tyrosine 30, the amino 
acid starting material of the complex pathway.116 The photoprotective role 
played by melanin is exemplified when one considers the ease with which a 
light-skinned individual burns compared to their naturally dark-skinned 
counterpart, e.g. Negro.115
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2.8.2 TYROSINASE
This aerobic oxidase enzyme is unique to the melanocyte cell where it 
plays a crucial role in melanisation.114 The enzyme catalyses the conversion of 
tyrosine 30 into dopaquinone 31, a reaction believed to proceed via the catechol 
L-dopa 32.118 However, recent studies indicate that L-dopa arises from the 
disproportionation of dopaquinone and acts as an activator of the Tyrosinase 
enzyme.119 This also explains the unusual kinetic properties found with 
Tyrosinase oxidation of tyrosine and other phenols.119 Dopaquinone 31 then 
reacts further to yield eumelanin 28 and on combining with sulfur-rich cysteine 
33, phaeomelanin 29 is produced (via cysteinyldopa 34 and subsequent 
intermediates) (Scheme 2).114 The Tyrosinase activity is subject to regulatory 
control including negative feedback inhibition by melanin and control from 
intracellular cyclic AMP.120 Perhaps of greater relevance to this discussion is 
the increase in tyrosinase activity caused by ultraviolet light.121
2.8.3 MELANOSOME
The synthesis of melanin occurs within this subcellular organelle.116 Four 
stages of this melanisation take place.122 In stages I and II the melanosome 
changes from a spherical to an oval shape. The development of melanin 
synthesis proceeds from a partial state in stage III to completion by stage IV. 
The few melanosomes seen in pale-skinned individuals are found to be in 
stages I and II only. However, in Negroes for example, mostly stage IV 
melanosomes are present. The resultant effects of overexposure to UV light in 
the paler Caucasians can be observed with stage III melanosomes appearing 
following exposure.122
2.8.4 MELANOCYTES113
Within these specialised cells melanosomes and the melanocyte enzyme 
Tyrosinase can be found.113 Melanocytes are found in the mucous membranes, 
nervous system and eye (ureal tract and retinal epithelium) as well as the skin. 
Malignancy can arise in all these sites except the retinal pigment epithelium.113 
No correlation between melanocyte number and skin colour is thought to exist. 
However, exposure to UV light can increase the number of melanocytes.116
2.8.5 KERATINOCYTES
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The transfer of melanin from the melanocyte to the keratinocyte is 
essential in the pigmentation process.122 Within the keratinocyte, while the 
larger melanosomes function individually, the smaller melanosomes congregate 
to maintain their functional purpose.122
2.8.6 EPIDERMAL MELANIN UNIT
This functional unit is formed when the components of the melanin 
pigmentary system combine and interact functionally. The epidermal melanin 
unit is made up of one melanocyte surrounded by 20 to 36 keratinocytes.116-123 
The transfer of melanin from the melanocyte to the keratinocytes is believed to 
be crucial for pigmentation. Additional major factors in determining skin colour 
include the stage of melanisation, and the size and number of 
melanosomes.116-123
2.9 STRATEGY FOR SPECIFIC DRUG DESIGN
2.9.1 TYROSINASE - THE KEY TARGET124
The target strategy for malignant melanoma drug design is to exploit 
specifically Tyrosinase, an enzyme crucial to melanin synthesis. As Tyrosinase 
is unique to the melanocytes this provides a facilitative modem for distinguishing 
the melanocyte from non-melanocytic cells.124
Phenolic prodrugs modelled on tyrosine 30 (see Scheme 2), the natural 
substrate of the enzyme can be accepted by Tyrosinase. However, catecholic 
compounds were removed promptly from drug design programmes as toxicity 
arose from oxidation via a non-enzymatic route.125 The lead compound to 
emerge from this area of malignant melanoma drug design which specifically 
targets Tyrosinase was compound 35.126-127
OH
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2.9.2 THE JOURNEY OF DISCOVERY TO PARENT DRUG 35
The ground breaking progress in the search for new melanocytic agents 
was made by Miura and co-workers who prepared a series of phenolic thioether 
compounds.128 The novel introduction of sulfur aimed to increase lipophilicity. In 
this early work the most potent compound 36 was found to possess significant 
in vivo and in vitro antimelanoma activity.128 However Padgette and co-workers 
reported129 that phenylaminoethyl sulfides including compound 36 were 
substrates for monoamine oxidase (MAO) and the action of this enzyme 
produced the corresponding aldehyde. Further to these findings it was later 
revealed that the potent melanocytic activity of compound 36 was completely 
lost on inhibition of MAO.130
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To circumvent this catabolic enzyme's action, the preliminary lead 
compound 36 was derivatised and it was from this work that the A/-acetyl 
derivative 35 emerged displaying marked improvements over previous 
compounds.126 This compound displayed in vivo melanocytic behaviour which 
included remarkably high depigmentation of black mice hair follicles while in 
vitro inhibition of B16F10 murine melanoma cell lines was equally as 
successful.127
Alena and co-workers furthered this study127 by combining lead 
compound 35 with buthionine sulfoximine (BSO) 37 whereupon enhanced in 
vitro and in vivo antimelanoma effects of the lead compound were found. BSO 
facilitates this improved activity by depleting melanocytes of glutathione, a 
component involved in the pathway of phaeomelanin synthesis.
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2.9.3 PHENOLIC PRODRUG MECHANISM OF ACTION131
Within the melanocytic cells the targeted enzyme Tyrosinase catalyses 
the conversion of inactive phenol prodrug 38 into the corresponding o-quinone 
39. These active oxygenated species mediate cytotoxicity and impair the 
melanocytes' metabolism by combining with sulfhydryl containing entities 40 
such as DNA polymerase or membrane ion pumps which are crucial to the cell 
cycle. Alternatively the o-quinone may participate in a cyclic redox process 
whereupon active oxygen species 41 are produced.
Q © OHOH
OHTyrosinase
38
ENZ -S H
40
OH
ENZ - S OH
Scheme 3132
2.9.4 THE RESEARCH STORY SO FAR
The significant in vivo antimelanoma activity exhibited by compound 35 
inspired the beginning of a comprehensive drug design and synthesis 
programme within the Robins research group. Preliminary investigative work
28
was performed by McKeown133 followed immediately by the extensive research 
of Lant.134 These workers modified systematically the structure of lead 
compound 35 in an attempt to reveal the pharmacophoric moieties of the drug. 
The detailed studies of McKeown and Lant provided a wealth of compounds 
which can be represented in the summary below (Diagram 1).
Ring substituent —s
changes
Replacement i s
for sulfur
OH
Amide isosteres
O
N 
H
/ ------1 Amide alkyl
group changes
Alkyl side chain 
changes
Diagram 1
2.9.5 PROPOSED WORK
A major structural feature of the parent drug which remained untouched 
throughout the before-mentioned investigations was the secondary amide group 
functionality. One programme of structural modifications proposed for this 
project involved the production of a series of tertiary amide derivatives of the 
parent drug. The series 42 would also incorporate variations in the amide alkyl 
group some of which had previously showed enhanced activity.134 Through this 
modification of two structural features the series of compounds 42 were 
anticipated at the very least to improve the lipophilic nature of the drug, remove 
the hydrogen bonding possibilities of the amide group and furthermore enhance 
the antimelanoma activity.
OH 42
R = Me, Ph, cydoC6H
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This programme of research also included two additional structural 
attacks on the parent compound. The first area of this additional work involved 
the synthesis of a series of amidine salts 43. These compounds introduced a 
novel structural feature to the antimelanoma agents with this amidine group. 
The effect of this more water-soluble moiety on activity was hoped to be 
beneficial with enhanced biological activity anticipated. The third area of work 
was concerned with the development of a range of tyrphostins 44. These 
phenolic compounds have already shown interesting antiproliferative activity136 
and possess similarity to the structure of the substrates of Tyrosinase.
Following the completion of each of the three programmes of research, 
the in vitro melanocytotoxicity of the target compounds and their potential as 
Tyrosinase substrates would be investigated. The results from these biological 
studies will then enable the test compounds' potential as antimelanoma agents 
to be assessed. Concurrently the hypothesis behind the design of the three 
compounds series' will also be explored. The synthesis and biological evaluation 
of these potential antimelanoma agents is discussed in Chapter 4.
44
X = H, OH, OMe
R = CN, C 02Et, CONH2i 
C(NH2)=C(CN)2
n = 1,2
R = Me, Et, Ph, cycloC6\-\u
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CHAPTER 3
CELL SIGNALLING 
AND MAP KINASE INHIBITORS
3.1 PROTEIN KINASES AND CELL SIGNALLING PATHWAYS
The successful transduction of signals from the cell surface to the 
nucleus is crucial to cellular function. These signals are transferred via a 
complicated sequence of events within pathways termed cell signalling 
pathways.137 Protein kinases play a vital regulatory role within these 
transduction pathways whereby they phosphorylate target proteins at specific 
sites in the pathways. The importance of protein kinases and their protein 
phosphorylating function to the cell is exemplified by the number of protein 
kinase genes present in human genetic makeup. It is estimated that as many as 
2000 protein kinase genes are possessed by man and the protein kinases are 
considered one of the largest families of proteins and genes.138
3.1.1 PROTEIN KINASE SUPERFAMILY
Over the past 20 years the discovery of new protein kinases has 
progressed at such an incredibly fast rate that these protein kinases are now 
described as a superfamily.139-140 The rate of discovery was a direct result of 
implementing developing molecular cloning techniques and the realisation that 
many oncogenes encode protein kinases.139 The members of the superfamily 
are related through structure and function. There is a common structural feature 
present in the catalytic kinase region of the protein where approximately 250 to 
350 amino acids are found. The three dimensional catalytic core results from 
the folding of the 12 subdomains of the protein.140
Consider the phosphorylation function common to the superfamily of 
kinases (Scheme 4). This involves the enzymatic-catalysed transfer of the y- 
phosphate of ATP to the alcohol (serine/threonine) or phenol (tyrosine) group of 
the protein 45 whereupon the phosphate monoester 46 and ADP are 
formed.140
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Although the superfamily proteins share similar three dimensional core 
structures and phosphorylate via a common mechanism, two main subdivisions 
of the family exist: the protein serine/threonine (ser/thr) kinases and the protein 
tyrosine (tyr) kinases.139 A method for distinguishing the two protein groups 
from one another exists in examination of the major autophosphorylation site in 
the catalytic region. Discovery of a tyrosine residue in the presence of acidic 
amino acids identifies a protein tyrosine kinase.139
The detailed discussion from this point will concentrate on the protein 
serine/threonine kinases with particular emphasis on one member of this family, 
the mitogen-activated protein (MAP) kinases.
3.1.2 MITOGEN-ACTIVATED SER/THR KINASE PATHWAYS
An area of ongoing research and great interest involves the cell 
signalling pathways in which mitogen-activated (ser/thr) kinases participate. 
Insulin, growth factors and cytokines, the mediators of these pathways,142-143 
bind to specific receptors on the cell surface. These receptors are 
transmembrane tyrosine kinases or are associated with intracellular tyrosine 
kinases.143 Binding produces tyrosine phosphorylation of the receptors which 
triggers the intracellular signalling pathway. In the cascade of events which 
follows many ser/thr proteins kinases are activated and a veritable flood of
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ser/thr phosphorylation events ensues.143 Mitogen-activated protein (MAP) 
kinases are a family of ser/thr kinases involved in such pathways.
3.2 MAP KINASE FAMILY
3.2.1 PIONEERING WORK
The pioneering work in the MAP kinase field of research was carried out 
by Sturgill and Ray144 who were investigating insulin-promoted ser/thr 
phosphorylation of polypeptides. They employed a protein phosphatase-1 
regulatory protein, Inhibitor-2 (I-2), as a substrate to probe for kinase activity in 
insulin-treated 3T3-LI cells. A ser/thr phosphorylated polypeptide extracted from 
the I-2 isolate was identified as microtubule-associated protein-2 (MAP-2).144 
The MAP-2 kinase then isolated from the insulin-treated 3T3-LI cells was 
identified as the insulin-promoted ser/thr phosphorylating enzyme.144
These early observations of Sturgill and Ray generated further interest 
with two observations. Firstly via a collaboration with Erikson and Mailer145 they 
demonstrated phosphorylation and activation of Rsk enzymes S6 kinase II by 
MAP-2 kinase and secondly that MAP-2 kinase activation required both tyrosine 
and threonine residues on the MAP-2 kinase polypeptide to be 
phosphorylated.145
This pioneering work discovered MAP-2 kinase, which was later 
renamed mitogen-activated protein (MAP) kinase.146 MAP kinase is now 
recognised to play a vital role in cell signalling by converting tyrosine 
phosphorylation into serine/threonine phosphorylation essential for regulation of 
pathways within the cell.147
3.2.2 MAP KINASES IN YEAST
The role of MAP kinases in yeast cell signalling pathways has been well 
explored with many pathways elucidated. It is believed that the distinct 
similarities in mammalian and yeast MAP kinases should enable the application 
of the understanding of yeast pathways to those in mammals.148
Yeast MAP kinases are known to participate in at least four distinct 
pathways. For example, in the mating pathway of Saccharomyces cerevisiae, 
two gene products FUS3149 and KSSI150 are kinases which function at G i in
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the yeast cell cycle thereby arresting growth. Such are the similarities in 
mammalian MAP kinases and yeast kinases that sequences encoding newly 
identified mammalian kinases are compared to those of known yeast 
kinases.148
3.2.3 MAP KINASE SUBFAMILIES
Boulton and co-workers dominated the discovery of extracellular signal- 
regulated kinases (ERKs), an insulin-activated MAP kinase subfamily.151 ERK- 
1 was the first ERK family member to be purified and cloned. This 44kDa 
insulin-activated MAP kinase was found to possess remarkable homology 
(56%) to the FUS3 and KSS1 yeast genes. Using the same molecular cloning 
techniques two other ERK subfamily members were discovered, ERK-2 and 
ERK-3.152 ERK-2 was found to correspond to the original kinase isolated by 
Sturgill and Ray (MAP-2 kinase). ERK-2 possessed the same identity with the 
yeast genes (56%) as ERK-1. However, ERK-3 was found to possess 
homology to a lower extent (37%) thereby implicating ERK-3 as belonging to a 
separate subfamily.152
A second MAP kinase subfamily was uncovered by Kyriakis and 
Arruch.153 The p54 SAP kinase was purified from rat liver following 
cycloheximide injection. This MAP kinase subfamily also exhibits homology with 
FUS3 and KSSI (42%). The p54 SAP and ERK subfamilies are all highly 
expressed in the mammalian brain. This along with the homology the 
subfamilies exhibit towards the MAP kinases involved in the arrest of yeast cell 
growth indicates the potential role played by MAP kinases in post mitotic cells. 
The MAP kinases discussed here can be divided into 3 main subfamilies of 
ERK-I and ERK-2 in the first subfamily and the other two subfamilies composed 
of ERK-3 and the p54 SAP kinases.154 However, such is the pace of discovery 
in this area that novel subfamilies will continue to emerge.
3.3 MAP KINASE PATHWAYS
As is the case for many signalling pathways, the prime concern for the 
MAP kinase pathways is to transport the extracellular signal successfully to the 
predetermined destination within the cell which more often than most is the 
nucleus of the cell.148 The cellular instructions contained within the signal must 
be conserved throughout the biochemical cascade of events. In MAP kinase 
pathways where the signal instructions are directed towards transcription of
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specific genes, expression of these genes controls a variety of cell functions 
which include proliferation.155
Fundamental to the MAP kinase (MAPK) pathways is a functional triad of 
serine/threonine protein kinases: MAPK is activated through threonine/tyrosine 
phosphorylation by MAPKK, a dual-specificity protein kinase which is in turn 
activated via serine phosphorylation by MAPKKK, the third member of the 
MAPK pathway core.147
Four distinct MAP kinase pathways have been identified in yeast and 
three in mammals but progress is such that more are destined to be uncovered. 
Perhaps the best way to discuss the mammalian MAP kinase pathways is 
through an example using the most well-known ras/ERK MAPK pathway (see 
Diagram 2).
3.3.1 RAS/ERK MAP KINASE COMPONENTS
W ith in  the known ras/ER K MAPK pathw ay the com ponen ts  
corresponding to the functional triad are ERK (MAPK), MEK (MAPKK) and raf 
(MAPKKK).147 Each of these components will now be discussed as well as ras 
which functions as the link between the extracellu lar signal and the MAPK 
cascade (Diagram 2).
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3.3.1.1 MEK
The entity controlling activation of MAP kinase (later known to be a MAP 
kinase kinase) was first discovered by Ann and co-workers.157 They revealed 
that this activator could reactivate ERK-1 and ERK-2 MAP kinases previously 
inactivated by treatment with phosphatase. Further to these findings Gomez 
and Cohen158 reported that MAP kinase kinase (MKK) required 
serine/threonine phosphorylation to function and later the ERK-specific MKK 
gene was identified and named mek (MAP/ERK kinase).159 The dual specific 
nature of MEK unfolded from the discovery that phosphorylation of both 
tyrosine and threonine residues is required for activation of the ERK MAP 
kinases (ERK-1 and ERK-2).160
3.3.1.2 Raf
The immediate upstream activator of MEK in the ras/ERK pathway is raf. 
This kinase has been shown to activate MEK by phosphorylation of two 
adjacent serine/threonine (ser/thr) residues, an activation mechanism 
consistent to MAPKKs alike.161 Raf was identified as the upstream kinase of 
MEK and has been likened to protein kinase C (PKC), another ser/thr 
kinase.162 Although structural and operational similarities exist between the two 
kinases, the operational aspects for PKC are understood to a far greater extent. 
Raf is believed to be regulated by multiple mechanisms of control.162
3.3.1.3 Ras
Ras is a small (21 kDa) guanine nucleotide binding protein.163 This G- 
protein plays a pivotal role in the ras/ERK pathways by linking receptor tyrosine 
kinase activation to the intracellular MAP kinase pathway (see Diagram 2). Ras 
is positioned immediately upstream of raf in this pathway and is only active in a 
GTP-bound state as guanine nucleotide binding controls the activity of the G- 
protein.164 However, raf is not directly activated by binding to the GTP-bound 
ras. It is proposed that raf bound to ras positions raf at the membrane, 
whereupon an additional as yet undefined event follows resulting in raf kinase 
activation.163
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3.3.1.4 ERKs
MAPK is the effector of the MAPK pathway and many MAP kinases have 
the potential to regulate gene expression by targeting transcription factors in the 
final phosphorylation of the pathway.
In the ras/ERK pathway the transcription factor target is TCF (ternary 
complex factor) in particular the SAP-1 and Elk-1 family members.165 Found 
within the nucleus the ERK-1 and ERK-2 MAP kinases activate these TCFs by 
phosphorylating ser/thr residues on the SAP-1 and Elk-1. This phosphorylation 
is reportedly crucial to stimulation of the c-fos gene transcription process which 
follows.165 The ras/ERK MAPK pathway represents how a signal produced 
from extracellular mitogen-activation of a tyrosine kinase receptor is then 
involved in a ser/thr cascade of intracellular phosphorylation events to deliver 
the signal to its destination in the nucleus where the signal's instructions can be 
implemented.155
3.3.2 JNK/SAPK MAPK PATHWAY
The predeterminant for the activation of the ERKs (ERK-1 and -2) and 
p54 SAP MAP kinases is dual ser/thr and tyr phosphorylation.166 However, the 
modulator for this process is quite different for each of the two MAPK 
subfamilies. The ERKs' activator MEK was reported as unable to activate 
bacterially expressed p54 and in a variety of cell lines, the mitogenic activators 
of the ERKs which act via ras were functionally redundant with the p54 
MAPK.166 However, in response to cellular stress the p54 kinases were 
strongly activated and hence the name stress-activated protein kinases (SAPK) 
was introduced. Other SAPK activators include heat-shock, ultraviolet light and 
tumour necrosis factor (TNf-a). It is believed that this activation is not coupled to 
ras and the MAPK pathway.166
The SAPKs target the transcription factor c-jun and phosphorylate ser63 
and ser73 in the amino-terminal activation domain. SAPKs stimuli were shown 
to stimulate phosphorylation and activation of c-jun and the SAPKs are believed 
to be the main c-jun kinases (JNK).166
In summary, this JNK/SAPK pathway represents a distinct MAPK cell 
signalling pathway. Activated in response to stress stimuli the pathway targets
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proliferation.166-167 However, as yet not all of the upstream components of the 
cascade have been identified but of interest are the similarities found in yeast 
reported with the stress-activated HOG1 MAP kinase pathway.167
3.4 MAPK PATHWAYS AND CANCER
A great many genes have been implicated in the malignant 
transformation of cells leading to the development of cancer.20 A large number 
of these genes are oncogenes or cancer-causing genes as they are sometimes 
called. These oncogenes facilitate the aberration of normal cell behaviour by 
disturbing the regulatory systems central to the cell, e.g. the cell signalling 
pathways.20 More than 20 oncogenes have been identified and these arise 
from mutation, amplification or altered expression of normal genes called proto­
oncogenes found within the cell.19 The protein products encoded by the proto­
oncogenes are components of cell proliferation and differentiation processes 
such as growth factors, growth factor receptors, signal transduction machinery 
and transcription factors.20-168 Therefore, in theory aberration can occur 
potentially at many points along the pathway.
For the MAPK pathways oncogenic components identified include the 
protein products encoded by the ras, raf, jun and fos oncogenes.19 These 
transformed genes facilitate the malignant transformations of cells which 
employ the deregulated MAPK signalling pathways.
The G-protein ras is a key player in MAPK pathways especially the 
ras/ERK MAPK pathway. The ras oncogenes were discovered following lengthy 
research into the existence of dominant oncogenes in human tumours.169 The 
first such gene transfer assays were performed by Harvey170 and Kirsten171 on 
strains of rat sarcoma viruses. In human cancers ras oncogenes are the most 
prevalent family found and about 10% of the most common human cancers 
contain these transformed ras genes.172 The genetic transformation occurs via 
a single point mutation within the phosphate binding region, whereupon the 
mutant ras protein is locked in the activated GTP-bound state. Loss of G-protein 
control results in continued signal transduction and ultimately uncontrolled cell 
growth.172
A further oncogenic MAPK pathway component is mutated raf protein.173 
In normal raf the N-terminal domain of the protein functions to suppress kinase 
activity.174 Transformation of the gene involves the deletion of this domain,
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whereupon high levels of deregulated kinase activity are exhibited by the 
oncogene raf.173
This very brief outline, depicts the powerful role played by genetics in cell 
function regulated by enzymes such as MAPK. Identification of the components 
in such signal transduction pathways and the genes encoding these functional 
entities is the key to a thorough understanding of cell proliferation in normal and 
malignant states. Such a wealth of information is pivotal to the development of 
targets for anti cancer treatment.
3.5 MAPK INHIBITION
For the protein kinase superfamily the protein tyrosine kinases dominate 
the area of research devoted to inhibitors. During the past 5 years there has 
been a veritable explosion in this area with drastic improvements in the potency 
and specificity of protein tyrosine kinase inhibitors reported.175 However, the 
situation for protein serine/threonine kinase inhibitors is not quite as awe­
inspiring. While some members of this family such as protein kinase C (PKC) 
have been studied in depth with resultant potent and selective inhibitors 
reported,176-177 the MAP kinase family remains untouched with respect to 
successful inhibition of members of this enzyme group. Encouraging reports 
however have involved inhibition of other member of the MAPK pathway such 
as MEK, the upstream kinase activator of MAP kinase.177-178
At present progress in the area of cell signalling is so rapid that 
revelations regarding MAPK inhibitors must be imminent. With biological probes 
developing and understanding of cellular pathways improving, interest in this 
field of research continues apace.
3.6 MODEL FOR MAPK INHIBITORS IN THIS WORK
Very limited work has been carried out within the Robins research group 
in the area of MAPK inhibitors. However, a preliminary biological screen179 of a 
series of compounds prepared provided encouraging results with a lead 
compound identified possessing potential for further work in the development of 
novel MAP kinase inhibitors.
This compound 47 was modelled on serine 4 8, an amino acid 
phosphorylated on MAPK substrates by the enzyme's action. The structure is a
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conformationally restricted form of serine incorporating an electron rich benzene 
ring. Furthermore, it has been reported that such compounds exist in an 
iminolactone form 49 rather than the open form of 47180 and require careful 
handling due to the sensitive nature of these compounds.181’182
OH OH
OHMeO
MeO CN
NC CN
47
The research proposal to develop the lead compound 49 within this 
project involved preparation of three sets of compounds.
1 A series of iminolactones 50 derived from 49 would investigate ring 
substitution position.
2 A series of compounds fixed in the open form 51 might enhance the 
serine-like moiety within the structure further.
OMeNH
MeO-f- MeO
50 51 NC 52
R = CN, CONH
3 The iminolactones 50 would be employed as starting materials for the 
facile conversion into the corresponding lactones 52. These compounds 
are coumarins, a family of compounds known to possess a variety of 
interesting biological activities.183
On completing these synthetic targets, the three sets of compounds 
would be biologically evaluated for MAP kinase inhibitory potential. The 
synthesis and biological test results are discussed in Chapter 5.
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CHAPTER 4
SYNTHESIS AND BIOLOGICAL EVALUATION OF 
ANTIMELANOMA AGENTS
4.1 PHENOLIC THIOETHER TARGET COMPOUNDS
4.1.1 OXAZOLINES184
The century-old 2-oxazoline ring system185 53 has evolved well beyond 
its established origin as a masked carboxylic acid moiety and the stability of 
this heterocyclic compound is such that it remains resistant to most reagents 
with the exception of mineral and Lewis acids.186 Indeed, the 2-oxazolines 53 
provide synthetic precursors for various other heterocycles187 including 
oxazolidines 54 and oxazoles 55.
NH
54 55
The functionality of the 2-oxazoline and its derivatives enables these 
compounds to penetrate into diverse fields of interest from pharmaceuticals 
and agriculture to protective coatings and plasticizers.187 However, to the 
synthetic organic chemist the 2-oxazoline ring provides a system with potential 
for modifications at the 2-, 4- and 5-positions. With these levels of structural 
variety possible the resultant chiral and achiral 2-oxazolines possess a whole 
host of synthetic uses184<188 which include applications as protecting groups, 
analytical probes and monomers in polymerisation processes. This synthetic 
utility of 2-oxazolines extends to the preparation of conformationally 
constrained peptides which are of increasing importance to the medicinal 
chemist. Moreover, optically active oxazolines enjoy participation in asymmetric 
syntheses and play the role of recoverable ligands in asymmetric catalytic 
processes.184
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The variety of the structural modifications possible on the 2-oxazoline 
ring system is reflected in the wealth of synthetic routes reported alone for 
these compounds.184 However, as the 2-oxazolines involved in our work are a 
simple form featuring substitution at the 2-position only, the synthesis of these 
2-oxazolines is very straightforward. Therefore the synthesis of 2-oxazolines 
detailed in section 4.1.1.1 is not to be considered representative of the 
synthetic area as a whole.
4.1.1.1 Synthesis of oxazolines
The 2-oxazolines 56 were prepared in a single step catalytic 
procedure189 from ethanolamine 57 and the appropriate nitrile 58. Following 
fractional distillation of the solvent-free reaction mixture, the products were 
obtained in moderate yields (see scheme 5). This cadmium acetate-catalysed 
synthesis was found to be of particular use in our work with its application 
extended to the preparation of oxazines required for application in section 4.2. 
For the oxazine series (56, n=2) rather than ethanolamine, 3-amino-1-propanol 
was used which maintained the continued use of cheap, readily available 
materials. The structures of these known compounds 59 to 64 were confirmed 
by the spectroscopic data collected. This information together with the boiling 
points recorded were found to be in agreement with the findings reported in the 
literature.
Cd(OAc)2.2H20  (cat.) / (^ )n
R-CN + HO 2    Ov N
n 130 °C, 1.5 - 7 d I
58 57 29 -49% R 56
n R Product Yield
1 Et 59 34%
cycloC6Hu 60 42%
2 Me 61 49%
Et 62 43%
cycloC6Hu 63 37%
Ph 64 29%
Scheme 5
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A mechanism is proposed134 for this catalytic preparation of 2- 
oxazolines and oxazoles for a general case in scheme 6. Notice that although 
cadmium acetate was our catalyst of choice, soluble heavy-metal salts 
including zinc acetate and zinc chloride are also recommended.189
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4.1.1.2 Reactivity of 2-oxazolines
For our purposes the 2-oxazolines were employed as an electrophilic 
source poised for ring opening attack by selected nucleophilic sources. The 
chemical nature of this heterocyclic species is such that the 2- and 5-ring 
positions are potentially most susceptible to nucleophilic attack. Fazio 
confirmed this with spectroscopic investigations he performed on the neutral 59 
and cationic 65 forms of 2-ethyl-2-oxazoline.190 The oxazolinium cation formed 
by protonation in ring opening reactions was created in the study through Lewis 
acid coordination. In table 1 the 13q NMR values found for the two ethyl-2- 
oxazoline species can be seen. The deshielding of the 2- and 5-ring carbons is 
very clear and identifies the electrophilicity of these two positions. This
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therefore confirms the 2- and 5-ring oxazoline positions as the potential sites 
for attack by an incoming nucleophile.
H
1 1 
59 65
13C NMR Shift
Carbon 5 59 5 65 5 59 - 5 65
2 168.4 182.3 -13.9
4 55.0 45.7 +9.3
5 67.4 73.8 -6.4
6 21.5 21.2 +0.3
7 10.5 8.0 +2.5
Table 1
Consider the 2-oxazoline ring opening reaction presented in a 
generalised form below.
Nu
66
+ Nu-H
Nu
R Nu 54
Scheme 7
The oxazolidine 54 and carboxamide 66 are the products of opening the 
oxazoline ring at the 2- and 5-positions, respectively.190 The pathway taken, 
and therefore the product obtained, are controlled by the nucleophilic source 
involved. Later we illustrate this effect with the use of aryl thiols and primary 
aryl amine salts - two very different nucleophiles.
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4.1.2 SYNTHESIS OF THE PHENOLIC THIOETHER TARGET COMPOUNDS
The strategy behind our melanoma drug design together with the three 
programmes of research we proposed are outlined in section 2.9. The first of 
the three programmes of research involved the preparation of a series of 
phenolic thioether compounds which incorporated a tertiary amide into the alkyl 
side arm. However, before embarking on the synthesis of this first set of target 
compounds, the simple parent compounds 67 from which they originate had to 
be prepared. The parent compounds were to be included in the biological 
studies performed on the target compounds to provide base values for 
comparison purposes. In fact, one of these compounds, 35, is the lead drug in 
the antimelanoma field on which our compounds are modelled.
4.1.2.1 The Wehrmeister reaction
The Wehrmeister reaction191 was employed to prepare the two parent 
compounds 35 and 68 and this reaction is an example of the exclusive opening 
of the 2-oxazoline ring system at the 5-position (discussed in section 4.1.1.2). 
Under neat heating at reflux and catalytic conditions, p-hydroxybenzenethiol 69 
and 2-oxazoline 53 were combined to afford the carboxamide 67. Notice the 
nucleophilic supremacy demonstrated by the thiol over the phenol within the p- 
hydroxythiophenol reagent 69. The Wehrmeister reaction will play a pivotal role 
in the three step synthesis of the phenolic thioether target compounds in 
section 4.1.2.2.
OH OH120 °C
59 - 74%
SH
6769 53
Product YieldSubstrate
Me 74%
59%
70
60 cyc/oCeH-ii 68
Scheme 8
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The reaction was found to proceed smoothly with both products obtained 
in high yields. In the preparation of compound 68, the 2-cyclohexyl-2-oxazoline 
60 was provided by the cadmium acetate catalysed reaction189 presented in 
section 4.1.1.2 while commercially available oxazoline 70 was used to prepare 
compound 35. The sharp melting points and spectroscopic data of 35 and 68 
were in agreement with the literature findings for these known compounds.
4.1.2.2 Overall route to general phenolic thioether target compounds
The series of phenolic thioether compounds 42 were of a structurally 
similar nature which enabled the devising of one scheme for the preparation of 
all nine target compounds. In the three step synthesis, the first step provided 
the basic starting compounds 71 which would be transformed over the following 
two steps. Each step will be discussed in turn.
OMe OMe
r~ \ 
+ ° y N
R 50 - 75%
1  
R1 R
43 - 72%
N R
n : R
27-91%
130 °C, N2, 3d  
i. NaH; R1X, THF, 40 °C; 80 °C, 15 h - 4 d 
i. BBr3, DCM-78 °C;-78 °C ^  rt, 2 h - 3 d
R = Me, Ph, 
cycloC6Hu 
R1 = Me, Et, Bn
Scheme 9
4.1.2.2.1 Stepl: Oxazoline ring-opening
The first step was crucial to the synthesis as the products 71 incorporate 
the basic structural skeleton required for the final target compounds. The 
oxazoline ring-opening Wehrmeister reaction191 was employed with the
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nucleophilic source provided by 4-methoxybenezenethiol 72. As expected the 
reaction furnished the carboxamide product 71.
The reaction produced compounds 73, 74 and 75 in high yields, with 
sharp melting points and analytical purity. Spectral confirmation of the products' 
formation centred around the amide functionality with IR observations including 
characteristic absorption frequencies in the 1630-1645 cm""* region for the 
carbonyl bond and the NH stretching vibrations at ca. 3300 cm'"*. The "*^c 
NMR spectra supported these findings with the carbonyl carbon signal at ca. 6 
170. As expected the p-disubstituted benzene ring produced 1H NMR signals 
characteristic of an AA'BB' system at ca. 6 6.8 and 7.3. The corresponding 
signals on "*^C NMR spectra resonated at ca. 5 115 and 134.
4.1.2.2.2 Step 2: A/-Alkylation of secondary amides
The straightforward conversion192 of secondary amide 71 into the 
corresponding tertiary amide 77 was facilitated using sodium hydride and three 
alkylating sources; methyl iodide, ethyl bromide and benzyl bromide. As a 
result, nine products were obtained from the three starting compounds. 
Preparative attempts using isopropyl bromide as an alkylator proved to be 
unsuccessful even under forcing conditions. This result was attributed to the 
hindered nature of the secondary alkyl halide. On completion of the successful 
reactions the sodium halide side product was removed by filtration from the
Substrate R Product Yield
70 Me 73 75%
60 cycloCeHu  74 65%
76 Ph 75 50%
70 and 76 commercially available
Scheme 10
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reaction mixture and the solution worked-up in a standard manner192 to yield 
the crude amide. Following purification by column chromatography, the nine 
compounds were isolated as oils in a range of yields (mean value 60%) and the 
structures were confirmed by full spectroscopic characterisation. A discussion 
of the most pertinent features of these spectroscopic results will follow.
OMe
N R
i. NaH (1.8-2 eq.)
ii. R1X (3.5-4 eq.), 
THF, 40—>80 °C
27-91%
OMe
n : R
R Substrate R1X Product Yield
Me 73 Mel 78 91%
Me 73 EtBr 79 90%
Me 73 BnBr 80 52%
cyc/oCeH^ 74 Mel 81 81%
cycloC6\-\u 74 EtBr 82 27%
cyc/oCgH-i-, 74 BnBr 83 38%
Ph 75 Mel 84 68%
Ph 75 EtBr 85 52%
Ph 75 BnBr 86 41%
Scheme 11
NMR spectroscopy provided the data of greatest interest. However, the 
IR spectra are deserving of a mention as the successful conversion of 
secondary into tertiary amide was confirmed by the absence of any absorption 
frequencies for the amide NH bonds. The interest in the NMR spectra arose 
from the doubling of signals observed on both the 1H and 13C NMR spectra 
thus indicating that the tertiary amides exist in rotameric forms. Integration of 
peak heights on the 1h NMR spectra enabled the rotameric ratio for each 
compound to be established. A range of ratios for the minor:major rotamer 
signals from 1:1.2 to 1:1.5 for the nine compounds was calculated. The 1H and 
13C NMR spectra of compound 81 were chosen to exemplify this NMR 
phenomenon exhibited by the tertiary amide series (see diagrams 3 and 4).
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From the 1H NMR spectrum of compound 81 (diagram 3) a ratio of 1:1.2 
for the minor:major rotamers was established. The signals for the cyclohexyl 
moiety were evident in the upfield region 5 0.90 to 2.34. In particular the 
methine proton produced a pair of triplet of triplets at 8 2.00 and 2.34. Notice 
the coupling constant values of 11.6 and 3.3 Hz for each signal consistent with 
cis- and trans-vicinal coupling expected for such a six-membered saturated ring 
system. This NMR spectrum demonstrates pairing of signals with beautiful 
clarity such that even the pairs of rotameric signals for the AA'BB' system in the 
downfield region 8 6.76-7.33 show distinct separation. The 13c NMR spectrum 
(diagram 4) maintains this illustrative pleasure by exhibiting a paired signal for 
the deshielded carbonyl carbon at 8 176.4 and 176.5, a feature not preserved 
throughout the nine compound series.
The three phenyl compounds 84, 85 and 86 were found to produce 
broad pairs of signals in their 1H NMR spectra. This broadening of signals may 
be due to an electronic effect with perhaps conjugation of the phenyl ring with 
the amide causing the change in amide bond character.
4.1.2.2.3 Step 3: Methyl ether deprotection
The final step in the three step synthesis of the phenolic thioether target 
compounds 42 employed a boron tribromide-mediated reaction to deprotect the 
methyl phenyl ethers 77 (see scheme 12). Preliminary investigations into 
reagents for this synthetic transformation included the chlorotrimethyl 
silane/sodium iodide reagent193 and boron trichloride.194 The former proved 
rather disappointing with very poor yields obtained and although boron 
trichloride was a successful reagent its bromide counterpart proved to be the 
better boron-based Lewis acid for the ether cleavage.
51
OMe
i. BBr3 (1M, 4 eq.) 
DCM, -78 °C 
ii. -78 °C-> rt
43 - 72%
R R1 Substrate Product Yield
Me Me 78 87 77%
Me Et 79 88 60%
Me Bn 80 89 76%
cycloC6Hu Me 81 90 68%
cyc/oCeH-j-i Et 82 91 43%
cyc/oC6H-|-| Bn 83 92 53%
Ph Me 84 93 88%
Ph Et 85 94 53%
Ph Bn 86 95 72%
Scheme 12
For all nine compounds the low temperature (-78 °C) deprotection 
proceeded in a satisfactory manner. Following an ice/water-mediated quench of 
the reaction, standard work-up conditions194 were employed. Eight of the nine 
compounds required purification by column chromatography and all of the 
purified products were obtained in moderate to high yields with a mean value of 
66%. The phenolic compounds provided sharp melting points and were fully 
characterised.
The successful deprotection of most phenyl ethers is a transformation 
easily followed by spectroscopic analysis and this was found to be the case 
here with the phenol group providing the most important feature in the IR 
spectra. Characteristic OH absorption frequencies were found in the 3400-2500 
cm"1 region and at ca. 1270 cm-1 for the respective stretching and bending OH 
vibrational modes. Trade mark phenolic behaviour also prevailed in the UV 
spectra with the main absorption band common to all nine compounds found at 
ca. X 253 nm (e 6000-10120). This UV activity was in agreement with the 
findings reported by Lant134 for compounds containing the same chromophore.
NMR spectra produced the rotameric observations expected for these 
tertiary amides. The NMR of phenol 90 are included here (diagrams 5 and 6).
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These spectra provide another demonstration of very clearly paired 
signals. Consider the 1H NMR spectrum (diagram 5); the successful 
deprotection is quite apparent through the absence of the methyl ether signal at 
8 3.6-3.8 while the phenol produces a pair of broad singlets in the characteristic 
downfield region 8 7.8-9.1. However, it should be noted that such paired phenol 
signals are not a feature conserved throughout the series of nine target 
compounds. The 13C NMR spectrum (diagram 6) 90 was found to demonstrate 
the same evidence for the deprotection through the absence of the methyl 
ether signal at ca. 8 55. A continuation of this exploration into the NMR 
behaviour of these rotameric compounds found changes in the rotamer ratios 
occurred on deprotecting the phenol. For example, a 1.3 fold increase in the 
ratio of minor to major rotamers is found on deprotecting 81 to afford 90.
4.1.3 BIOLOGICAL EVALUATION OF PHENOLIC THIOETHER  
COMPOUNDS
4.1.3.1 In vitro 96 hour sulforhodamine growth inhibition assay
The first of two investigations into the biological activity of the phenolic 
thioether compounds was performed by Dr Lloyd Kelland of The Institute of 
Cancer Research, Surrey.195 In this in vitro evaluation the test compounds were 
incubated in a 96 hour sulforhodamine B (SRB) growth inhibition assay where 
the inhibitory activities of the compounds were assessed against six melanoma 
cell lines (B008, B0010, G361, HT144, SKMeL24 and SKMeL2) and an ovarian 
cancer cell line (SKOV-3) which acted as the non-melanoma control. The 
SKMeL24 is a specialised melanoma cell line which lacks the biochemical 
machinery required to convert the phenolic prodrugs into the corresponding 
ortho-quinones. This non melanotic cell line provides an indication of cytotoxicity 
produced by a mechanism of action independent of Tyrosinase. Since we 
designed our compounds to target Tyrosinase this specific cell line was an 
important feature of the assay. The cytotoxicity of the compound was assessed 
from the size of the GI50  value quoted for the assay. The GI50  value is the 
concentration of drug which causes 50% inhibition of cell growth. Ideally we 
required a test compound to demonstrate cytotoxicity and selectivity for 
melanoma cell lines containing Tyrosinase. To do so we wanted low GI50  
values for the five Tyrosinase-containing melanoma cell lines together with high 
values for the non melanotic and ovarian cancer cell lines.
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4.1.3.1.1 R esults
As we discussed eariier in section 4.1.2 the parent N-H compounds 35, 
68 and 96 were included in the assay to provide comparison results. The assay 
results for all the test compounds can be seen in the following three tables 
which house separately the results for the methyl, cyclohexyl and phenyl 
analogues prepared. Compound 96 was kindly supplied by Lant.134
HO 42
Table 2 GI50 values (pM) for compounds 42 (R = Me) in 96 h SRB assay
Cmpd R1 B008 B0010
Cell line 
G361 HT144 SKMeL2 SKMeL24 SKOV-3
35 H >100 >100 >100 >100 >100 >100 >100
87 Me 78 >100 >100 >100 >100 >100 >100
88 Et 33.5 >100 70 92 92 >100 >100
89 Bn 30 12 17
. . ■
>100 >100
Table 3 GI50 values (pM) for compounds 42 (R =
96 h SRB assay
cycloC6 H11) in
Cmpd R1 B008 B0010
Cell line 
G361 HT144 SKMeL2 SKMeL24 SKOV-3
68 H 29 >100 77 >100 61 >100 >100
90 Me 7.8 41 90 13.5 14.5 >100 51
91 Et5? 1 Ci 14.5 74 39 53 49 >100 >100
92 Bn 14 24.5 14 20 32 >100 53
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Table 4 GI50 values (pM) for compounds 42 (R = Ph) in 96 h SRB assay
Cmpd R1 B008 B0010 G361
Cell line 
HT144 SKMeL2 SKMeL24 SKOV-3
96 H >100 >100 >100 52 >100 >100 >100
93 Me 34 110* 69 93 105* >100 >100
94 Et 24 85 43 63 73 v '-V 0 0 >100
95 Bn 16 34 15.5 30 37 >100 56.5
* Obtained by extrapolation 
j§ results of particular interest
4.1.3.1.2 General observations
In general most of the compounds exhibited improved cytotoxicity over 
the lead compound 35. Attention must be drawn to compounds 89, 91 and 94, 
three potentially exciting new compounds. In particular the /V-benzylmethyl 
analogue 89 exhibited better selectivity and cytotoxicity than our group has seen 
before. This compound produced low GI50 values against the melanotic cell 
lines and this together with a high GI50 value for the SKMeL24 cell line 
demonstrated the good selectivity possessed by compound 89 for the 
Tyrosinase-containing cell lines. This significant improvement in cytotoxicity and 
selectivity was facilitated by the simple action of converting the parent drug 35 
into the corresponding A/-benzyl compound 89. Compounds 91 and 94 also 
demonstrated similiar selectivity but the cytotoxicity levels were not as high. 
Selectivity problems were found with cyclohexyl compounds 90 and 92 as well 
as phenyl compound 95. Because these three compounds showed low GI50 
values against the SKOV-3 cell line as well as the melanotic ones, selectivity 
appeared to be lower.
4.1.3.1.3 Conclusions
The lead compound 89 from this assay cannot be disputed. It exhibited 
good levels of cytotoxicity and some desirable selectivity. This level of biological 
activity was followed by 91 and 94 but with less potency.
In general A/-alkylation of the simple parent compounds was found to 
improve cytotoxicity greatly and in most cases selectivity for the melanoma cell 
lines. This improved cytotoxicity could be attributed to the lipophilic character of 
the test compounds. These tertiary amides would be expected to be more
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lipophilic than the corresponding secondary amides and as such the lipophilicity 
may increase drug absorption and therefore distribution in the tissues. 
However, lipophilicity alone cannot be used to explain the improvement in both 
cytotoxicity and selectivity observed because these attributes were not common 
to all the tertiary amide compounds tested. It would appear that some sort of 
balance is required between the size of the two substituents (R and R1) in the 
compounds found to produce the desirable antimelanoma activity in vitro. 
Consider the lead compound 89, an A/-benzylmethyl derivative. Selectivity was 
lost when the other A/-benzyl compounds 92 and 95 were created. Could this 
reduced selectivity be attributed to too much steric bulk offsetting the proposed 
delicate balance between the size of the two substituents required for the 
success found with compound 89. In addition it was found on replacing the N- 
benzyl group in compound 89 with A/-ethyl that an overall loss in cytotoxicity and 
selectivity occurred. Therefore we would propose that the suggested balance 
between the two substituents could have been disturbed again but this time as a 
result of too little steric bulk.
4.1.3.2 In vitro mushroom Tyrosinase spectrophotomeric assay
To widen the biological evaluation of our potential antimelanoma 
compounds a spectrophotomeric enzyme assay196 was employed to investigate 
the relative substrate activity of these compounds for the enzyme Tyrosinase. 
The assay was performed by Miss Isabel Freer of the Tissue Culture Unit, 
University of Glasgow. As Tyrosinase of mammalian origin was not available to 
us, commercially available mushroom Tyrosinase was used instead. Like 
mammalian Tyrosinase, the mushroom enzyme is a copper-containing aerobic 
oxidase which catalyses the conversion of L-Tyrosine into dopaquinone.197 
However it must be remembered that any observations made and conclusions 
that may be drawn from the assay are to be used only as a guide to how the test 
compounds might behave with mammalian Tyrosinase. Nonetheless, we hoped 
the results would compliment the in vitro SRB inhibition assay results (section 
4.1.3.1).
The mushroom Tyrosinase assay used UV spectroscopy at wavelength 
280 nm to follow the production of ortho -quinone from the phenolic test 
compound. The spectrophotomeric assay measurements enabled us to 
determine the relative substrate activity of the test compound by comparing the 
relative activity of the unnatural substrate when it replaced the natural substrate 
in the assay at the same concentration. Obviously L-tyrosine, the natural
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substrate of Tyrosinase, would produce a value of 100% relative substrate 
activity. The assay results can be seen in table 5.
4.1.3.2.1 Results and discussion
HO 42
Table 5 Relative substrate activities (%) of compound 42 
for mushroom Tyrosinase
P|1
H Me Et Bn
R = Me Compound 35 87 88 89
% Relative substrate activity 4.5 7.9 17.5 20.7
R = cyclohexyl Compound 68 90 91 92
% Relative substrate activity 37.8 7.1 16.8 0
R = Ph Compound 96 93 94 95
% Relative substrate activity 6.4 17.8 28.3 0
•£. results of particular interest
From the results the best substrate appears to be 68 and this compound 
had showed modest cytotoxity against some cell lines in the SRB inhibitory 
assay. The A/-ethyl compounds 88, 91 and 94 were the next best substrates in 
the assay. However, 93 and 89 were also found to produce values in this range. 
These Tyrosinase assay results can be used as an indication that the 
compounds are substrates for Tyrosinase and may exhibit their cytotoxicity by 
Tyrosinase-mediated oxidation. Surprising results were found for the AFbenzyl 
compounds 92 and 95 with 0% relative substrate activities recorded in the 
assay, an indication that these compounds may be poor substrates for the 
enzyme.
4.1.3.3 Correlation of assay results
The results appeared to compliment the in vitro assay observations. As 
was already discussed (section 4.1.3.1) the most successful candidate from the 
in vitro assay was compound 89 followed by 91 and 94. These compounds
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showed good cytotoxicity and selectivity for Tyrosinase-containing cell lines. 
The Tyrosinase assay results complimented these findings with 89, 91 and 94 
being among the test compounds which showed good values for relative 
substrate activity, an indication of their potential as Tyrosinase substrates. The 
inhibitory assay findings had also revealed 90, 92 and 95 to be cytotoxic but 
what is more important is that they lacked selectivity. Perhaps this lack of 
selectivity can be explained by the Tyrosinase assay results which found both 
92 and 95 as poor potential substrates for the enzyme with zero values for 
relative substrate activity recorded.
4.1.3.3.1 Conclusions on biological test results
Armed with the results of the two assays we propose that compounds 89, 
91 and 94 are cytotoxic and selective for the Tyrosinase-containing melanoma 
cell lines and that the cytotoxicity might be the result of Tyrosinase-mediated 
oxidation of those phenolic test compounds. Furthermore we propose that the 
lack of selectivity exhibited by compounds 90, 92 and 95 could be the result of 
cytotoxicity produced from a non-Tyrosinase mediated mechanism of action.
4.2 AMIDINE SALTS TARGET COMPOUNDS
The second programme of research we proposed for the antimelanoma 
field involved the preparation of a series of amidine salts. This would introduce 
a novel structural feature to the phenolic thioether-based compounds already 
prepared. As outlined in section 2.9.5, we anticipated that the amidine moiety 
might confer some hydrophilic character to these compounds, an effect which 
we hoped would be beneficial in the biological assay results. Moreover, in 
preparing these compounds the ring opening of 2-oxazolines and oxazines by 
aryl amine salts would be investigated, a reaction very much dependent on the 
nucleophilic reagent employed (see section 4.1.1.2).
4.2.1 AMINES AND 2-OXAZOLINE RING-OPENING REACTIONS
In sections 4.1.2.1 and 4.1.2.2 we illustrated the reaction between aryl 
thiols and 2-oxazolines, which is an exclusive ring opening reaction at the 
oxazoline 5-position. However, on substituting the aryl thiol with an amine or 
amine salt far less clear-cut results are obtained.
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Fazio190 identified carboxamide products from the reaction between 2- 
oxazolines and a selection of secondary aliphatic and aromatic amines. 
Although primary aromatic amines provided a mixture of products, these too 
were afforded from oxazoline ring opening at the 5-position.190 On the other 
hand, Magosch198 found that 1,2- and 1,3-alkylene diamines provided 
oxazolidine products characteristic of 2-position attack on oxazolines. These 
findings were also mirrored by Fazio using other primary alkyl amines.190 
However the reaction pathway taken changed on introducing an oxazoline 
substituted at the 2-position with the bulky tertiary butyl group. As a 
consequence ring opening at the 5-position was forced to occur and the 
carboxamide product was obtained.190
Our work followed the investigations of Kormendy et a/199 into the 
reaction of aryl amine salts 97 and 2-position opening of oxazoline ring systems 
76 (see scheme 13). In this amine addition reaction the oxazolidine 98 can 
afford the corresponding amidine 99. However, purely on the premise of IR 
data Kormendy et a/199 concluded that they had isolated the oxazolidine 98. On 
the basis of investigative work performed by Lant134 it would appear Kormendy 
et al had misassigned the product and so we employed the reported 
experimental protocol to prepare a series of amidine salts from aryl amine salts 
and a selection of 2-oxazolines and oxazines.
N-~. ©N--.
Ph—<( J + Ph-NH2.HCI ----- -  Ph—< J  + Ph-NH2
O c r
76 97
H2 H H
   ©N--.  - N-~  -  r,u^Nw N ^ ^ ^ , ,
P h Y  Ph—1(, ^  Ph Y  OH
h T c t  HNO  qQ Ph
Ph Ph 98 "
Scheme 13
4.2.2 SYNTHESIS OF AMIDINE SALTS
The synthesis of the amidine salt target compounds 4 3 was a 
straightforward, single step procedure performed at room temperature (scheme 
14). The experimental conditions employed to couple the 4-aminophenol 
hydrochloride 100 to a series of 2-oxazoline and oxazines 56 were those
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reported by Kormendy et a/.199 The oxazine reagents (56, n=2) were 
introduced to extend the alkyl side chain length by one carbon in the product. 
The synthesis of these compounds and the 2-oxazolines is detailed in section
4.1.1.1 using a cadmium acetate catalysed procedure189 to combine the 
appropriate nitrile and aminoalcohol under neat reflux conditions. The alkyl 
groups in the phenolic thioether series were also introduced into the amidine 
series through the use of oxazolines and oxazines substituted with these alkyl 
groups.
NHo.HCI
BOH, rt, H @ H
1.5-3 d ^  rN"
c , 0
63 - 77% HO
43
n R Substrate Product Yield
1 Me 70 101 77%
1 Et 59 102 69%
2 Me 61 103 63%
2 Et 62 104 68%
Scheme 14
In this series only the amidine salts prepared from the methyl and ethyl 
substituted ring systems were isolated. The four products (101 to 104) were 
easily isolated from the reaction mixture through dropwise addition of chilled 
diethyl ether. The filtered products were recrystallised affording the purified 
products in high yields (mean value of 70%) with sharp melting points. 
Combustion data confirmed the molecular formulae for the hydrochloride salts 
with elemental analyses recorded within 0.1% of the theoretical values. 
Meanwhile EIMS for the four compounds confirmed the molecular ion for the 
free base and a common base peak (m/z 109) was identified as the p- 
hydroxyanilinium fragment ion.
However, following numerous attempts the preparation of the amidine 
salts containing cyclohexyl and phenyl moieties proved to be unsuccessful. 
These findings were attributed to attack at the 2-position of the oxazoline being 
blocked by the bulk of the substituent positioned there. This is analogous to
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Fazio's report190 on the reaction of primary alkyl amines and 2-oxazolines 
which suffered from a similar handicap from bulk preventing attack at the 
oxazoline's 2-position (see section 4.2.1). Nevertheless, the four target 
compounds isolated provided interesting NMR observations which indicated 
that the amidine salt was present as geometric isomers.
Ar CHoCHoOH
Me Me 106105
Ar" Ar"
Me Me
108107
In theory four geometric isomers of the amidine salt are possible. 
Consider the example shown for amidine 101. Using simple molecular 
modelling the more thermodynamically favourable conformation for the 
geometric isomers can be visualised. In the conformation where the aromatic 
and amidine moieties are arranged coplanar, the steric interference would be 
greatest for 105 and 106 and therefore we propose that the product is 
composed of geometric isomers 107 and 108.
On the 1 H and 13c NMR spectra, pairs of peaks were observed for the 
two isomeric product forms and the NMR spectra of the simplest amidine salt 
101 are included (diagrams 7 and 8).
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Integrating the peak heights of the signals on the 1H NMR spectrum 
(diagram 7) revealed the two geometric isomers to be present in a 1:1 ratio. In 
fact this was found to be the case for all four compounds prepared. The 1H 
NMR spectra is simplified by the absence of OH and NH signals which the 
NMR solvent D2 O exchanged (HOD peak is very obvious at 5 4.69). The 
methyl group can be clearly seen as a pair of sharp singlets at 5 1.96 and 2.29. 
The two methylene groups were observed as two pairs of triplets in the 5 3.2- 
3.8 region with vicinal coupling behaviour exhibited by the protons in each of 
the two groups. The 13c NMR spectrum (diagram 8) was also beautifully clear 
with all the isomeric pairs of signals readily identified. The pair of signals for the 
methylene carbon alpha to the hydroxyl group resonated downfield at 5 58.9 
and 60.1 and can be compared to the paired signals for the less deshielded 
methylene carbon alpha to the amidine moiety which was found to resonate at 
5 44.7 and 46.0.
The IR spectra yielded evidence for the more prominent features of the 
amidine salts with strong absorption bands at ca. 1650 cm"1 observed for the 
C=N stretching vibration and characteristic NH stretching bands in the 3200- 
2800 cm-1 region. The phenolic OH absorption bands for bending vibrations 
were sharp at ca. 1270 cm-1 while the stretching vibration found some overlap 
with the NH absorption bands in the ca. 3400 cm-1 region.
These phenolic compounds were anticipated to possess UV activity and 
all four compounds recorded main absorption bands at ca. X 224 nm (e 16700- 
9600). The p-substitution of the phenol with an amidine group appears to have 
extended the conjugation of the phenol chromophore and therefore the amidine 
moiety is considered to be behaving as a complementary auxochrome. The UV 
activity of the amidine salts can be compared to phenol (^max 211 nm, e 
6200200) which demonstrates this observed UV behaviour.
4.2.3 BIOLOGICAL EVALUATION OF AMIDINE SALTS
4.2.3.1 Results and discussion
The amidine salts were evaluated biologically using the same 96 hour 
sulforhodamine (SRB) inhibitory assay used to investigate the activity of the 
phenolic thioether compounds in section 4.1.3.1. The results from this in vitro 
assessment of the cytotoxicity and selectivity of test compounds 43 are shown 
in tables 6 and 7.
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Table 6 GI50 values (jaM) for compounds 43 (n = 1) in 96 h SRB assay
Cmpd R B008 B0010 G361
Cell line 
HT144 SKMeL2 SKMeL24 SKOV-3
101 Me 28 45 51 42 60 110* >100
102 Et 15.5 32.5 43 22 58 >100 >100
* Obtained by extrapolation m results of particular interest
Table 7 GI50 values (pM) for compounds 43 (n = 2) in 96 h SRB assay
Cell line
Cmpd R B008 B0010 G361 HT144 SKMeL2 SKMeL24 SKOV-3
103 Me >100 >100 >100 >100 >100 >100 >100
104 Et >100 66 >100 78 >100 >100 >100
From the test results it would appear that the two carbon chain feature in 
the amidine salts (table 6) improves the inhibitory activity of these test 
compounds. In particular the ethyl analogue 102 proved to be the most potent 
and selective for the Tyrosinase-containing cell lines. Although the 
corresponding methyl compound 101 was found to be inhibitory, the modest 
level of toxicity it showed against the non melanotic SKMeL24 cell line does 
question the selectivity of the compound. Compounds 103 and 104 which 
contain a three carbon chain (table 7) did not demonstrate any notable activity 
against the panel of cell lines used in the study. Nevertheless, all four amidine 
salts were further investigated by their inclusion in the mushroom Tyrosinase 
assay detailed in section 4.1.3.2. The results from this study into the 
compounds' potential as Tyrosinase substrates are shown in table 8.
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Table 8 Relative substrate activities (%) of compounds 43 
for mushroom Tyrosinase
R
Me Et
n = 1 Compound 101 102
% Relative substrate activity 0.1 0
n = 2 Compound 103 104
% Relative substrate activity 0 1.3
The trend previously observed for the phenolic thioether compounds 
between the cell line testing and enzymatic assay results was not detected for 
the amidine salts. Extremely low values of less than 1% for relative substrate 
activity were found for all the amidines including the two compounds 101 and 
102 that had shown inhibitory activity in the cell line tests. The results shown in 
table 8 indicate that the amidine test compounds are poor substrates for 
Tyrosinase.
4.2.3.2 Conclusions
We can conclude that while the in vitro cell tests indicated that the 
amidine 102 is cytotoxic and selective towards cell lines containing Tyrosinase, 
the enzyme assay indicated that the cytotoxic nature of the compound is the 
effect of a non-Tyrosinase mediated mechanism of action. Perhaps then these 
results reflect the hydrophilic character of the amidine salts, an indication that 
these compounds may not be absorbed as readily into the tissues and as such 
are unable to exert their antimelanoma activity. Furthermore we believe that the 
amidine salts may be structurally too dissimilar from the original lead compound.
4.3 TYRPHOSTIN TARGET COMPOUND SERIES
4.3.1 THE KNOEVENAGEL CONDENSATION REACTION22
The Knoevenagel condensation is a fundamental carbon-carbon bond 
forming reaction regularly used by synthetic chemists. Early investigations into 
this type of reaction by Knoevenagel in 1894202 were followed two years later 
with the reaction shown in scheme 15.203 This piperidine-catalysed production 
of the benzylidene-1,3-dicarbonyl 109 from benzaldehyde 110 and ethyl 
acetoacetate 111 remains a good illustration of the traditional Knoevenagel 
condensation.
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Piperidine (cat.) Piv COMePhCHO + MeOC C 02Et
o ° c C 02Et
110 111 109
Scheme 15
The limited reactivity of ketones in the reaction restricts the source of 
carbonyl compounds to aldehydes.201 However the range of aldehydes in 
existence is far from restricted. Similarly, a large range of active methylene 
compounds are available with the presence of two electron withdrawing 
moieties flanking the methylene group being the only structural requisite.201 
This great variety in the two reactant sources therefore creates a potentially 
abundant supply of Knoevenagel products, many of which assume the role of 
crucial intermediates in synthetic transformations.
The homogeneous conditions of this condensation reaction most 
commonly employ as a catalyst a weak base such as an amine or ammonium 
salt or Lewis acids such as ZnCl2204 and TiCl4 /base.205 However, more 
recently the nature of the Knoevenagel catalyst has been changing, a timely 
reminder of the economic and environmental pressures to which modern 
synthetic chemists must respond. The desire for high yielding reactions under 
milder conditions with no side products has prompted the application of 
heterogeneous catalysis to the Knoevenagel reaction. Through the use of 
inorganic solid supports low cost, recyclable catalytic sources are available with 
some recent examples including rare-earth exchanged NaY zeolite206 and 
caesium/sodium cation-exchanged mesoporous MCM-41.207 As well as the 
use of these synthetic zeolites, aluminium oxide208 and xonotlite or xonotlite 
doped with potassium tert-butoxide209 are also established heterogeneous 
catalytic sources while the inorganic solid potassium fluoride210 is an 
alternative base. These heterogeneous catalysts are useful to enable industrial 
application of the reaction.
4.3.1.1 Mechanism for Knoevenagel reaction
Two mechanistic pathways are proposed for the Knoevenagel reaction 
and it is the base employed which decides the mechanism to be taken. The 
Knoevenagel mechanism211 proposed by the reaction's founder occurs under 
the more traditional conditions when a primary or secondary amine 112 is
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employed. Knoevenagel proposed the formation first of an imine 113 which on 
reacting with the active methylene compound 114 affords an intermediate 115. 
Following elimination on 115, the desired alkene product 116 is obtained. In the 
presence of a tertiary amine the Hann-Lapworth mechanism212 is proposed. 
This is a shorter mechanism and assumes the formation of p-hydroxy 
compound 117 directly from the two reactants 114 and 110 followed by 
dehydration to yield the Knoevenagel product 116 as before.
Knoevenagel mechanism
PhCHO Pl\  © H2NOC NR2
   > = n r 2 --------------- >— \
+ HNR2 H .  NC Ph
112 113 NC CONH2 115
114
h 2n o q
NC Ph 
116
Hann-Lapworth mechanism
PhCHO n o  H2NOC ^OH H2NOq
+ .  NC Ph NC Ph
NC CONH2 117 116
114
Scheme 16
Scheme 16 details the Knoevenagel product of benzaldehyde 110 and 
2-cyanoacetamide 114. As depicted here and in accordance with the literature 
findings consistently reported for such a reaction, the geometric isomer formed 
is assumed to be in the E-form. This is the less sterically hindered and more 
thermodynamically stable form.
4.3.2 SYNTHESIS OF TYRPHOSTIN TARGET COMPOUNDS
The third and final programme of research we proposed for the 
antimelanoma area in section 2.9.5 involved the preparation of a tyrphostin 
series 44. In a manner similar to the amidine series we would move away from 
the phenolic thioether structure common to the previous antimelanoma
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compounds. Although the third compound series 44 would maintain the 
phenolic character we planned to introduce a p-substituent with alkene 
character. In fact these tyrphostins compounds 44 are the Knoevenagel 
products of phenolic benzaldehydes and malononitrile derivatives.
44 118
X = H, OH, OMe 
R = CN, C 02Et, CONH2, 
C(NH2)=C(CN)2
The tyrphostins 44 were included in the target antimelanoma compounds 
as they had already been found to possess antiproliferative activity.136-213 
Gazit made this discovery in compounds which incorporated the benzylidene 
malononitrile (BMN) nucleus 118. He coined the name "tyrphostin" for these 
compounds, a name which describes many compounds even those which 
devia te  from  the BMN structu re . M oreover, it was the 
hydroxybenzylidenemalononitriles which were found to possess the most 
distinctive activity.213 Therefore, we planned to investigate whether our 
tyrphostin series 44 would exhibit selectivity for melanoma by behaving as 
unnatural substrates for the target enzyme Tyrosinase.
4.3.2.1 Synthesis results
The tyrphostins 44 were prepared under traditional Knoevenagel 
conditions of homogeneity with piperidine providing the catalytic source (see 
Scheme 17).213 Piperidine is one of the more popular bases employed for a 
simple Knoevenagel transformation.201 Three groups of tyrphostins were 
prepared, each derived from the aldehyde 119 employed with four malononitrile 
derived compounds 120 providing the active methylene reactants. In total 
twelve target compounds 121 to 132 were prepared. Notably, the reactions with 
p-hydroxybenzaldehyde and vanillin favoured room temperature reaction 
conditions whereas for the preparation of the catechol compounds reflux 
conditions were preferred (scheme 17). Following completion of the reaction, 
product precipitation was achieved (only if required) by the addition of water to 
the cooled ethanolic reaction mixture.
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r ^ r
.CHO r  Piperidine (cat.), x  
^ f  EtOH, rt or reflux W R
HO"
119
X
CN
120
R
19 - 94% 
Product
H O ^ ^
44
Conditions Yield
H CN 121 rt 81%
H C 02Et 122 rt 58%
H c o n h 2 123 rt 61%
H C(NH2)=C(CN)2 124 rt 19%
OH CN 125 reflux 59%
OH C 02Et 126 reflux 43%
OH c o n h 2 127 reflux 30%
OH C(NH2)=C(CN)2 128 reflux 25%
OMe CN 129 rt 81%
OMe C 02Et 130 rt 94%
OMe c o n h 2 131 rt 64%
OMe C(NH2)=C(CN)2 132
Scheme 17
rt 29%
The recrystallised products were brightly coloured compounds with sharp 
melting points. The three malononitrile dimer reaction products 124, 128 and 
132 recorded the lowest yields of the series at less than 30%. However, the 
remaining products were obtained in moderate to high yields with a mean yield 
of 64%.
The eight compounds from the phenol and catechol tyrphostin series 121 
to 128 were known compounds and their melting points and spectroscopic data 
were in agreement with those reported in the literature. On the other hand, the 
vanillin-derived series 129 to 132 required full characterisation which confirmed 
their structures. The prominent nitrile, alkene and phenol features of these 
compounds were easily identified by IR spectroscopy. The series of bands in 
the 1500-1600 cm""* region were characteristic of the alkene moieties while the 
strong nitrile and phenol stretching frequencies could be observed at ca. 2200 
cm""* and ca. 3400 cm""*, respectively. The NMR spectra for the four 
compounds were straightforward with successful reactions confirmed on "*H 
NMR spectra by the absence of the vanillin aldehyde proton at ca. 5 10 and the 
appearance of the alkene proton singlet at ca. 6 8.2. Similarly on "*3c NMR
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spectra the nitrile group common to all four compounds afforded a signal at ca. 
§117. However, it was the UV spectra for these highly conjugated compounds 
which produced the results of greatest interest. The alkene moiety creates an 
electronic compliment for the phenol within these tyrphostins. This delocalised, 
electron-withdrawing group behaves as an auxochrome by creating a shift in 
the absorption maximum of the phenol chromophore from Vnax 211 nm200 to 
ca. Vnax 365 nm 'n tar9et compounds. This red shift towards longer 
wavelength is also visually observed by the bright colouring characteristic of the 
compounds.
4.3.3 BIOLOGICAL EVALUATION OF TYRPHOSTINS
4.3.3.1 Results and discussion
The tyrphostins were biologically evaluated in the same way as the 
phenolic thioether compounds and amidine salts. The results from the in vitro 
SRB inhibitory cell line testing of the tyrphostins are shown in tables 9, 10 and 
11 .
CN
HO
44
Table 9 GI50 values (pM) for compounds 44 (X = H) in 96 h SRB assay
Cmpd R B008 B0010 G361
Cell line 
HT144 SKMeL2 SKMeL24 SKOV-3
121 CN 47 27.5 33 38 49 >100 71
122 C02Et 59 45 54 54 54 >100 95
123 CONH2 81 26.5 53 53 50 >100 >100
124 dimer >100 >100 >100 >100 >100 >100 >100
results of interest 
dimer = C(NH2)=C(CN)2
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Table 10 GI50 values (juM) for compounds 44 (X = OH) in 96 h SRB assay
Cmpd R B008 B0010 G361
Cell line 
HT144 SKMeL2 SKMeL24 SKOV-3
125 CN 43.5 20 20.5 30 53 >100 >100
126 C02Et >100 >100 88 100 >100 >100 >100
127 CONH2 >100 >100 >100 >100 >100 >100 >100
128 dimer 41 23 21 29 56 >100 >100
j  results of interest 
dimer = C(NH2)=C(CN)2
Table 11 GI50 values (pM) for compounds 44 (X = OMe) in 96 h SRB assay
Cmpd R B008 B0010 G361
Cell line 
HT144 SKMeL2 SKMeL24 SKOV-3
129 CN >100 82 85 82 >100 >100 >100
130 C 02Et >100 >100 >100 >100 >100 >100 >100
131 CONH2 >100 >100 >100 >100 >100 >100 >100
132 dimer >100 >100 >100 >100 >100 >100 >100
dimer = C(NH2)=C(CN)2
Overall no real patterns of inhibitory activity were found for the 
tyrphostins with only compounds 123, 125 and 128 found to exhibit modest 
cytotoxic and selective behaviour towards the Tyrosinase cell lines. Compounds 
121 and 122 were found to be moderately potent but with less selectivity as 
cytotoxicity was shown against the SKOV-3 ovarian cancer cell line. 
Furthermore very low levels of cytotoxicity were demonstrated against most cell 
lines by the four tyrphostins derived from vanillin, 129 to 132 (table 11). Despite 
these generally disappointing results, to complete the biological evaluation 
process all the tyrphostins were included in the mushroom Tyrosinase 
enzymatic assay. The results from the Tyrosinase assay are shown in table 12.
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Table 12 Relative substrate activities (%) of compounds 44 
for mushroom Tyrosinase
Ft
CN CONH2 C02Et dimer
X = H Compound 
% Relative substrate activity
121
6.1
122
0
123
2.0
124
0.3
X = OH Compound 
% Relative substrate activity
125
5.0
126
14.1
127
6.0
128
12.1
X = OMe Compound 
% Relative substrate activity
129
2.5
130
1.4
131
1.1
132
0
Of the three compounds, 123, 125 and 128, which demonstrated 
moderate inhibitory activity in the cell line tests, only compound 128 produced a 
significant result in the Tyrosinase assay. This was only a modest value for 
relative substrate activity and suggests there would be some Tyrosinase- 
mediated cytotoxicity by the compound. All of the other tyrphostins apart from 
126 exhibited low values for relative substrate activity.
4.3.3.2 Conclusions
When considering compounds for their potential antimelanoma activity 
the tyrphostins would not be a good choice. Perhaps the mushroom Tyrosinase 
assay provided the most useful information regarding the biological activity of 
these compounds. Indeed the cytotoxicity exhibited by these compounds could 
be attributed to a non-Tyrosinase mediated mechanism of action. The results 
from the biological evaluation of the tyrphostins would also appear to confirm 
the findings from the amidines' test results which led us to propose that moving 
too far away from the structure of the phenolic thioether parent compound 35 
appeared to reduce the biological characteristics required for specific 
antimelanoma activity.
4.4 RECENT DEVELOPMENTS
Following their early discoveries into the antimelanoma potency of 35,127 
Jimbow and co-workers recently proposed to manipulate the lipophilic character 
of the drug in an attempt to improve its activity.214 This compound change was 
achieved by preparing the propionyl derivative of the lead compound. In recent
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studies this new phenolic thioether compound 133 was found to produce very 
interesting in vitro and in vivo results.214-215
OH
R = Me 35 
Pr 133
From the in vitro studies compound 133 was found to be both a better 
substrate for Tyrosinase215 and more melanocytotoxic than 35.214 
Furthermore, the in vivo investigations revealed that the new compound 
significantly inhibits melanoma tumour growth and increases the life span of the 
melanoma-bearing study group of C57 black mice.214 in vivo 
melanocytotoxicity of the drug was confirmed by its depigmentation of mice hair 
follicles with potency comparable to 35 214 These in vivo findings established 
133 as a new phenolic thioether lead compound for melanogenesis-based 
antimelanoma agents.
These recent findings by Jimbow and co-workers were quite surprising to 
us as Lant prepared this propionyl derivative 133 during his research 
programme of work and following the inclusion of 133 in an in vitro SRB 
inhibition growth study (see table 13) this compound was not considered to 
possess significant antimelanoma activity.
Table 13 GI50 values (pM) for compound 133 in 96 h SRB assay
Cell line
B008
82
B0010
>100
G361
>100
HT144
>100
SKMeL2
>100
SKMeL24
>100
SKOV-3
>100
The results from the assay shown in table 13 indicate that compound 
133 exhibits only modest levels of cytotoxicity and selectivity.
4.5 CONCLUSIONS AND FUTURE PLANS
The biological evaluation of the target compounds prepared enabled us 
to assess their potential as antimelanoma agents. The most obvious conclusion
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must be that the phenolic thioether compound series afforded the candidates 
with the most potential. However, both the tyrphostin and amidine salt series 
did produce a range of cytotoxicty values with some selectivity observed. 
Indications of their non-Tyrosinase mediated cytotoxicty were not too surprising 
and accordingly we proposed that the structures of these two series may be too 
far removed from the parent compound 35 to enable them to exhibit specific 
antimelanoma activity. Furthermore, we believed the lipophilicity of the tertiary 
amide compounds together with a certain combination of alkyl groups may 
contribute to the activity exhibited by many members of that series.
The phenolic thioether compounds proved particularly successful in the 
in vitro studies with levels of potency and selectivity for melanotic cell lines 
observed. We believe that the more attractive candidates from the series merit 
further biological evaluation. Hence we suggest that the collaboration with 
Professor Rona MacKie, Department of Dermatology216 should be re­
established. This collaboration previously provided an in vivo evaluation of a 
selection of compounds prepared by Lant.134 Moreover in vivo assessment of 
the melanocytotoxicity and antimelanoma activity of these compounds is 
imperative to complete their biological evaluation and should be carried out with 
compounds 89, 91 and 94.
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CHAPTER 5
SYNTHESIS AND BIOLOGICAL EVALUATION OF 
MAP KINASE INHIBITORS
5.1 BACKGROUND
The inhibition of MAP kinases in cell signalling pathways is the second 
area of cancer research which our studies embrace. In Chapter 3 this area was 
discussed in some detail together with the proposed research work (section 
3.6). There we introduced the lead compound 49. This 2-iminolactone or 2- 
iminochromene derivative as it is also known, provided a model for our 
synthetic investigations into compounds with MAP kinase inhibitory potential.
NH
MeO CN
49
5.2 2-IMINOLACTONE TARGET COMPOUNDS
5.2.1 2-IMINOLACTONE RING SYSTEM
The 2-iminolactone ring system enjoys positions of importance in both 
biological and chemical fields. Originally used in the design of conformationally 
constrained mimics of active compounds such as 134, the bicyclic iminolactone 
compounds 135 and many of their derivatives are now established as a source 
of biologically active compounds in their own right.217-218 Behaviour which they 
exhibit includes significant antitumour activity.218
CN
135134
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Furthermore, the functionality of these 2-iminolactone compounds 
enables them to provide the structural base for the synthesis of polycyclic 
com pounds such as substitu ted  benzopyranopyrid ines  and 
benzopyranopyridopyrimidines.219
5.2.2 STRUCTURE ELUCIDATION OF 2-IMINOLACTONES
Schiemenz implemented infrared-based product characterisation to 
formulate 2-iminolactones 136 and 137 correctly as the products obtained from 
the Knoevenagel condensation of salicylaldehyde 138 and malononitrile 
derivative 120 (scheme 18).180 Previously the products were assigned the 
isomeric open chain structure 139 and 140, which is the traditional type of 
Knoevenagel product.182 IR spectroscopy was crucial to confirming the 
misassignment of the products 136 and 137. In particular the characteristic 
nitrile stretch at ca. 2260 cm-1 for the amide 140 in the open chain form should 
have been obvious on the IR spectrum. However, this was not present and 
bands attributed to NH groups were observed in the 3500-3300 cm-1 region 
thus confirming the cyclic iminolactone structure 137.
PHOH CN CN
CHO
138 120 139 R = CN
140 R = CONH
NH
136 R = CN
137 R = CONH
Scheme 18
Iminolactone formation also provides information for the stereospecific 
nature of this carbon-carbon bond forming reaction as the nitrile group must be 
cis to the phenyl group in 140 to enable cyclisation affording the iminolactone 
137. This trans-stereospecific nature of the Knoevenagel condensation reaction 
is discussed later in section 5.3.2.2.
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5.2.3 SYNTHESIS OF 2-IMINOLACTONE TARGET COMPOUNDS
5.2.3.1 Strategy for synthesis
Our first synthetic proposal as outlined in section 3.6 involved an 
investigation into the optimum position of the methoxy substituent on the 
benzene ring of the lead compound 49. In order to do this a series of 
iminolactone compounds 50 featuring methoxy substitution on the 5-, 6-, 7- and 
8-benzene ring positions were prepared as well as the unsubstituted 
compounds. Although the lead compound 49 featured a nitrile group, in keeping 
with the reported finding on the biological activity of iminolactones (see section 
5.2.1) we also planned to prepare the corresponding amide derivatives.
MeO-
O ^ N H
R
50
R = CN, CONH2
5.2.3.2 Synthesis
The o-hydroxyaldehyde 141 and malononitrile-derived compound 120 
were condensed under the mild reaction conditions of room temperature and a 
catalytic amount of piperidine182 (scheme 19). For each reaction the 2- 
iminolactone product 135 was found to precipitate readily from the alcohol 
reaction mixture. However, the literature reports that these isolated crude 
products cannot be recrystallised unchanged.181-182 Therefore in order to 
obtain analytical purity the compounds were triturated in cold alcohol. Further 
handling difficulties were encountered due to the powerful sternutative and 
irritant properties of these bicyclic compounds.
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3
4 ^ ^ O H
EtOH, rt,
ON piperidine (cat.), ^ W NH
x—T [1 + r — x  [  1
6 CHO R
62 - 86%
141
X
120
R Product
135
Yield
H CN 136 62%
H c o n h 2 137 75%
3-OMe CN 142 84%
3-OMe c o n h 2 143 86%
4-OMe CN 144 86%
5-OMe CN 49 62%
5-OMe c o n h 2 145 74%
6-OMe CN 146 67%
6-OMe c o n h 2 147 74%
Scheme 19
The products were obtained in good yields (mean value 74%) and their 
structures were confirmed from the spectroscopic data collected. Compounds 
136, 137, 143 and 145 were identified as known compounds and the data 
recorded for these four compounds were found to be in agreement with the 
findings reported in the literature. As already mentioned in section 5.2.2 
perhaps the most important spectroscopic features of the iminolactones are 
found on the IR spectra as the characteristic nitrile band at ca. 2300 cm-"* was 
absent for the amide iminolactones and this together with the NH stretching 
vibrations in the 3400-3200 cm"1 region, confirmed the cyclic iminolactone 
structure. From the 1 H NMR spectra of the iminolactones the imine proton 
signal was observed at ca. 5 8.4 while on the NMR spectra the nitrile group 
carbons of the 3-cyanonitriles were found to resonate at ca. 8 116.
5.2.4 BIOLOGICAL EVALUATION OF 2-IMINOLACTONE TARGET 
COMPOUNDS
5.2.4.1 In vitro JNK MAP kinase assay
The 2-iminolactones prepared were assessed for their MAP kinase 
inhibition by Dr David Gillespie at the Beatson Institute for Cancer Research,
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Glasgow.220 This investigative assay was designed as a screen to identify the 
best compounds as candidates for a more detailed study. The MAP kinase 
enzyme employed in the assay was the c-Jun A/-terminal kinase (JNK), a 
component of the stress-activated protein kinase (SAPK) pathway which 
regulates c-Jun transcriptional activity (The JNK/SAPK MAPK pathway was 
discussed in section 3.3.2.). The principles behind this assay221 involved the 
use of a recombinant GST-c-Jun protein (purified from E.coli) bound to 
Sepharose beads. This behaved as a combined affinity matrix and substrate for 
the JNK MAP kinases. Cell extracts were prepared from primary avian 
fibroblasts treated with anisomycin to provide the source of activated 
endogenous JNK to be incubated with the GST-c-Jun beads. The assay 
followed standard experimental protocol221 and reactions were performed for 
each 2-iminolactone test compound at concentrations of 500, 50 and 5 
micromolar. SDS gel electrophoresis was used to resolve the bead-bound 
reaction mixtures and following electroblotting, the labelling of the GST-c-Jun 
from each reaction was visualised by autoradiography.
5.2.4.2 Results
Although the results from the assay were determined by visually 
analysing the autoradiography plates, this qualitative approach still enabled 
iminolactones that exhibited inhibitory activity to be identified. Test compounds 
which failed to show any inhibitory activity were easily identified from the 
autoradiograph by a stain of intensity comparable to that exhibited by the 
experimental control. The autoradiography results for the 2-iminolactones 135 
are represented in table 14.
135
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Table 14 JNK MAPK inhibitory assay results for 2-iminolactones 135
X R Cmpd
Cmpd conc. (p,M)
5 50 500
H CN 136 t " )
H CONH2 137 &
8-OMe CN 142 m * a
8-OMe CONH2 143
7-OMe CN 144 mm e a
6-OMe CN 49 mm B B CZ)
6-OMe CONH2 145 mm B B C J
5-OMe CN 146 mm CZD
5-OMe CONH2 147 ■ »
Experiment control • • •
( ) clearly inhibitory activity C l  modest inhibitory activity
S B  no inhibitory activity
At first glance it is clear that at the lower concentrations of 5 and 50 p,M 
none of the 2-iminolactones exhibited inhibitory activity. As the next 
concentration is 500 jiM we cannot assess the inhibitory behaviour within the 50 
and 500 pM range. The model compound 49 showed clear inhibitory activity at 
500 pM concentration as did the corresponding amide iminolactone 145. 
Compound 146 was the third iminolactone with methoxy ring substitution to 
show such inhibitory activity. The simplest iminolactones 136 and 137 both 
exhibited activity; however it was the 3-cyanonitrile 136 which exhibited better 
activity. The modest inhibitory activity of 137 was also shown by 144. The only 
compounds which did not show inhibitory activity at any concentration were 142 
and 143, the two 8-methoxy substituted iminolactones and iminolactone 147.
5.2.4.3 Trends
As we would have anticipated the model compound 49 exhibited clear 
inhibitory activity as did the amide iminolactone 145. An additional two 
compounds, 136 and 146, were also clearly seen to inhibit. Like the lead 
compound 49, these two iminolactones were also cyanonitriles. Finally, the two 
compounds, 137 and 144, which were found to possess less potent inhibitory
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activity were amide and nitrile iminolactones which featured no substitution on 
the benzene ring and methoxy group at the 5-position respectively.
5.3 TYRPHOSTIN TARGET COMPOUNDS
5.3.1 BACKGROUND
Following the proposal of an investigative study into the cyclic 2- 
iminolactones it was considered to be a good idea to explore the synthesis of 
the corresponding open chain derivatives. These compounds would provide 
analogues of the iminolactones. Prepared in exactly the same manner as their 
cyclic counterparts this series would employ o-methoxybenzaldehyde 
(anisaldehyde) rather than o-hydroxybenzaldehyde (salicylaldehyde) to ensure 
no cyclisation onto the nitrile group could occur. This second series of potential 
MAP kinase inhibitors are tyrphostins 148 which can be prepared easily under 
Knoevenagel reaction conditions. A phenolic series of tyrphostins was prepared 
during the antimelanoma research programme and so in sections 4.3.1 and
4.3.2 the history, mechanistics and alternative reaction conditions of the 
Knoevenagel condensations have already been presented.
5.3.2 SYNTHESIS OF TYRPHOSTIN TARGET COMPOUNDS
5.3.2.1 Synthesis
The open chain olefinic compounds 148 were prepared under piperidine- 
catalysed Knoevenagel reaction conditions.213 The anisaldehyde 149 was 
combined with malononitrile or 2-cyanoacetamide 120 to afford a series of 
amide and nitrile tyrphostins 150 to 159 (scheme 20). Room temperature 
reaction conditions were sufficient for most of the compounds with only 151 and 
159 requiring conditions of reflux. Unlike their cyclic iminolactone counterparts 
these open chain compounds were far easier to handle and following isolation 
of the products from the reaction mixture the tyrphostins were recrystallised 
from a selection of alcohols to afford the purified products in good yields (mean 
value 67%).
84
.OMe
CHO
149
<
,CN
X
R
120
R
EtOH, 
piperidine (cat.), 
rt or reflux
43 - 87%
Product Conditions Yield
OMe
CN
148
H CN 150 rt 43%
H CONH2 151 reflux 46%
3-OMe CN 152 rt 68%
3-OMe c o n h 2 153 rt 70%
4-OMe CN 154 rt 80%
4-OMe c o n h 2 155 rt 80%
5-OMe CN 156 rt 57%
5-OMe c o n h 2 157 rt 81%
6-OMe CN 158 rt 87%
6-OMe c o n h 2 159
Scheme 20
reflux 61%
Infrared spectroscopy confirmed the open chain structure of these 
compounds. Unlike the iminolactones the derivatives prepared from 2- 
cyanoacetamide produced the nitrile stretch at ca. 2220 cm-1 on the IR spectra. 
Furthermore there were no bands observed in the 3400-3200 cm-1 range 
common to iminolactone NH stretching vibrations. The success of the 
condensation reaction was also observed on the NMR spectra. On the 1H NMR 
spectra of the tyrphostins the olefinic proton produced a singlet at ca. 8 8.4 
which replaced the starting material aldehyde proton signal at ca. 8 10.5. 
Similarly on the 13c NMR spectra the olefinic methylene carbon of the products 
was found to resonate at ca. 8 150 (compared to ca. 8 190 for the aldehyde 
carbonyl carbon). The NMR spectra obtained for the amide target compounds 
indicated that the product was present as a single geometric isomer and on 
considering the thermodynamics of the geometric isomers it is assumed that the 
amide group is positioned trans to the phenyl group. This stereospecific nature 
of the Knoevenagel reaction was briefly mentioned in section 4.3.1.1. In fact the 
stereochemistry of the Knoevenagel products has been reported in the literature
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and in particular 151 along with several other compounds relevant to our work 
have been investigated.
5.3.2.2 NMR Studies into stereoselective Knoevenagel reaction products
NMR spectroscopy has been used by many groups to confirm the 
stereochemistry of Knoevenagel condensation products.222-223 We followed 
these examples in order to confirm the trans stereochemistry we had assigned 
to tyrphostins prepared in sections 4.3.2.1 and 5.3.2.1. A "I^C NMR long-range 
selective proton decoupling (LSPD) experiment was performed on compound 
151 chosen to represent the tyrphostins prepared during the course of our 
research. In the coupled 13c  NMR experiment the cyano and amide carbons 
were each found to produce a doublet with coupling constants of J 14.3 Hz and 
J 6.2 Hz respectively (see diagram 9).
OMe
fc N -H = 14.3 Hz 8  116.9CN
NH
ko-H = 6.2 Hz 8163.0
151
fcN -H = 8.7Hz 8 119.4
CN
160
Diagram 9
The LSPD experiment which followed irradiated the olefinic proton in 151 
whereupon the coupling behaviour exhibited by the two carbons mentioned was 
removed. This identified three-bond heteronuclear coupling between the cyano 
and amide carbons with the olefinic proton and the J values were in agreement 
with the reported values for this compound (3Jqn-H 14.2 Hz and 3 jco .H 6.6 
Hz).222 Indeed, these long distance heteronuclear coupling constants recorded 
for 151 confirmed the frans-stereochemistry assigned to this compound. 
Furthermore, the cyano carbon J value of 14.3 Hz is characteristic of trans 
positioned coupling nuclei and similarly the c/'s-arranged olefinic proton and 
amide group were confirmed from the smaller J value of 6.2 Hz. Confirmation 
for assigning trans stereochemistry to compound 151 on the basis of J values
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was obtained from considering the three-bond coupling constants for the cyano 
group and olefinic proton in cinnamonitrile 160 (see diagram 9). In this 
compound, where the olefinic proton and cyano carbon are arranged cis, 3 J c n -  
H 8.7 Hz was recorded. This provides a J value for cis-coupled nuclei to 
compare with the values recorded for the coupling nuclei of interest within 
151  223
Other 13C NMR LSPD experiments as well as X-ray crystallographic 
studies have been used to elucidate the trans stereochemistry found in various 
3-, 4- and 5-phenolic substituted tyrphostins with amide and ester groups 
present in the olefinic side arm.223 Many of these compounds possess the 
same or very similar structures to the tyrphostin target compounds which we 
prepared during our MAP kinase inhibitory and antimelanoma work. These 
reports222-223 together with the NMR study performed on compound 151 are 
good evidence for the trans stereochemistry we assigned to our products.
5.3.3 BIOLOGICAL EVALUATION OF TYRPHOSTIN TARGET COMPOUNDS
5.3.3.1 Results
The tyrphostin target compounds were biologically evaluated using the 
same JNK MAPK inhibitory assay employed to assess the inhibitory potential of 
the 2-iminolactone compounds in section 5.2.4. The autoradiography results are 
represented in table 15.
OMe
CN
148
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Table 15 JNK MAPK inhibitory assay results for tyrphostins 148
X R Cmpd
Cmpd conc. (pM)
5 50 500
H CN 150 G 3
H CONH2 151 M i mm a
3-OMe CN 152 • < ) c >
3-OMe CONH2 153 M l mm a
4-OMe CN 154 m t m
4-OMe CONH2 155 M i mm
5-OMe CN 156 M i mm
5-OMe CONH2 157 M l mm a
6-OMe CN 158 mm «
6-OMe CONH2 159 M l mm
Experiment control a mm mm
( ) clearly inhibitory activity C~1 modest inhibitory activity
M l no inhibitory activity
As was found with the 2-iminolactones, no inhibitory behaviour was 
exhibited by the tyrphostins at the lower concentrations of 5 and 50 pM except 
for compound 152 which showed almost complete inhibitory activity at 50 pM. 
This identified the malononitrile-derived tyrphostin 152 as the most active of the 
series mirroring the inhibitory activity of the best iminolactones (see section 
5.2.4.2). The other five active tyrphostins displayed inhibitory activity of only 
modest proportions. Among these compounds were 150 and 151, the two 
compounds possessing the simplest benzene ring substitution and the 
cyanoacetamide-derived tyrphostin 153. The 2,5- and 2,6-dimethoxy substituted 
tyrphostins (157 and 159) were the other two JNK MAPK inhibitory compounds 
identified.
5.3.3.2 Trends
Compound 152 was identified as the lead tyrphostin in the JNK MAPK 
inhibitory assay. Although a further five tyrphostins exhibited inhibitory 
behaviour it was of more modest potency. The main pattern observed among 
these less active compounds was that four of the five compounds were
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cyanoacetamide-derived tyrphostins. These active compounds featured 2-, 2,3-,
2,5- and 2,6-patterns of methoxy substitution on their benzene rings. 
Compound 150 was the only malononitrile-derived tyrphostin among the less 
potent JNK MAPK inhibitory compounds.
5.4 3-COUMARIN TARGET COMPOUNDS
5.4.1 TARGET COMPOUND DESIGN STRATEGY
The 3-substituted coumarins 161 were the third series modelled on the 
lead compound 49. These target compounds were included in the design of 
potential MAP kinase inhibitors for the following reasons: their structural 
closeness to the 2-iminolactone ring system; their ease of preparation from the 
corresponding 2-iminolactone; and the diverse activities that the coumarin 
family as a whole are known to possess.
5.4.2 COUMARINS183
5.4.2.1 Naturally occurring coumarins
Coumarin is the commonly used name for compounds which are derived 
from or incorporate the skeleton 162. This aryl lactone 162 was first isolated 
from tonka beans in 1820224 and synthesised some 50 years later by Perkin.225
Most naturally occurring coumarins have been isolated from higher 
plants of the Umbelliferae and Rutaceae families and although their role in plant
161
R = CN, CONH2 
X = H, OMe
5 4
162 163
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metabolism is not fully understood, it is believed that coumarins may behave as 
growth regulators. Out of the nearly 800 natural coumarins identified, only 35 
are found to lack an oxygen function at 0-1. As a result therefore 7- 
hydroxycoumarin 163, also commonly referred to as umbelliferone, is regularly 
found to be the basic framework of complex coumarins.
5.4.2.2 Properties of coumarins
Among the many coumarins of natural origins some notable examples 
are dicoumarol (3,3l-methylenebis(4-hydroxycoumarin)) 164,  the blood 
anticoagulant226 and the antibiotics novobiocin 165 and coumermycin A-j 
166.227 Notice that dicoumarol 164 does not feature any substituents on the 
benzene ring, in particular the most commonly observed oxygenation at 0-7. 
However, the two antibiotics incorporate the umbelliferone structural base with 
the main structural difference between them arising from the three 
methylpyrrolyl units in coumermycin A i 166.
OHOH OH
MeQ
RO"
HO
164 OH
R =165 X =
Me
166 n = 2
Me'
The fluorescence possessed by many natural coumarins affords 
extensive uses for these compounds and their synthetic counterparts. This 
important physical property allows 7-hydroxy and 7-aminocoumarins which 
contain an aryl or heteroaryl group at C-3 to be employed as laser dyes and 
fluorescent brightening agents in detergents, paper and textiles which mask 
yellowing of white materials.228’229 Further exploitation is possible with some of
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the structurally more simple coumarin derivatives such as 7-hydroxy-4- 
methylcoumarin which is used in fluorimetric enzyme assays.229
As can be seen the coumarins, whether of natural or synthetic origins, 
enjoy a whole host of applications based on the compounds' wealth of biological 
and physical properties. The coumarins mentioned here and their applications 
described represent a small cross-section of a far larger area of interest.
5.4.2.3 Syntheses of coumarins
As already mentioned in section 5.4.2.1, Perkin in 1868 was the first to 
synthesise coumarin 162. This classical reaction combined salicylaldehyde 138 
with acetic anhydride 167 and anhydrous sodium acetate 168. The intermediate 
sodium salt 169 spontaneously cyclised to the final product 162 (scheme 
21).223
OH ONa
© © 
OO2 NaCHO
138 169
162
Scheme 21
This synthesis is limited to those coumarins which possess no 
substitution in the pyrone ring. Indeed the need for structurally different 
coumarins for both chemical and biological applications is reflected in the 
ongoing investigations into synthetic approaches to these compounds.
Substitution in the C-7 position is important to this family of compounds 
(see section 5.4.2.1) and Wittig230 and Pechmann231 chemistry in particular 
find common applications in the preparation of these coumarins. In order to 
prepare 3- and 4-substituted coumarins the requisite substituents should be in 
place before construction of the pyrone ring. Accordingly the Reformatsky 
reaction232 is often used for preparing such coumarins with substituents 
positioned on carbon-4 of the coumarin pyrone ring. However, as we designed 
3-substituted coumarins in our research programme our synthetic interest lies
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more towards the preparation of these compounds. The majority of syntheses 
reported for such compounds (170) can be generalised as Knoevenagel-based 
one pot procedures. These tend to employ substituted salicylaldehyde 171 and 
active methylene compounds 172 derived from malononitrile under catalytic 
conditions of homo- or hetero-geneity (see scheme 22).232>233 In fact these 
syntheses where the intermediate compound 173 is not isolated are almost 
identical to those outlined in section 4.3.1 for the Knoevenagel preparation of 
tyrphostins. The pressures of trying to attain environmentally and ecologically 
friendly reaction conditions for the preparation of these 3-coumarins have seen 
the use of inorganic solid support catalysts233 and solid-phase syntheses234 to 
mention two synthetic conditions applied.
OH OH
CHO catalytic
source
173171 172
R1 = C 02R, CN, COMe 
R = alkyl, aryl, etc
170
Scheme 22
5.4.3 SYNTHESIS OF 3-COUMARIN TARGET COMPOUNDS
The 3-substituted coumarins 161 were prepared in a facile acid 
hydrolysis reaction which employed the freshly-prepared 2-iminolactones 135 
(see section 5.2.3) as starting materials (scheme 23). On warming the aqueous 
solution of dilute hydrochloric acid and 2-iminolactone 135, the corresponding 
lactone 161 was quickly afforded. Unlike the 2-iminolactone starting materials, 
the products 174 to 182 provided no handling difficulties and the 3-coumarins 
were recrystallised and obtained in high yields (mean value 84%).
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X“f  I  I2
5 4
135
Substrate X
136 H CN 174 86%
137 H c o n h 2 175 89%
142 8-OMe CN 176 89%
143 8-OMe c o n h 2 177 59%
144 7-OMe CN 178 91%
49 6-OMe CN 179 66%
145 6-OMe c o n h 2 180 96%
146 5-OMe CN 181 96%
147 5-OMe c o n h 2 182 82%
Scheme 23
dil. HCI, OCX
59 - 96% M
161
R Product Yield
The structural similarity between the iminolactones and lactones was 
most obvious from comparing the compounds' NMR spectra where the only 
difference observed was the absence of the imine proton signal at ca. 5 8.3 on 
the 3-coumarins' NMR spectra. IR spectroscopy also supported the success 
of the iminolactone hydrolysis with the NH stretching bands of the starting 
material common to the 3400-3200 cm-1 region being replaced by the carbonyl 
absorption at ca. 1700 cm'"* region on the IR spectra of the coumarins. This 
observation was more prominent for the 3-cyanonitrile coumarins as the 
corresponding amide compounds' carbonyl stretch masked the new lactone IR 
band. Further data of interest were the melting points of the 3-coumarins which 
were found to be consistently higher than those of the corresponding 2- 
iminolactones. The coumarin melting points were generally greater than 220 °C 
compared to ca. 140 to 180 °C for the 2-iminolactones.
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5.4.4 BIOLOGICAL EVALUATION OF 3-COUMARIN TARGET COMPOUNDS
5.4.4.1 Results
The 3-coumarins, the final set of target compounds, were assessed for 
their inhibitory potential in the JNK MAPK assay using the same in vitro 
conditions employed to investigate the 2-iminolactones and tyrphostins. In an 
identical manner as before the autoradiography results obtained are 
represented in tabular form (table 16).
161
Tables 16 JNK MAPK inhibitory assay results for coumarins 161
X R Cmpd
Cmpd conc. (pM)
5 50 500
H CN 174 a a mm
H CONH2 175 O i mm mm
8-OMe CN 176 mm s «
8-OMe CONH2 177 mm mm mm
7-OMe CN 178 « mm mm
6-OMe CN 179 mm a
6-OMe CONH2 180 mm mm «
5-OMe CN 181 « mm mm
5-OMe CONH2 182 mm «
Experiment control mm mm mm
( ) clearly inhibitory activity fZ7i modest inhibitory activity
no inhibitory activity
At the 5, 50 and 500 pM compound concentrations none of the lactones 
were found to exhibit inhibitory activity in the assay. Therefore we would
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conclude that the 3-substituted coumarins did not provide candidates for further 
investigations into their JNK MAPK inhibitory activity.
5.5 OVERALL RESULTS FROM BIOLOGICAL EVALUATION OF 
TARGET COMPOUNDS
5.5.1 CORRELATION OF RESULTS
The results from this investigative inhibitory assay allowed us to 
conclude that the 2-iminolactones provided the most number of inhibitory 
compounds while the structurally very similar 3-substituted coumarins did not 
afford inhibitory compounds. However, the tyrphostins which were designed as 
analogues of the iminolactones provided one potent inhibitory compound and a 
very simplistic structural relationship was tentatively assigned between the 2- 
iminolactones and their open chain derivatives. This structural relationship was 
identified for three of the potent inhibitory iminolactones 136, 49 and 146 which 
were 3-cyanonitrile iminolactones featuring no substitution, 6-methoxy and 5- 
methoxy substitution patterns on the benzene ring of these bicyclic compounds. 
Of the tyrphostins modelled on these three iminolactones it was the 
cyanoacetamide derivatives 151, 157 and 159 which were found to possess 
inhibitory activity.
5.5.2 CONCLUSIONS
As mentioned in section 5.2.4 the in vitro biological evaluation of the 
target compounds was designed as a screen to identify candidates which 
showed significant MAP kinase inhibitory activity. Dr Gillespie proposed to 
investigate the active compounds in a more detailed study. From the results 
shown in sections 5.2.4, 5.3.3 and 5.4.4 the compounds for further evaluation 
would be those 2-iminolactones and tyrphostins found to exhibit JNK MAPK 
inhibitory activity at 500 pM concentration.
5.6 THIOPHENE ISOSTERE TARGET COMPOUNDS
5.6.1 SYNTHETIC PROPOSAL
Following the results from the biological evaluation of our target 
compounds where the most active compounds were electron rich aromatic 
derivatives, an extension of the original research programme was undertaken.
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This design strategy involved the preparation of thiophene isosteric 
replacements of the 2-iminolactones and tyrphostins which were found to 
exhibit MAP kinase inhibitory activity (see section 5.5.2). The target compounds 
183 and 184 featured 2,3-ring substitution patterns on the bicyclic iminolactones 
183 and their open chain derivatives 184. This approach where electron-rich 
heterocyclic compounds are prepared as analogues of aromatic compounds to 
investigate structure-activity relationships is an approach commonly employed 
in medicinal chemistry research.
NH ,OMe
CN
R = CN, CONH
183 184
5.6.2 SOME BIOLOGICALLY ACTIVE THIOPHENE SYSTEMS
Thiophene derivatives are pharmacologically active compounds with 
applications which include central nervous system (CNS) and cardiovascular 
drugs. They are also employed in metabolic and infectious disease therapies. 
When we consider that infectious diseases include bacterial, fungal and viral 
infections the scope of thiophene derivatives in biological applications is very 
wide indeed.235
The use of thiophenes in biologically active compounds can be illustrated 
with the following examples. Consider taclamine 185 and QM-7184 186, both 
pyschotropic agents.236 While taclamine is used to treat anxiety its thiophene 
isostere QM-7184 provides drug therapy for schizophrenia.236 This 
demonstrates the change in pharmacological activity produced on preparing the 
simple thiophene isostere of compound 185.
a
i-r / r— H*
185
n ^ \ h
186
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Quite separate from the use of thiophene as a benzene isostere in drug 
design is the importance of the substitution patterns on the thiophene ring of 
active compounds. This can be exemplified with two terthienyl isomers 187 and 
188 used in infectious disease therapy. The a-terthienyl 187 exhibits antifungal 
and nematicidal behaviour while isomer 188 is a cytotoxic agent.235-237
5.6.3 THIOPHENE TYRPHOSTIN TARGET COMPOUNDS
5.6.3.1 3-Methoxythiophene
The two thiophene tyrphostin target compounds were prepared before 
the iminolactones. The differences and resultant difficulties in the syntheses of 
these thiophene tyrphostins compared to their benzene counterparts became 
apparent immediately. The synthesis of the benzene-based tyrphostins 
described in section 5.3.2.1 used cheap, commercially-available anisaldehyde 
as starting material in the Knoevenagel condensation reaction. However, for the 
thiophene isosteric compounds the corresponding starting material possessing 
the aldehyde and methoxy groups in adjacent positions was not available. 
Therefore, the 2,3-disubstituted thiophene had to be synthesised.
The preparation and reactivity of 3-methoxythiophene systems have 
been reported in the literature238-239 and it is possible to prepare 3- 
methoxythiophene from 3-bromothiophene in a cupric oxide-catalysed reaction 
with sodium methylate in methanol.239 However on consideration of the 
economics we preferred to employ commercially available 3-methoxythiophene 
in our synthesis.
5.6.3.2 Formylation of 3-methoxythiophene
The key to the carbon-2 formylation of 3-methoxythiophene 189 is the 
metalation of this compound or more specifically ortho-lithiation.238-239 The
CM341
188
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metalation of 3-methoxythiophene 189 with n-butyllithium was found to occur 
exclusively at position 2 (scheme 24). Aldehyde 190 formation in the 2-position 
substantiated the formation of the 2-thienyllithium species 191 which was 
treated with /V,/V-dimethylformamide at 0 °C to afford the final product 190. On 
warming the reaction mixture slowly to room temperature and quenching with 
water, the mixture was worked up in a standard manner. Following purification 
by column chromatography, the recrystallised product was obtained in 58% 
yield.
OMe
189
OMe
191
58%
OMe
£
190
CHO
i nBuU (1.6 M, 1 eq.), rt; reflux
ii DMF (1 eq.), 0 °C; 0 °C -> rt
Scheme 24
The combustion data confirmed the elemental composition of the 
formylated 3-methoxythiophene 190 and high resolution mass spectroscopy 
identified the compound's accurate mass. However, it was NMR spectroscopy 
that provided the conclusive evidence for the aldehyde group introduction into 
the 2-position. The NMR spectrum confirmed the presence of two thiophene 
ring protons in the downfield region (5 6.8-7.6) in the form of two doublets and 
the large J value of 5.2 Hz was consistent with ortho coupled protons. The 13c 
NMR spectrum confirmed two aromatic CH carbons (at 8 116.2 and 135.6) 
together with the deshielded aldehyde carbon at 8 181.7. IR spectroscopy 
further confirmed the successful formylation with a strong absorption at 1643 
cm'"' characteristic of an aryl carbonyl stretch.
The metalation of 3-f-butoxythiophenes has also been reported in the 
literature240 and the o-lithiations of these compounds along with their 3- 
methoxy counterparts we have dealt with demonstrates a very powerful method 
for selectively introducing 2-position substituents such as acetyl, carbethoxy 
and alkyl groups to 3-alkoxythiophene compounds. In fact the important role 
played by the methoxy group in the thiophene 3-position is reflected in the 
metalation of 3-methylthiophene where lithiation is directed to the 5-position,238 
a site electronically favoured by the sulfur and the least hindered position.
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5.6.3.3 Synthesis of thiophene tyrphostin target compounds
Preparation of the thiophene compounds 184 was not as straightforward 
as the previous syntheses of tyrphostins (see section 4.3.2 and 5.3.2). The 
reaction conditions employed for the compounds 192 and 193 were different 
(see scheme 25).
^ M edS CHO 
190
^CN
R
120
i or ii
OMeOX
184
i EtOH, rt, neat piperidine (cat.)
ii EtOH, reflux
R Product Conditions Yield
c o n h 2
CN
192
193
i
ii
72%
68%
Scheme 25
The thiophene compounds 184 were the condensation products of the 
freshly prepared 2-formyl-3-methoxythiophene 190 (section 5.6.3.2) and active 
methylene compound 120 (malononitrile or 2-cyanoacetamide) (see scheme 
25). The synthesis of 192 which employed 2-cyanoacetamide proceeded 
smoothly under Knoevenagel reaction conditions of neat piperidine catalysis 
and ethanol at room temperature. The product 192 was recrystallised from 
isopropanol to provide the target compound in 72% yield. However, the second 
thiophene tyrphostin 193 was not as easy to prepare. Standard piperidine- 
catalysed Knoevenagel reaction conditions were not conducive to obtaining the 
product in an acceptable yield and therefore different reaction conditions where 
the thiophene aldehyde and malononitrile were condensed under reflux 
conditions were employed. These catalyst-free reaction conditions were 
reported by Henrio and co-workers241 who performed the condensation 
reaction with 2-formyl-3-f-butoxythiophene and malononitrile. The recrystallised 
product 193 was obtained in 68% yield and the yellow needles were found to be 
particularly light sensitive requiring storage in the dark.
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The success of the syntheses of the two tyrphostins 192 and 193 was 
most obvious from their NMR spectra. The 1H NMR spectra identified the 
products from the olefinic proton signal at ca. 8 8.1 and the absence of the 
aldehyde proton signal at 8 9.91 of the starting material. Similarly on the 13C 
NMR spectra the aldehyde's carbon signal which resonated downfield at 8 
181.7 was absent and replaced with the nitrile carbon signal at ca. 8 144 for 
both 192 and 193 and the carbonyl carbon at 8 164.6 for compound 192. NMR 
spectroscopy confirmed the synthesis of a single geometric isomer for the 
amide 192 which we assigned trans stereochemistry on thermodynamically 
favoured grounds and in accordance with the stereoselective nature of 
Knoevenagel condensation products which was discussed in detail in sections
4.3.1.1 and 5.3.2.2. On the IR spectra the success of the reaction could also be 
observed with the presence of a characteristic nitrile stretch at ca. 2200 cm" 1 
for both condensation products as well as the carbonyl vibrational band at 1704 
cm'1 for the amide 192.
5.6.4 THIOPHENE IMINOLACTONE TARGET COMPOUNDS
5.6.4.1 Two synthetic routes proposed
Following the successful synthesis of the thiophene tyrphostin target 
compounds in section 5.6.3.3, the corresponding iminolactones 183 were to be 
prepared. We designed and investigated two different synthetic routes towards 
this target (scheme 26). It was anticipated that both routes would proceed via 
the 2-hydroxy open chain compound 194 which would spontaneously cyclise to 
form the bicyclic iminolactone compound 183 as their benzene counterparts 
were found to do in section 5.2.
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PH jOMeCN CN
CHO
195 120 184
Route 2Route PH
CN
194
NH
R = CN, CONH
183
Scheme 26
However, the thiophene iminolactone compounds 183 were not formed. 
The attempted syntheses of these target compounds by routes 1 and 2 will now 
be presented in turn.
5.6.4.2 Attempted synthesis of iminolactones using route 1
5.6.4.2.1 Synthesis of 2-formyl-3-hydroxythiophene
The 3-hydroxy-2-formyl thiophene 195 required as starting material in the 
first proposed synthetic route (route 1, scheme 26) was prepared from the 
corresponding 3-methoxy compound 190. This thienyl methyl ether deprotection 
allowed us to apply synthetic experience gained from an analogous procedure 
performed on a series of aryl methyl ether compounds during the antimelanoma 
research programme of work (section 4.1.2). As we had done previously, the 
Lewis acid boron tribromide was employed to facilitate this deprotection. This 
mild reaction was performed under conditions of low temperature and the 
methyl ether protection group was readily removed to afford the desired 
compound (scheme 27).
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OMe OH
190
S ^ C H O
195
i BBr3 (1 M in DCM, 3 eq.), -78 °C
ii -78 °C —> rt
Scheme 27
Purification provided the 3-hydroxythiophene compound 195 in a good 
yield (59%) with a sharp melting point and the spectroscopic data were found to 
be in agreement with the selected data reported in the literature. IR 
spectroscopy confirmed the presence of the hydroxyl group with a broad band 
in the region of 3100-2593 cm-1 which we believed to be indicative of 
intramolecular hydrogen bonding. The relatively low value for the carbonyl 
absorption of 1613 cm""* provided further evidence suggesting the existence of 
this interaction between the thiophene 2- and 3-ring substituents. NMR 
spectroscopy confirmed the successful deprotection through the absence of the 
methyl ether signal at 8 3.92 and 8 59.2 on the respective "*H and "*3c NMR 
spectra.
5.6.4.2.2 Attempted synthesis of iminolactone
The first route designed to obtain the iminolactone compounds involved 
condensing 2-formyl-3-hydroxythiophene 195 and the appropriate malononitrile 
derivative 120 (malononitrile or 2-cyanoacetamide). However, various reaction 
conditions were investigated and applied but without success. The standard 
Knoevenagel condensation reaction conditions which we had successfully 
employed in section 4.3.2 and 5.3.2 were used with the catalytic source of 
piperidine (neat and diluted in ethanol) as well as aqueous potassium 
hydroxide. However under room temperature and refluxing reaction conditions 
neither of these bases was successful in catalysing the reaction. Furthermore 
the catalyst-free conditions used to condense 3-formyl-2-methoxythiophene and 
2-cyanoacetamide in section 5.6.3.3 proved to be equally unsuccessful.
Naturally this synthetic outcome was disappointing but surprising too as 
we assumed that the 2-formyl-3-hydroxythiophene 195 would be a reactive 
species with respect to the aldehyde and hydroxyl groups enabling iminolactone
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synthesis with ease. However, on reflection, perhaps the intramolecular 
hydrogen-bonded character of this compound may have reduced the reactivity 
of the thiophene and this may have adversely affected the outcome of the 
reaction.
5.6.4.3 Attempted synthesis of iminolactones using route 2
The second route designed to synthesise the thiophene iminolactone 
target compounds like the first route featured a thienyl methyl ether 
deprotection reaction. In fact within these methoxythiophene tyrphostins 184 the 
olefinic bond holds the cyano group in close proximity to the methoxy group 
such that it was anticipated that on demethylation the unmasked hydroxyl group 
would cyclise on to the nitrile carbon providing the bicyclic target compound 183 
(see scheme 26, section 5.6.4.1).
We investigated boron tribromide and pyridinium hydrochloride as 
demethylating reagents to mediate the reaction in question but to no avail. 
Following numerous attempts, our synthesis of the thiophene iminolactone 
target compounds 183 by either condensing the hydroxythiophene and 
malononitrile derivative or in a demethylative ring closure reaction of the 
appropriate 2-methoxythiophene tyrphostin proved to be unsuccessful. As a 
result we could only supply the two methoxythiophene tyrphostin compounds 
192 and 193 for biological evaluation by Dr David Gillespie.
5.6.5 BIOLOGICAL EVALUATION OF THIOPHENE TYRPHOSTIN TARGET 
COMPOUNDS
5.6.5.1 Results
The thiophene tyrphostins 184 were biologically evaluated for JNK 
MAPK inhibitory activity and the in vitro assay conditions employed are detailed 
in section 5.2.4. The autoradiography results are presented in table 17.
OMe
CN
184
103
Table 17 JNK MAPK inhibitory assay results for tyrphostins 184
Cmpd conc. (mM)
R Cmpd 5 50 500
CONH2 192 mm (_
CN 193 mm C 3 C
Experiment control • •
( ) clearly inhibitory activity C ~ l modest inhibitory activity
I B  no inhibitory activity
From the results it is obvious that both the thiophene tyrphostins 192 and 
193 showed some inhibitory activity at 50 pM concentration and complete 
inhibition at 500 pM.
5.6.5.2 Conclusions
The inhibitory activity shown by the thiophene tyrphostins would appear 
to support the strategy behind their design (see section 5.6.1). The thiophene 
compounds were modelled on the corresponding electron rich benzene-based 
compounds found to possess inhibitory activity in sections 5.2.4, 5.3.3 and 
5.4.4. We therefore propose future investigations could continue this use of 
electron rich heterocyclic compounds to prepare more isosteres of the active 
compounds e.g. using pyrroles and furans.
Following the successful biological evaluation of all the target 
compounds prepared, those possessing JNK MAPK inhibitory behaviour have 
been identified. As mentioned earlier in section 5.2.4 we now await a more 
detailed study involving these inhibitory compounds.
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CHAPTER 6 
EXPERIMENTAL
6.1 GENERAL
Reagents were purchased from Aldrich Chemical Company (Gillingham, 
UK) or Lancaster Synthesis (UK) and were used without further purification. 
Organic solvents were obtained from Rhone-Poulenc Rorer and were dried, as 
necessary, using the procedures described in Leonard, Lygo and Procter.242 
Melting points were determined in open capillaries using Gallenkamp apparatus 
and are uncorrected. and 13c NMR spectra were obtained on a Bruker 
AM200-SY spectrometer operating at 200 MHz and 50 MHz respectively, or 
where stated, on a Bruker DPX/400 spectrometer operating at 400 MHz and 
100 MHz respectively. 13q NMR spectra were assigned with the aid of 
Distortionless Enhancement by Polarisation Transfer (DEPT)-edited spectra 
and 1h NMR coupling constants were calculated and reported in Hz. The 
numbering schemes shown are used for ease of assigning the NMR spectra 
and do not refer to the system of nomenclature. Mass spectra (MS) were 
recorded on a Jeol JMS700 high resolution mass spectrometer and percentage 
figures refer to relative intensity as a percentage of the base peak. MS were 
obtained using electron-impact ionisation (El) mode or, where stated, chemical 
ionisation (Cl) mode. Infrared (IR) spectra were recorded on a JASCO FT/IR 
410 spectrometer. Ultraviolet (UV) spectra were recorded on a Shimadzu UV- 
1601 spectrophotometer and combustion data were obtained from a Carlo-Erba 
1106 elemental analyser. Retention factors (Rf) were obtained by analytical 
Thin Layer Chromatography (TLC) on Merck aluminium-backed silica plates of 
0.25 mm thickness and chromatograms were visualised using UV conditions at 
254 nm or using a variety of common stains prepared using the procedures 
described in Leonard, Lygo and Procter.242 All column chromatography was 
carried out on silica gel (particle size 70-230 mesh).
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6.2 EXPERIMENTAL FOR CHAPTER 4
6.2.1 GENERAL PREPARATIVE METHODS 1 AND 2 
General method 1
The method of Gazit and co-workers213 was modified as follows. To a 
stirred solution of hydroxybenzaldehyde (1 equiv.) and malononitrile derivative 
(1 equiv.) in ethanol (ca. 0.5 mL/mmol), neat piperidine (a few drops) was 
added. The reaction mixture was heated at reflux until TLC indicated the 
reaction to be complete whereupon the mixture was cooled to room 
temperature. If precipitation of product was not observed dropwise addition of 
water was employed. The precipitated product was then filtered, dried under 
suction filtration and recrystallised from an appropriate solvent.
General method 2
General method 2 followed the same experimental protocol outlined for 
general method 1 with the exception that the reaction mixture was stirred at 
room temperature rather than heating under reflux.
6.2.2 EXPERIMENTAL DATA
4,5-Dihydro-2-ethyloxazole 59
Et
Compound 59 was prepared in 34% yield on a 36.3 mmol scale by the 
method of Witte and Seeliger189 and gave bp 130-134 °C (760 mmHg) (lit. 243 
124-126 °C/760 mmHg). The spectroscopic data were in agreement with the IR 
and 1H NMR data reported.134
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4,5-Dihydro-2-cyclohexyloxazole 60
/ \
Compound 60 was prepared in 42% yield on a 45.8 mmol scale by the 
method of Witte and Seeliger189 and gave bp 60-65 °C (1.5 mmHg) (lit.,244 125 
°C/15 mmHg). The spectroscopic data were in agreement with the IR and 1H 
NMR data reported.134-245
5,6-Dihydro-2-methyl-4H-1,3-oxazine 61
Me
Compound 61 was prepared in 49% yield on a 48.7 mmol scale by the 
method of Witte and Seeliger189 and gave bp 25-30 °C (1.5 mmHg) (lit.,246 132- 
133 °C/760 mmHg). The spectroscopic data were in agreement with the IR and 
1H NMR data reported.246
5,6-Dihydro-2-ethyl-4H-1,3-oxazine 62
Et
Compound 62 was prepared in 43% yield on a 36.3 mmol scale by the 
method of Witte and Seeliger189 and gave bp 38-40 °C (1.5 mmHg) (lit.,243 70- 
71 °C/43 Torr). The spectroscopic data were in agreement with the IR and 1H 
NMR data reported.243
107
5,6-Dihydro-2-cyclohexyl-4H-1,3-oxazine 63
Compound 63 was prepared in 37% yield on a 23.1 mmol scale by the 
method of Witte and Seeliger189 and gave bp 88-90 °C (1.5 mmHg) (lit.,134 74- 
76 °C/2 mmHg). The spectroscopic data were in agreement with the IR and 1H 
NMR data reported.134
5,6-Dihydro-2-phenyl-4H-1,3-oxazine 64
Ph
Compound 64 was prepared in 29% yield on a 38.8 mmol scale by the 
method of Witte and Seeliger189 and gave bp 80-82 °C (2 mmHg) (lit.,247 115 
°C/1.5 mmHg). The spectroscopic data were in agreement with the IR and 1H 
NMR data reported.248
A/-{2-[(4-Hydroxyphenyl)thio]ethyl}acetamide 35
OH
Compound 35 was prepared in 74% yield on a 48.2 mmol scale by the 
method of Padgette and co-workers129 and gave mp 120-122 °C (EtOAc) 
(lit.,129 123-125 °C). The spectroscopic data were in agreement with the IR, 
high resolution mass spectroscopy and ^H NMR data reported.133
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/V-{2-[(4-Hydroxyphenyl)thio]ethyl}cyclohexanecarboxamide 68
OH
Compound 68  was prepared in 59% yield on a 25.5 mmol scale by the 
method of Padgette and co-workers129 and gave mp 92-93 °C (EtOAc) (lit.,134 
94-95 °C). The spectroscopic data were in agreement with the IR, high 
resolution mass spectroscopy and 1H NMR data reported.134
A/-{2-[(4-Methoxyphenyl)thio]ethyl}acetamide 73
The method of Padgette and co-workers129 was used. A mixture of 2- 
methyl-2-oxazoline (1.38 ml_, 1.38 g, 16.3 mmol) and 4-methoxybenzenethiol 
(2.00 mL, 2.28 g, 16.3 mmol) was heated at reflux neat for 3 d under N2 - The 
reaction was cooled to 0 °C whereupon scratching induced crystallisation. The 
product was purified by column chromatography, eluant ethyl acetate, and the 
title compound 73 (2.74 g, 12.2 mmol, 75%) was recrystallised from ethyl 
acetate to provide white needles, mp 100-101 °C (Found: C, 58.48; H, 6.74; N, 
6.14. C11H15NO2 S requires C, 58.67; H, 6.67; N, 6 .22%); vmax (KBr disc)/cm" 
1 3288m (NH), 2951w and 2936w (CH), 1636s (CO), 1562m and 1496m (C=C), 
1441m (CH), 1249m and 1030m (C-O) and 815m (CH); 5h (400 MHz; CDCI3 )
1.87 (3 H, s, 11-H), 2.86 (2 H, t, J6.4 Hz, 7-H), 3.32 (2 H, m, 8 -H), 3.72 (3 H, s, 
12-H), 5.88 (1 H, br. s, 9-H), 6.78 (2 H, AA'BB', d, J 8.8 Hz, 2,6-H) and 7.29 (2 
H, AA'BB', d, J 8.8 Hz, 3,5-H); 8c  (100 MHz; CDCI3 ) 23.6 (H -C H 3 ), 36.0 (7- 
CH2 ), 38.9 (8 -CH2 ), 55.7 ( I2 -CH3 ), 115.2 (2 ,6 -CH), 125.2 (4-quat. C), 134.0 
(3,5-CH), 159.7 (1-quat. C) and 170.5 (10-CO); m/z (El) 225.0823 (M+*.
109
C 11H15NO2 S requires 225.0822); m/z (%) 225 (36.2), 166 (100), 139 (21.3), 
135 (9.9), 109 (11.3), 86 (52.5), 77 (7.8) and 63 (5.0).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}cyclohexanecarboxamide 74
Compound 74 was prepared from oxazoline 60 (500 mg, 3.27 mmol) and 
4-methoxybenzenethiol (0.40 mL, 458 mg, 3.27 mmol) by the method used to 
prepare compound 73. Purification by column chromatography, eluant diethyl 
ether-hexane (2 :1), and subsequent recrystallisation from ethyl acetate provided 
compound 74 (627 mg, 2.14 mmol, 65%) as pale tan crystals, mp 68-71 °C 
(Found: C, 65.28; H, 7.78; N, 4.69. C16H2 3NO2 requires C, 65.53; H, 7.85; N, 
4.78%); vmax (KBr disc)/cm'1 3313m (NH), 2927m and 2851m (CH), 1632s 
(CO), 1539m and 1493m (C=C), 1591w (NH), 1438w (CH), 1236m and 1027m 
(C-O) and 818m (CH); 5h (400 MHz; CDCI3) 1.21 (6 H, m, 14 to 16-H), 1.70 (4 
H, m, 12,13-H), 1.95 (1 H, m, 11-H), 2.86 (2 H, t, J6.2 Hz, 7-H), 3.32 (2 H, m, 8- 
H), 3.72 (3 H, s, 17-H), 5.85 (1 H, br. s, 9-H), 6.78 (2 H, AA'BB', d, J 8.8 Hz, 2,6- 
H) and 7.29 (2 H, AA'BB', d, J 8.8 Hz, 3,5-H); 8c  (100 MHz; CDCI3 ) 26.1 (14 to 
I 6-CH2 ), 30.0 (12,13-CH2), 36.1 (7 -CH2 ), 38.7 (8-CH2 ), 45.8 (11-CH), 55.7 
(17-CH3), 115.2 (2 ,6-CH), 125.3 (4-quat. C), 134.0 (3,5-CH), 159.7 (1-quat. C) 
and 176.5 (10-CO); m/z (El) 293.1447 (M+*. C16H2 3NO2 S requires 293.1444); 
m/z (%) 293 (19.5), 166 (100), 154 (36.9), 139 (17.7), 83 (17.7), 77 (31.9) and 
55 (18.1).
o c h 3
1I17
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A/-{2-[(4-Methoxyphenyl)thio]ethyl}benzamide 75
o c h 3
' 8 14
16
15
Compound 75 was prepared from 2-phenyl-2-oxazoline (0.54 mL, 600 
mg, 4.08 mmol) and 4-methoxybenzenethiol (0.50 mL, 572 mg, 4.08 mmol) by 
the method used to prepare compound 7 3. Purification by column 
chromatography, eluant diethyl ether-hexane (2:1), and subsequent 
recrystallisation from ethyl acetate provided the title compound 75 (588 mg,
2.05 mmol, 50%) as a cream powder, mp 63-65 °C (Found: C, 66.77; H, 5.90; 
N, 4.73. C 16H17NO2 requires C, 66.90; H, 5.92; N, 4.88%); v max (KBr 
disc)/cm"1 3315m (NH), 1644s (CO), 1541m and 1494m (C=C), 1454m (CH), 
1243s and 1029m (C-O) and 810s, 695s and 676s (CH); 8h (400 MHz; CDCI3) 
2.97 (2 H, t, J 6.3 Hz, 7-H), 3.53 (2 H, m, 8 -H), 3.69 (3 H, s, 17-H), 6.57 (1 H, br. 
s, 9-H), 6.75 (2 H, AA'BB', d, J 8.8 Hz, 2,6-H), 7.32 (4 H, m, 3,5-H and 14,15-H), 
7.40 (1 H, m, 16-H) and 7.62 (2 H, m, 12,13-H); 8c  (100 MHz; CDCI3) 35.9 (7- 
CH2 ), 39.6 (8 -CH2 ), 55.7 ( I7 -CH3 ), 115.3 (2 ,6-CH), 125.2 (4-quat. C), 127.3 
(14,15-CH), 128.9 (12,13-CH), 131.9 (16-CH), 134.1 (3,5-CH), 134.7 (11-quat. 
C), 159.7 (1-quat. C) and 167.8 (10-CO); m /z  (El) 287.0977 (M+V 
C16H17NO2 S requires 287.0974); m/z (%) 287 (25.4), 166 (100), 14.8 (34.6), 
139 (9.2), 105 (55.8), 77 (46.3) and 51 (9.5).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-methylacetamide 78
o c h 3 
ll 13
12 CH
111
A modified version of the method of Orito and co-workers192 was used. 
To a stirred suspension of sodium hydride (60% dispersion in mineral oil, 427 
mg, 10.7 mmol) in tetrahydrofuran (20 mL), at rt, was added dropwise/V- 
acetamide 73 (1.20 g, 5.33 mmol) in tetrahydrofuran (20 mL) followed by methyl 
iodide (1.16 mL, 2.65 g, 18.7 mmol). The reaction was slowly heated to 40 °C. 
After hydrogen gas evolution ceased the reaction was maintained at a gentle 
reflux for 24 h. On cooling to rt white precipitates of sodium iodide were 
removed by suction filtration and the reaction mixture concentrated in vacuo. 
The oily residue was dissolved in chloroform (30 mL), washed with 10% sodium 
thiosulfate solution ( 2 x 1 5  mL) and water ( 2 x 1 5  mL), dried over anhydrous 
sodium sulfate and concentrated in vacuo. Purification by column 
chromatography, eluant ethyl acetate, provided the title compound 78 (1.16 g, 
4.85 mmol, 91%) as a yellow oil. vmax (thin film)/crrr1 3002w and 2933w (CH), 
1646s (CO), 1593m and 1495s (C=C), 1246s and 1030m (C-O) and 828m (CH); 
5h (400 MHz; CDCI3 ) [1.95 (1.2 H, s) and 2.02  (1.8 H, s) 11-H], [2.85 (1.2 H, s) 
and 2.98 (1.8 H, s) 12-H], [2.94 (0.8 H, t, J7.4 Hz) and 3.01 (1.2 H, t, J7.0 Hz)
7-H], [3.42 (0.8 H, t, J 7.6 Hz) and 3.51 (1.2 H, t, J7.2 Hz) 8-H], [3.78 (1.2 H, s) 
and 3.80 (1.8 H, s) 13-H], 6.86 (2 H, m, 2,6-H) and 7.37 (2 H, m, 3,5-H); 5c 
(100  MHz; CDCI3 ) 21.5 and 22.2  (H -C H 3 ), 32.9 and 34.3 (7-CH2), 33.5 and
37.6 ( I 2 -CH3 ), 48.3 and 50.7 (8 -CH2 ), 55.7 and 55.7 ( I 3 -CH3 ), 115.0 and
115.2 (2 ,6 -CH), 125.2 and 126.2 (4-quat. C), 132.9 and 134.2 (3,5-CH), 159.2 
and 159.8 (1-quat. C) and 170.7 and 171.0 (10-CO); m/z (El) 239.0980 (M+*. 
C 12H17NO2 S requires 239.0980); m/z (%) 239 (19.3), 166 (100), 139 (15.0), 
135 (8.9), 100 (85.7), 86 (5.7), 77 (5.0) and 58 (14.6).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}/V-ethylacetamide 79
13
Compound 79 was prepared from compound 73 (1.80 g, 8.00 mmol), 
ethyl bromide (2.1 mL, 3.05 g, 28.0 mmol) and sodium hydride (60% dispersion 
in mineral oil, 576 mg, 14.4 mmol) by the method used to prepare compound
112
78. Purification by column chromatography, eluant ethyl acetate-hexane (4:1), 
provided title compound 79 (1.82 g, 7.21 mmol, 90%) as a yellow oil. vmax (thin 
film)/cm- 1 2971 w and 2933w (CH), 1639s (CO), 1593m and 1495s (C=C), 
1459m and 1442m (CH), 1246m and 1030m (C-O) and 829m (CH); 8h (400 
MHz; CDCI3 ) [0.98 (1.2 H, t, J7A  Hz) and 1.03 (1.8 H, t, J1.2  Hz) 13-H], [1.84 
(1.2 H, s) and 1.95 (1.8 H, s) 11-H], [2.84 (0.8 H, t, J  7.8 Hz) and 2.94 (1.2 H, t, 
J 7 A  Hz) 7-H], 3.23 (2 H, m, 12-H), [3.31 (0.8 H, t, J7 .8  Hz) and 3.38 (1.2 H, t, 
J 7 A  Hz) 8 -H], [3.70 (1.8 H, s) and 3.71 (1.2 H, s) 14-H], 6.78 (2 H, m, 2,6-H) 
and 7.30 (2 H, m, 3,5-H); 8c  (100  MHz; CDCI3 ) 13.4 and 14.5 (13-CH3), 21.7 
and 21.8  (H -C H 3 ), 32.9 and 34.8 (7-CH2), 40.8 and 44.7 (12-CH2), 46.2 and
48.4 (8 -CH2 ), 55.7 and 55.8 (H -CH 3 ), 115.0 and 115.2 (2 ,6 -CH), 125.1 and
125.2 (4-quat. C), 132.7 and 134.4 (3,5-CH), 159.1 and 159.9 (1-quat. C) and
170.2 and 170.6 (10-CO); m/z (El) 253.1134 (M+*. C13H19NO2 S requires
253.1132); m/z(%) 253 (20.6), 166 (100), 151 (9.2), 139 (20.6), 114 (93.6), 100
(6.4), 72 (11.3) and 58 (87.2).
/V-{2-[(4-Methoxyphenyl)thio]ethyl)A/-benzylacetamide 80
Compound 80 was prepared from compound 73 (225 mg, 1.00 mmol), 
benzyl bromide (0.42 mL, 599 mg, 3.50 mmol) and sodium hydride (60% 
dispersion in mineral oil, 72 mg, 1.80 mmol) by the method used to prepare 
compound 78. Purification by column chromatography, eluant diethyl ether, 
provided title compound 80 (165 mg, 0.52 mmol, 52%) as a cloudy yellow oil. 
vmax (thin film)/cm'1 2930w (CH), 1645s (CO), 1592w and 1494s (C=C), 
1464m (CH), 1245s and 1029m (C-O) and 827m and 729m (CH); 8h (400 MHz; 
CDCI3 ) [1.94 (1.3 H, s) and 1.99 (1.7 H, s) 11-H], [2.74 (0.9 H, t, J  8.0 Hz) and
2.94 (1.1 H, t, J 7.2 Hz) 7-H], [3.26 (0.9 H, t, J 7.8 Hz) and 3.43 (1.1 H, t, J 7 A  
Hz) 8 -H], [3.70 (1.7 H, s) and 3.73 (1.3 H, s) 19-H], 4.43 (2 H, s, 12-H), 6.76 (2 
H, m, 2 ,6 -H), 7.05 (2 H, m, 3,5-H) and 7.24 (5 H, m, 14 to 18-H); Sc (100 MHz;
113
CDCI3 ) 20.3 and 20.7 (II-C H 3 ), 31.4 and 32.9 (7-CH2), 45.5 and 46.5 (8 -CH2 ),
47.3 and 52.3 (12-CH2), 54.3 and 54.4 (19-CH3), 113.7 and 113.8 (2 ,6 -CH),
123.6 and 124.8 (4-quat. C), 126.4 and 126.7 (18-CH), 125.4 and 127.2 (16,17- 
CH), 127.6 and 127.9 (14,15-CH), 131.3 and 133.3 (3,5-CH), 135.7 and 136.5 
(13-quat. C), 157.8 and 158.5 (1-quat. C) and 169.4 and 170.1 (10-CO); m/z 
(El) 315.1296 (M+*. C18H21NO2 S requires 315.1299); m/z{%) 315 (14.9), 272
(1.4), 176 (67.4), 166 (89.4), 139(19.9), 120 (32.6), 91 (100) and 65 (6.4).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-methylcyclohexanecarboxamide 81
Compound 81 was prepared from compound 74 (610 mg, 2.08 mmol), 
methyl iodide (0.45 mL, 1.03 g, 7.29 mmol) and sodium hydride (60% dispersion 
in mineral oil, 167 mg, 4.16 mmol) by the method used to prepare compound 
78. Purification by column chromatography, eluant ethyl acetate-hexane (1:1), 
provided title compound 81 (520 mg, 1.69 mmol, 81%) as a clear yellow oil. 
vmax (thin film)/cm'1 2929s and 2853m (CH), 1638s (CO), 1593m and 1495s 
(C=C), 1463m (CH), 1246s and 1031m (C-O) and 828m (CH); 8h (400 MHz; 
CDCI3 ) 0.90-1.64 (10 H, m, 12 to 16-H), [2.00 (0.4 H, tt, J11.6 and 3.6 Hz) and 
2.34 (0.6 H, tt, J 11.6 and 3.3 Hz) 11-H], [2.79 (1.4 H, s) and 2.95 (1.6 H, s) 17- 
H], [2.83 (0.9 H, t, J 7.6 Hz) and 2.91 (1.1 H, t, J 7.2 Hz) 8 -H], [3.71 (1.9 H, s) 
and 3.73 (1.6 H, s) 18-H], [6.76 (1.1 H, AA'BB', d, J  8.8 Hz) and 6.81 (0.9 H, 
AA'BB', d, J  8.8 Hz) 2,6-H] and [7.29 (1.1 H, AA'BB', d, J 8.8 Hz) and 7.33 (1.1 
H, AA'BB', d, J 8.8 Hz) 3,5-H]; 8c  (100 MHz; CDCI3 ) 26.0 and 26.1 (14 to 16- 
CH2 ), 29.4 and 29.9 (12.13-CH2), 32.9 and 34.9 (7-CH2), 33.9 and 36.1 (17- 
CH3 ), 40.8 and 41.3 (11-CH), 48.7 and 49.5 (8 -CH2 ), 55.7 and 55.8 ( I 8 -CH3 ),
115.1 and 115.2 (2,6-CH), 125.1 and 126.2 (4-quat. C), 133.0 and 134.6 (3,5- 
CH), 159.2 and 160.0 (1-quat. C) and 176.4 and 176.5 (10-CO); m/z (El) 
307.1605 (M+V C17H2 5 NO2 S requires 307.1604); m/z (%) 307 (8 .6 ), 166 
(100), 139(15.0), 111 (5.0), 83 (37.9) and 55 (16.4).
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/V-{2-[(4-Methoxyphenyl)thio]ethyl)A/-ethylcyclohexanecarboxamide 82
OCH
13 14
12 15
Compound 82 was prepared from compound 74 (1.80 g, 6.14 mmol), 
ethyl bromide (1.60 mL, 2.34 g, 21.5 mmol) and sodium hydride (60% 
dispersion in mineral oil, 442 mg, 11.1 mmol) by the method used to prepare 
compound 78. Purification by column chromatography, eluant diethyl ether- 
hexane (3:1), provided title compound 82 (524 mg, 1.63 mmol, 27%) as a yellow 
oil. vmax (thin film)/cm'1 2929s and 2854m (CH), 1638s (CO), 1593m and 
1494s (C=C), 1450m and 1427m (CH), 1246s and 1031m (C-O) and 828m 
(CH); 8h (400 MHz; CDCI3 ) [0.97 (1.7 H, t, J  7.1 Hz) and 1.06 (1.3 H, t, J 7.1 
Hz) 18-H], 1.07-1.70 (10 H, m, 12 to 16-H), [1.91 (0.4 H, tt, J 11.4 and 3.6 Hz) 
and 2.30 (0.6 H, tt, J11.6 and 3.3 Hz) 11-H], [2.80 (0.9 H, t, J  8.0 Hz) and 2.91 
(1.1 H, t, J 6.4 Hz) 7-H], 3.21-3.30 (2 H, m, 17-H), [3.21-3.30 (0.9 H, m) and 
3.36 (1.1 H, t, J7 .4  Hz) 8 -H], [3.71 (1.7 H, s) and 3.73 (1.3 H, s) 19-H], [6.77 
(1.1 H, AA'BB', d, J  8.8  Hz) and 6.81 (0.9 H, AA'BB', d, J8 .4  Hz) 2,6-H] and 
[7.29 (1.1 H, AA'BB', d, J 8.8 Hz) and 7.34 (0.9 H, AA'BB', d, J  8.8  Hz) 3,5-H]; 
8c  (100 MHz; CDCI3 ) 13.5 and 15.3 ( I8 -CH3 ), 25.9 and 26.2 (14 to I 6 -CH2 ),
29.9 and 30.0 (12,13-CH), 33.0 and 35.5 (7-CH2), 41.2 (11-CH), 41.0 and 43.6 
(17-CH2), 46.4 and 47.2 (8 -CH2 ), 55.7 and 55.8 (19-CH3), 115.3 and 115.2 
(2 ,6 -CH), 125.1 and 126.3 (4-quat. C), 132.7 and 134.8 (3,5-CH), 159.2 and
160.0 (1-quat. C) and 176.0 and 176.4 (10-CO); m /z  (El) 321.1765 (M+*. 
C18H2 7 NO2 S requires 321.1767); m/z (%) 321 (14.9), 293 (1.4), 182 (100), 
166 (96.5), 139 (16.3), 111 (5.7), 83 (39.7) and 58 (29.8).
115
A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-benzylcyclohexanecarboxamide 83
OCH
13 14
22
23 20
16
21
Compound 83 was prepared from compound 74 (300 mg, 1.02 mmol), 
benzyl bromide (0.43 mL, 613 mg, 3.57 mmol) and sodium hydride (60% 
dispersion in mineral oil, 74 mg, 1.85 mmol) by the method used to prepare 
compound 78. Purification by column chromatography, eluant hexane-diethyl 
ether (1:1), provided title compound 83 (149 mg, 0.39 mmol, 38%) as a pale 
yellow oil. vmax (thin film)/cm_1 2928s and 2854m (CH), 1641s (CO), 1593m 
and 1494s (C=C), 1450m and 1424m (CH), 1246s and 1030m (C-O) and 828s 
and 699s (CH); Sh (400 MHz; CDCI3 ) 0.97 (4 H, m, 12,13-H), 1.13 (6 H, m, 14 
to 16-H), [2.02 (0.6 H, tt, J 11.2 and 3.5 Hz) and 2.35 (0.4 H, tt, J 11.6 and 3.3 
Hz) 11-H], [2.72 (1.1 H, t, J 8.0 Hz) and 2.90 (0.9 H, t, J 7.3 Hz) 7-H], [3.23 (1.1 
H, t, J  8.0 Hz) and 3.39 (0.9 H, t, J 7.3 Hz) 8 -H], [3.68 (1.4 H, s) and 3.69 (1.6 H, 
s) 24-H], [4.44 (1.1 H, s) and 4.47 (0.9 H, s) 17-H], [6.73 (0.9 H, AA'BB1, d, J 8.8 
Hz) and 6.78 (1.1 H, AA'BB1, d, J 8.8 Hz) 2,6-H], 7.01 (2 H, m, 3,5-H) and 7.20 
(5 H, 19 to 23-H); 5c (100 MHz; CDCI3 ) 24.6 and 24.7 (14 to I 6 -CH2 ), 28.5 and
28.6 (12.13-CH2), 31.4 and 33.7 (7-CH2), 39.6 and 39.9 (11-CH), 45.4 and 45.5 
(8 -CH2 ), 47.3 and 51.1 (17-CH2), 54.3 and 54.3 (24-CH3), 113.7 and 113.9 
(2 ,6 -CH), 123.6 and 124.8 (4-quat. C), 125.4 and 126.9 (21,22-CH), 126.3 and
126.6 (23-CH), 127.5 and 127.8 (19,20-CH), 133.4 and 136.2 (3,5-CH), 136.2 
and 137.1 (18-quat. C), 157.7 and 158.6 (1-quat. C) and 175.2 and 175.7 (10- 
CO); m/z (El) 383.1917 (M+#. C23H2 9NO2 S requires 383.1914); m/z (El) (%) 
383 (12.8), 272 (2.5), 244 (81.6), 230 (4.3), 217 (2.1), 166 (83.7), 120 (26.9), 83 
(100) and 55 (20.6).
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A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-methylbenzamide 84
OCH
15
Compound 84 was prepared from compound 75 (660 mg, 2.30 mmol), 
methyl iodide (0.57 mL, 1.31 g, 9.20 mmol) and sodium hydride (60% dispersion 
in mineral oil, 166 mg, 4.15 mmol) by the method used to prepare compound 
78. Purification by column chromatography, eluant diethyl ether-hexane (4:1), 
provided title compound 84 (475 mg, 1.58 mmol, 68%) as a yellow oil. vmax 
(thin film)/cm'1 2929w and 2836w (CH), 1634s (CO), 1593m and 1494s (C=C), 
1444m (CH), 1246s and 1028m (C-O) and 827m and 712m (CH); 8h (400 MHz; 
CDCI3 ) [2.78 (0.9 H, br. t) and 3.07 (1.1 H, br. t) 7-H], [2.88 (1.7 H, br. s) and
2.95 (1.3 H, br. s) 17-H], [3.33 (0.9 H, br. t) and 3.61 (1.1 H, br. t) 8-H], 3.70 (3 
H, s, 18-H), [6.63 (0.9 H, AA'BB', br. d) and 6.78 (1.1 H, AA'BB', br. d, AA'BB')
2,6-H], [7.01 (0.9 H, AA'BB', br. d) and 7.19-7.36 (1.1 H, AA'BB', br. d) 3,5-H],
7.21-7.36 (5 H, br. m, 12 to 16-H); 6c  (100 MHz; CDCI3 ) 31.5 and 32.6 (7- 
CH2 ), 32.1 and 37.6 ( I 7 -CH3 ), 46.6 and 49.9 (8 -CH2 ), 54.3 ( I 8 -CH3 ), 113.7 
and 113.9 (2,6-CH), 123.5 and 124.5 (4-quat. C), 125.5 and 126.0 (14,15-CH),
127.3 and 127.4 (12,13-CH), 128.3 and 128.6 (16-CH), 131.9 and 132.3 (3,5- 
CH), 135.2 (11-quat. C), 158.0 and 158.1 (1-quat. C) and 170.5 and 170.9 (10- 
CO); m/z (El) 301.1138 (M+*. C17H19NO2 S requires 301.1139); m/z (%) 301
(23.9), 166 (100), 162 (74.3), 139 (9.3), 105 (99.3), 77 (49.6) and 51 (6.4).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-ethylbenzamide 85
0 C H 3  
1] 19
18 15
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Compound 85 was prepared from compound 75 (287 mg, 1.00 mmol) 
ethyl bromide (0.26 mL, 381 mg, 3.50 mmol), and sodium hydride (60% 
dispersion in mineral oil, 72 mg, 1.80 mmol) by the method used to prepare 
compound 78. Purification by column chromatography, eluant hexane-ethyl 
acetate (3:2), provided title compound 85 (164 mg, 0.52 mmol, 52%) as a yellow 
o il. vmax (thin film)/cnr1 2969w and 2935w (CH), 1633s (CO), 1593m and 
1494m (C=C), 1464m and 1443m (CH), 1246s and 1029m (C-O) and 828m and 
707m (CH); 6h (400 MHz; CDCI3) [0.95 (1.8 H, br. t) and 1.11 (1.2 H, br. t) 18- 
H], [2.75 (0.8 H, br. t) and 3.09 (1.2 H, br. t) 7-H], [3.19 (1.2 H, br. q) and 3.29 
(0.8 H, br. q) 17-H], [3.42 (0.8 H, br. t) and 3.55 (1.2 H, br. t) 8 -H], 3.69 (3 H, s, 
19-H), [6.62 (0.8 H, AA'BB', br. d) and 6.78 (1.2 H, AA'BB', br. d) 2,6-H], [6.99 
(0.8 H, AA'BB', br. d) and 7.19-7.34 (1.2 H, AA'BB', br. d) 3,5-H] and 7.19-7.34 
(4 H, br. m, 12 to 16-H); 5c (100 MHz; CDCI3 ) 12.0 and 13.2 ( I 8 -CH3 ), 31.5 
and 32.8 (7-CH2), 39.1 and 47.5 (17-CH2), 43.8 and 43.9 (8 -CH2 ), 54.3 and
54.5 (19-CH3), 113.7 and 113.9 (2,6-CH), 125.3 (14,15-CH), 127.4 (12,13-CH),
128.1 (4-quat.C), 128.3 (16-CH), 131.5 and 132.3 (3,5-CH), 135.6 (11-quat. C),
157.9 (1-quat. C) and 170.8 (10-CO); m/z (El) 315.1291 (M+*. C18H2 1 NO2 S 
requires 315.1289); m/z (%) 315 (16.3), 176 (66.7), 166 (100), 139 (8.5), 105 
(100), 77 (39.7) and 51 (4.3).
A/-{2-[(4-Methoxyphenyl)thio]ethyl}A/-benzylbenzamide 86
Compound 86 was prepared from compound 75 (1.0 g, 3.48 mmol), 
benzyl bromide (1.66 mL, 2.38 g, 13.9 mmol) and sodium hydride (60% 
dispersion in mineral oil, 251 mg, 6.28 mmol) by the method used to prepare 
compound 78. Purification by column chromatography, eluant diethyl ether- 
hexane (2:1), provided title compound 86 (541 mg, 1.44 mmol, 41%) as a pale 
yellow oil. vmax (thin film)/cm"1 2938w and 2835w (CH), 1633s (CO), 1494s 
and 1593m (C=C), 1420m (CH), 1247s and 1029s (C-O) and 827m and 700s
o c h 3
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(CH); 5h (400 MHz; CDCI3 ) [2.67 (0.9 H, br. t) and 3.05 (1.1 H, br. t) 7-H], [3.25 
(0.9 H, br. t) and 3.52 (1.1 H, br. t) 8-H], 3.70 (3 H, s, 24-H), [4.45 (1.1 H, br. s) 
and 4.63 (0.9 H, br. s) 17-H], [6.62 (0.9 H, AA'BB', br. d) and 6.74 (1.1 H, 
AA'BB', br. d) 2 ,6 -H], [6.99 (1.1 H, AA'BB', br. d) and 7.19-7.31 (0.9 H, AA'BB', 
br. d) 3,5-H] and 7.19-7.31 (10 H, br. m, 12 to 16-H and 19 to 23-H); 6c  (100 
MHz; CDCI3 ) 32.8 and 33.9 (7-CH2), 45.5 and 48.4 (8 -CH2 ), 54.3 and 60.8 (17- 
CH2 ), 55.7 (24-CH3), 115.1 (2 ,6-CH), 126.8 (23-CH), 127.2 (14,15-CH), 127.4 
(20,21-CH), 128.6 (4-quat. C), 128.9 (12,13-CH), 129.2 (19,20-CH), 130.0 (16- 
CH), 132.9 (3,5-CH), 133.9 (11-quat. C), 136.6 (18-quat. C), 159.4 (1-quat. C) 
and 172.7 (10-CO); m/z (El) 377.1451 (M+*. C2 3 H2 3NO2 S requires 377.1453) 
m/z (%) 377 (8 .6 ), 328 (4.3), 272 (2.5), 238 (43.6), 224 (6.1), 166 (3.6), 139
(11.1), 105 (100), 91 (40.7) and 77 (32.1).
A/-{2 -[(4 -Hydroxyphenyl)thio]ethyl}A/-/77ethylacetamide 87
OH
1 2 C H 3
To a solution of acetamide 78 (600 mg, 2.51 mmol) in dichloromethane 
(20 mL), at -78 °C, was added dropwise boron tribromide (1 M in DCM, 10.0 
mL, 10.0 mmol). After stirring at -78 °C for 1 h the reaction mixture was allowed 
to slowly warm to rt whereupon stirring was continued for a further 2 h. The 
reaction mixture was poured into ice/water (40 mL) and the product extracted 
with chloroform (3 x 20 mL). The combined organic extracts were washed with 
saturated sodium bicarbonate ( 2 x 1 5  mL) and brine ( 2 x 1 0  mL), dried over 
anhydrous magnesium sulfate and concentrated in vacuo. Purification by 
column chromatography, eluant ethyl acetate, followed by recrystallisation from 
ethyl acetate provided the title compound 87 (434 mg, 1.93 mmol, 77%) as 
white needles, mp 95-97 °C (Found: C, 58.57; H, 6.60; N, 6.18. C11H15NO2 S 
requires C, 58.67; H, 6.67; N, 6.22%); A,max (MeOH)/nm 254 (e/dm^ moM cm"1 
7000); vmax (KBr disc)/cnr1 3078-2605m (OH), 1609s (CO), 1574s and 1495s 
(C=C), 1447s (CH), 1277s (OH), 1240s (C-O) and 827s (CH); 8h (400 MHz; 
CDCI3 ) [1.91 (1.0 H, s) and 1.97 (2.0 H, s) 11-H], [2.73 (1.0 H, s) and 2.93 (2.0 
H, s) 12-H], [2.87 (0.7 H, t, J 7.2 Hz) and 2.91 (1.3 H, t, J  7.2 Hz) 7-H], [3.83
119
(0.7 H, t, J 7.2 Hz) and 3.49 (1.3 H, t, J 7.2 Hz) 8 -H], 6.76 (2 H, m, 2,6-H) and 
[7.22 (0.7 H, AA'BB', d, J 8.8 Hz) and 7.26 (1.3 H, AA'BB', d, J 8.8 Hz) 3,5-H]; 
5c (100 MHz; CDCI3 ) 20.1 and 20.5 (H -CH 3 ), 31.1 and 33.4 (7-CH2), 32.2 and
36.0 (12-CH3 ), 47.2 and 49.5 (8-CH2 ), 115.3 and 115.6 (2 ,6 -CH), 122.2 and
122.5 (4-quat. C), 132.2 and 133.4 (3,5-CH), 155.9 and 156.3 (1-quat. C) and
170.5 and 170.9 (10-CO); m/z (El) 225.0823 (M+*. C11H15NO2 S requires 
225.0823); m/z (%) 225 (18.5), 166 (17.8), 152 (100), 125 (12.8), 100 (71.9), 83
(13.5) and 58 (14.2).
A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-ethylacetamide 88
OH
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Compound 88 was prepared from 79 (450 mg, 1.78 mmol) and boron 
tribromide (1 M in DCM, 7.10 mL, 7.10 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant ethyl acetate, and 
recrystallisation from benzene provided the title compound 88  (254 mg, 1.06 
mmol, 60%) as white needles, mp 68-70 °C (Found: C, 59.86; H, 6.75; N, 5.69. 
C12H17NO2 S requires C, 60.25; H, 7.11; N, 5.86%); Vnax (MeOH)/nm 254 
(e/dm3 moH cm"’* 7360); vmax (KBr disc)/crrr 1 3088-2608m (OH), 2964m and 
2932m (CH), 1611s (CO), 1576s and 1493s (C=C), 1434s (CH), 1271s (OH) 
and 828m (CH); 6h (400 MHz; CDCI3 ) [0.98 (0.9 H, t, J7.1 Hz) and 1.08 (2.1 H, 
t, J 7.2 Hz) 13-H], [1.84 (0.9 H, s) and 1.97 (2.1 H, s) 11-H], [2.84 (0.6 H, t, J 7 .5 
Hz) and 2.93 (1.4 H, t, J  7.5 Hz) 7-H], [3.21 (0.6 H, q, J 7.0 Hz) and 3.25 (1.4 H, 
q, J 7.2 Hz) 12-H], [3.33 (0.6 H, t, J7 .4  Hz) and 3.44 (1.4 H, t, J 7.6 Hz) 8 -H],
6.75 (2 H, AA'BB', d, J  8.8 Hz, 2 ,6 -H), 7.24 (2 H, m, 3,5-H) and [8.69 (0.3 H, br. 
s) and 9.09 (0.7 H, br. s) 14-H]; 6c  (100 MHz; CDCI3) 13.2 and 14.4 ( I3 -CH3 ),
21.3 and 21.6  (H -CH 3 ), 32.6 and 35.1 (7-CH2), 40.9 and 44.8 (12-CH2), 46.8 
and 48.5 (8 -CH2 ), 116.7 and 116.9 (2 ,6 -CH), 123.5 and 124.0 (4-quat. C),
133.2 and 135.0 (3,5-CH), 157.1 and 157.7 (1-quat. C) and 171.4 and 171.9 
(10-CO); m/z (El) 239.0983 (M+#. C12H17NO2 S requires 239.0986); m/z (%) 
239 (15.5), 237 (0.7), 152 (100), 114 (78.9), 100 (7.7), 72 (10.6) and 58 (79.6).
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A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-benzylacetamide 89
Compound 89 was prepared from 80 (400 mg, 1.27 mmol) and boron 
tribromide (1 M in DCM, 5.08 mL, 5.08 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant diethyl ether, and 
recrystallisation from chloroform/hexane provided the title compound 89 (291 
mg, 0.97 mmol, 76%) as white crystals, mp 90-92 °C (Found: C, 67.70; H, 6.49; 
N, 4.46. C17H19NO2 S requires C, 67.77; H, 6.31; N, 4.65%); \ max (MeOH)/nm 
253 (e/dm3 moH cm'1 6800); vmax (KBr disc)/cm"'* 3100-2500m (OH), 2933m 
(CH), 1606s (CO), 1494s and 1476s (C=C), 1433s (CH), 1360m (CH),1284s (C- 
O) and 835s and 695s (CH); 5h (400 MHz; CDCI3 ) [1.92 (1.2 H, s) and 2.01 
(1.8 H, s) 11-H], [2.74 (0.8 H, t, J  7.3 Hz) and 2.92 (1.2 H, t, J 6.9 Hz) 7-H], 
[3.30 (0.8 H, t, J 7.2 Hz) and 3.48 (1.2 H. t, J 6.9 Hz) 8 -H], [4.41 (0.8 H, s) and 
4.45 (1.2 H, s), 12-H], 6.75 (2 H, AA'BB', d, J8.0 Hz, 2,6-H), 7.03 (2 H, AA'BB', 
d, J 6.0 Hz, 3,5-H), 7.17-7.26 (5 H, m, 14 to 18-H) and [8.40 (0.4 H, br. s) and
8.76 (0.6 H, br. s) 19-H]; 8c  (100 MHz; CDCI3 ) 21.5 and 21.8 (H-CH3 ), 32.6 
and 34.6 (7-CH2), 47.4 and 53.6 (12-CH2), 48.0 and 48.8 (8 -CH2 ), 116.8 and
117.0 (2,6-CH), 123.5 and 124.2 (4-quat. C), 126.8 and 128.6 (16,17-CH),
128.0 and 128.3 (18-CH), 129.1 and 129.5 (14,15-CH), 133.3 and 135.1 (3,5- 
CH), 136.4 and 137.3 (13-quat. C), 157.0 and 157.7 (1-quat. C) and 171.9 and
173.0 (10-CO); m/z (El) 301.1134 (M+*. C17H19NO2 S requires 301.1132); m/z 
(%) 301 (13.4), 258 (1.4), 176 (54.9), 152 (93.7), 120 (42.3), 106 (4.2), 91 (100), 
65 (8 .8) and 63(1.4).
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A/-{2-[(4-Hydroxyphenyl)thio]ethyl}/V-methylcyclohexanecarboxamide 90
OH
13 14
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Compound 90 was prepared from 81 (400 mg, 1.30 mmol) and boron 
tribromide (1 M in DCM, 5.46 mL, 5.46 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant diethyl ether, and 
recrystallisation from diethyl ether provided the title compound 90 (259 mg, 0.88 
mmol, 68%) as cream crystals, mp 90-92 °C (Found: C, 65.55; H, 7.81; N, 4.73. 
C16H23NO2 S requires C, 65.53; H, 7.85; N, 4.78%); Vnax (MeOH)/nm 253 
(s/dm^ mol-1 cm-1 3960); vmax (KBr disc)/cm_1 3155m (OH), 2929m and 
2852m (CH), 1615s (CO), 1580s and 1497s (C=C), 1447m (CH), 1269m (OH), 
1234m (C-O) and 835m (CH) ; 5h (400 MHz; CDCI3) 0.96-1.72 (10 H, m, 12 to 
16-H), [2.13 (0.4 H, tt, J 11.6 and 3.2 Hz) and 2.38 (0.6 H, tt, J 11.6 and 3.2 Hz) 
11-H], [2.76 (1.2 H, s) and 2.99 (1.8 H, s) 17-H], 2.83-2.89 (2 H, m, 7-H), [3.38 
(0.8 H, t, J 7.4 Hz) and 3.46 (1.2 H, t, J 7 A  Hz) 8 -H], [6.71 (1.2 H, AA'BB', d, J 
8.8 Hz) and 6.80 (0.8 H, AA'BB', d, J 8.8 Hz) 2,6-H], [7.22 (0.8 H, AA'BB', d, J 
8.4 Hz) and 7.25 (1.2 H, AA'BB', d, J8.4 Hz) 3,5-H] and [8.00 (0.4 H, br. s) and
8.20 (0.60 H, br. s) 18-H]; 6c  (100 MHz; CDCI3) 26.0 and 26.1 (14 to I 6-CH2 ),
29.3 and 29.9 (12.13-CH2), 33.1 and 35.1 (7-CH2), 34.2 and 36.6 (17-CH3),
41.0 and 41.5 (11-CH),48.8 and 49.8 (8 -CH2 ), 116.8 and 117.0 (2 ,6 -CH), 123.7 
and 124.0 (4-quat. C), 134.0 and 134.9 (3,5-CH), 157.2 and 157.6 (1-quat. C) 
and 177.4 and 177.5 (10-quat. C); m/z (El) 293.1448 (M+#. C16H23NO2 S 
requires 293.1447); m/z (%) 293 (13.7), 170 (86.3), 152 (100), 142 (17.3), 125
(15.1), 83 (48.9) and 55 (20.5).
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A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-ethylcyclohexanecarboxamide 91
OH
13 14
Compound 91 was prepared from 82 (380 mg, 1.18 mmol) and boron 
tribromide (1 M in DCM, 5.92 mL, 5.92 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant ethyl acetate- 
hexane (3:1), and recrystallisation from benzene provided the title compound 91 
(154 mg, 0.50 mmol, 43%) as white crystals, mp 103-104 °C ; ^max (MeOH)/nm 
253 (e/dm^ moH cm“1 5990); vmax (KBr disc)/cm~1 3100-2900m (OH), 2933m 
and 2855m (CH), 1600s (CO), 1583s and 1499s (C=C), 1431m (CH), 1272s 
(OH), 1226m (C-O) and 833m (CH); 5h (400 MHz; CDCI3 ) [0.97 (1.5 H, t, J 6 .8 
Hz) and 1.09 (1.5 H, t, J 7.0 Hz) 18-H], 0.95-1.17 (6 H, m, 14 to 16-H), 1.33-
I.70 (4 H, m, 12,13-H), [2.02 (0.9 H, br. t, J 11.6 Hz) and 2.33 (1.1 H, br. t, J
I I .4  Hz) 11-H], [2.81 (0.9 H, t, J7.6 Hz) and 2.89 (1.1 H, t, J7.4 Hz) 7-H], 3.32-
3.20 (2 H, m, 17-H), [3.32 (0.9 H, t) and 3.41 (1.1 H, t, J7.4 Hz) 8-H], [6.70 (1.1 
H, AA'BB', d, J 8.2 Hz) and 6.81 (0.9 H, AA'BB', d, J 8.2 Hz) 2,6-H], [7.22 (1.1 
H, AA'BB', d, J  8.3 Hz) and 7.26 (0.9 H, AA'BB', d, J 8.2 Hz) 3,5-H] and [8.32 
(0.4 H, br. s) and 8.40 (0.6 H, br. s) 19-H]; 6c  (100 MHz; CDCI3 ) 13.4 and 15.3 
( I8 -CH3 ), 26.0 and 26.1 (14 to 16-CH2), 29.8 and 29.9 (12.13-CH2), 33.4 and
35.7 (7-CH2), 41.1 and 41.3 (17-CH2), 41.3 and 43.7 (11-CH), 46.8 and 47.5 
(8-CH2 ), 116.8 and 117.0 (2 ,6 -CH), 123.4 and 123.9 (4-quat. C), 133.9 and
135.1 (3,5-CH), 157.2 and 157.8 (1-quat. C) and 176.9 and 177.4 (10-CO); m/z 
(El) 307.1609 (M+#. C17H2 5 NO2 S requires 307.1612); m/z(%) 307 (14.2), 182 
(100), 232 (0.7), 152 (93.6), 125 (17.0), 111 (8.5), 83 (56.0) and 58 (46.1).
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A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-benzylcyclohexanecarboxamide 92
OH
22
23
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Compound 92 was prepared from 83 (265 mg, 0.69 mmol) and boron 
tribromide (1 M in DCM, 2.77 mL, 2.77 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant diethyl ether- 
hexane (2:1), provided the title compound 92 (135 mg, 0.37 mmol, 53%) as a 
pale tan powder, mp 117-120 °C; Vnax (MeOH)/nm 256 (e/dm^ moH cm""* 
10120); vmax (KBr disc)/crrr1 3100-2900m (OH), 2954m and 2958m (CH), 
1618s (CO), 1583s and 1495s (C=C), 1436s (CH), 1263s (OH), 1146m (C-O) 
and 836m and 696m (CH); 5h (400 MHz; CDCI3 ) 0.95-1.18 (4 H, m, 12,13-H),
I.41-1.68 (6 H, m, 14 to 16-H), [2.11 (0.5 H, tt, J11.4 Hz) and 2.39 (0.6 H, tt, J
I I .6  and 3.2 Hz) 11-H], [2.73 (1.0 H, t, J7.8 Hz) and 2.88 (1.0 H, t, J7.4 Hz) 7- 
H], [3.28 (1.0 H, t, J 7.8 Hz) and 3.43 (1.0 H, t, J7 .4  Hz) 8 -H], [4.44 (1.0 H, s) 
and 4.51 (1.0, s) 17-H], [6.69 (1.0 H, AA'BB1, d, J 6.8 Hz) and 6.77 (1.0 H, 
AA'BB', d, J 8.8 Hz) 2,6-H], 7.01 (2 H, m, 3,5-H), 7.14-7.29 (5 H, m, 19to23-H) 
and [7.77 (0.5 H, br. s) and 7.84 (0.5 H, br. s) 24-H]; 5c (100 MHz; CDCI3 ) 24.6 
and 24.7 (14,15,16 -CH2 ), 28.4 and 28.5 (12,13-CH2), 31.8 and 33.8 (7-CH2),
39.7 and 40.1 (11-CH), 45.6 and 45.8 (8-CH2 ), 47.5 and 51.1 (17-CH2), 115.4 
and 115.6 (2,6-CH), 122.3 and 123.0 (4-quat. C), 125.4 and 126.8 (21,22-CH),
126.4 and 126.7 (23-CH), 127.6 and 128.0 (19,20-CH), 132.3 and 133.7 (3,5- 
CH), 135.6 and 136.4 (18-quat. C), 155.5 and 156.1 (1-quat. C) and 176.1 and
176.7 (10-CO); m/z (El) 369.1761 (M+#. C2 2 H27NO2 S requires 369.1760); m/z 
(%) 369 (13.5), 244 (100), 218 (46.1), 205 (1.4), 152 (94.3), 120 (51.1), 91
(73.1), 83 (53.2) and 55 (33.3).
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A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-methylbenzamide 93
Compound 93 was prepared from 84 (300 mg, 1.00 mmol) and boron 
tribromide (1 M in DCM, 4.0 mL, 4.0 mmol) by the method used to prepare 
compound 87. Recrystallisation from ethyl acetate provided the title compound 
93 (253 mg, 0.88  mmol, 88%) as white crystals, mp 121-122  °C (Found: C, 
66.73; H, 5.87; N, 4.79. C16H17NO2 S requires C, 66.90; H, 5.92; N, 4.88%); 
^max (MeOH)/nm 253 (e/dm^ mol" 1 cm"1 9380); vmax (KBr disc)/cm ' 1 3100- 
2600m (OH), 2918m and 2859m (CH), 1608s (CO), 1574s and 1494s (C=C), 
1440s (CH), 1236s (C-O) and 831m and 698m (CH); 8h (400 MHz; CDCI3 ) 
[2.80 (0.6 H, t, J 7.2 Hz) and 3.04 (1.4 H, t, J7.0 Hz) 7-H], 2.92 (3 H, s, 17-H), 
[3.36 (0.6 H, t, J 7.2 Hz) and 3.66 (1.4 H, t, J7.0 Hz) 8-H], [6.56 (0.6 H, AA'BB', 
d, J 8.2 Hz) and 6.69 (1.4 H, AA'BB', d, J  8.4 Hz) 2,6-H], [6.98 (0.6 H, AA'BB', d, 
J8.1 Hz) and 7.22-7.33 (1.4 H, AA'BB', d) 3,5-H], 7.22-7.33 (5 H, m, 12 to 16-H) 
and 7.83 (1 H, br. s, 18-H); 5c (100 MHz; CDCI3 ) 32.2 and 37.5 (17-CH3), 31.7 
and 33.2 (7-CH2), 46.9 and 50.1 (8 -CH2 ), 115.4 (2 ,6 -CH), 122.5 (4-quat. C),
125.5 and 125.9 (14,15-CH), 127.5 (16-CH), 128.6 and 129.0 (12,13-CH), 132.6 
and 132.9 (3,5-CH), 134.5 and 137.1 (11-quat. C), 155.8 (1-quat. C) and 171.4 
(10-CO); m/z (El) 287.0977 (M+*. C16H17NO2 S requires 287.0974); m/z (%) 
287 (12.0), 163 (4.2), 152 (80.9), 136 (10.6), 105 (100), 77 (45.8) and 51 (7.7).
A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-ethylbenzamide 94
125
Compound 94 was prepared from 85 (880 mg, 2.79 mmol) and boron 
tribromide (1 M in DCM, 11.2 mL, 11.2 mmol) by the method used to prepare 
compound 87. Purification by column chromatography, eluant ethyl acetate- 
hexane (3:2), and recrystallisation from ethyl acetate provided the title 
compound 94 (441 mg, 1.47 mmol, 53%) as white needles, mp 120-122 °C 
(Found: C, 67.58; H, 6.32; N, 4.56. C17H19NO2 S requires C, 67.77; H, 6.31; N, 
4.65%); A,max (MeOH)/nm 253 (e/dm^ moH cm"1 7780); Vmax (KBr disc)/cm"1 
3109-2792m (OH), 3077m and 2934m (CH), 1604s (CO), 1572s and 1495s 
(C=C), 1431m (CH), 1269s (OH) and 829w (CH); 5h (400 MHz; CDCI3 ) [1.00 
(2.1 H, t, J7.0 Hz) and 1.22 (0.9 H, br. t) 18-H], [2.74 (0.6 H, br. t) and 3.07 (1.4 
H, t, J 7.2 Hz) 7-H], [3.24 (1.4 H, q, J 6.9 Hz) and 3.31 (0.6 H, br. q) 17-H], [3.41 
(0.6 H, br. t) and 3.60 (1.4 H, t, J 7.2 Hz) 8 -H], [6.53 (0.6 H, d, J 7.5 Hz) and 
6.67 (1.4 H, AA'BB', d, J 8.3 Hz) 2,6-H], [6.92 (0.6 H, AA'BB', d, J 7.4 Hz) and
7.22-7.45 (1.4 H, AA’BB', d) 3,5-H], 7.22-7.45 (5 H, m) and 8.05 (1 H, br. s, 19- 
H); 8c  (100 MHz; CDCI3 ) 11.9 and 13.1 ( I 8 -CH3 ), 31.7 and 33.3 (7-CH2), 39.4 
and 47.7 (17-CH2), 43.8 and 44.3 (8 -CH2 ), 115.4 and 115.5 (2 ,6 -CH), 121.9 
and 122.7 (4-quat. C), 125.2 (14,15-CH), 127.5 (12,13-CH), 128.5 and 128.7 
(16-CH), 132.3 and 132.9 (3,5-CH), 134.8(11-quat. C), 155.7 (1-quat. C) and
171.2 and 171.6 (10-CO); m/z (El) 301.1135 (M+V C17H19NO2 S requires
301.1133); m/z (%) 301 (15.5), 176 (36.9), 152 (68.1), 150 (12.8), 105 (100), 77
(36.9) and 51 (4.9).
A/-{2-[(4-Hydroxyphenyl)thio]ethyl}A/-benzylbenzamide 95
OH
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Compound 95 was prepared from 86 (346 mg, 0.92 mmol) and boron 
tribromide (1 M in DCM, 3.67 mL, 3.67 mmol) by the method used to prepare 
compound 87. Recrystallisation from ethyl acetate provided the title compound 
95 (241 mg, 0.66  mmol, 72%) as white crystals, mp 101-102 °C (Found: C, 
72.59; H, 5.79; N, 3.83. C2 2H2 1 NO2 S requires C, 72.73; H, 5.71; N, 3.86%);
126
Vnax (MeOH)/nm 254 (e/dm^ mol""* cm""* 9700); vmax (KBr disc)/cm'"* 3400- 
3000m (OH), 2949m (CH), 1613s (CO), 1598s and 1498s (C=C), 1465m (CH), 
1277s (OH), 1360m (CH), 1158m (C-O) and 826m and 698m (CH); 5h (400 
MHz; CDCI3 ) [2.68 (0.7 H, br. t) and 3.02 (1.3 H, t, J7.0 Hz) 7-H], [3.26 (0.7 H, 
br. t) and 3.55 (1.3 H, t, J 7.0 Hz) 8 -H], [4.48 (1.3 H, s) and 4.61 (0.7 H, s) 17- 
H], 6.36 (1 H, br. s, 24-H), [6.54 (0.6 H, AA'BB', d, J 7.7 Hz) and 6.67 (1.4 H, 
AA'BB', d, J 8.2 Hz) 2,6-H], [6.90 (0.6 H, AA'BB', d, J 7.7 Hz) and 7.02 (1.4 H, 
AA'BB', d, J 7.0 Hz) 3,5-H] and 7.16-7.34 (10 H, m, 12 to 16-H and 19 to 23-H); 
8C (100 MHz; CDCI3) 31.4 and 32.9 (7-CH2), 44.3 and 47.1 (8 -CH2 ), 52.8 (17- 
CH2 ), 116.7 (2 ,6 -CH), 123.0 (4-quat. C), 125.3 (23-CH), 125.7 and 126.0 
(14,15-CH), 126.0 (2 1 ,22 -CH), 126.8 and 127.2 (12,13-CH), 127.6 and 127.9 
(19,20-CH), 128.6 (11-quat. C), 129.0 (16-CH), 134.4 and 135.1 (18-quat. C),
155.4 (1-quat. C) and 171.9 (10-CO); m/z (El) 363.1296 (M+*. C2 2 H2 1 NO2 S 
requires 363.1299); m/z (%) 363 (10.2), 258 (2.1), 238 (37.3), 212 (20.4), 152
(80.3), 125 (7.0), 105 (100), 91 (35.9), 77 (33.5) and 65 (4.9).
A/-(2-Hydroxyethyl)-/V-(4-hydroxyphenyl)ethanamidine hydrochloride 101
Compound 101 was prepared in a 77% yield on a 13.7 mmol scale by the 
method of Kormendy and co-workers199 and gave mp 154-155 °C (yPrOH) 
(lit.,134 155-156 °C). The spectroscopic data were in agreement with the IR and 
"*H NMR data reported.134
A/-(2-Hydroxyethyl)-A/-(4-hydroxyphenyl)propionamidine hydrochloride 102
©ci
©Cl
6 11
127
The method of Kormendy and co-workers199 was used. To a solution of 
4-aminophenol hydrochloride (735 mg, 5.05 mmol) in ethanol (20 mL) was 
added oxazoline 59 (500mg, 5.05 mmol). The reaction mixture was stirred at rt 
for 3 d whereupon chilled diethyl ether was added drowise to precipitate the 
product. The precipitate was filtered and dried under suction. The title 
compound 102 (850 mg, 3.48 mmol, 69%) was recrystallised from isopropanol 
to provide cream crystals, mp 158-161 °C (Found: C, 53.90; H, 6 .8 8 ; N, 11.52. 
C11H17N2 O2CI requires C, 53.99; H, 6.95; N, 11.45%); Xmax (H2 0 )/nm 223 
(e/dm^ mol' 1 cm" 1 16670); vmax (thin film)/cm"1 3468m (OH), 3172-2920s 
(NH), 1639vs (C=N), 1585w (NH), 1516s (C=C), 1265m (OH) and 850w (CH); 
8h (400MHz, D2 O) 1.23 (3 H, t, J7 .6  Hz, 11-H) and 0.95 (3 H, t, J 7 .6 Hz, 11- 
H), 2.32 (2 H, q, J 7.6 Hz, 10-H) and 2.63 (2 H, q, J 7.6 Hz, 10-H), 3.37 (2 H, t, J
5.2 Hz, 8 -H) and 3.43 (2 H, t, J 5.2 Hz, 8 -H), 3.52 (2 H, t, J  5.2 Hz, 9-H) and 
3.73 (2 H, t, J 5.2 Hz, 9-H), 6.83 (2 H, AA'BB', d, J 8.8 Hz, 2,6-H) and 6.86 (2 H, 
AA'BB', d, J 8.8  Hz, 2,6-H) and 7.07 (2 H, m, 3,5-H); 8c  (100MHz, D2O) 10.1 
and 10.5 (H -C H 3 ), 23.7 and 24.4 (IO-CH2 ), 44.6 and 45.6 (8 -CH2 ), 59.0 and
60.0 (9-CH2), H6.5 and 117.3 (3,5-CH), 125.3 and 127.3 (4-quat. C), 128.4 
and 128.9 (2 ,6 -CH), 156.3 and 156.7 (1-quat. C) and 169.7 and 169.9 (7-quat. 
C); m/z (El) 208.1212 (M+-HCI. C11H16N2 O2 requires 208.1211); m/z (%) 208
(7.8), 189 (2.5), 163 (2.8), 148 (8.5), 134 (4.6), 109 (100), 99 (29.8), 80 (35.5), 
69 (31.2) and 54(16.3).
A/-(3-Hydroxypropyl)-A/-(4-hydroxyphenyl)ethanamidine hydrochloride 103
Compound 103 was prepared from oxazine 61 (612 mg, 6.18 mmol) and 
4-aminophenol hydrochloride (900 mg, 6.18 mmol) by the method used to 
prepare compound 102. Recrystallisation from isopropanol provided 103 (950 
mg, 3.89 mmol, 63%) as a white powder, mp 185-187 °C (Found: C, 53.88; H, 
7.01; N, 11.41. C11H17N2 O2CI requires C, 53.99; H, 6.95; N, 11.45%); ?imax 
(H2 0 )/nm 225 (e/dm^ mol'"* cm-1 9580); vmax (thin film)/cm"1 3409m (OH), 
3225-2923S (NH), 1649vs (C=N), 1520s and 1448s (C=C), 1280m (OH), 1068m 
(C-O) and 847w (CH); 8h (400MHz, D2O) 1.60 (2 H, m, 9-H) and 1.80 (2 H, m,
©ci
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9-H), 1.92 (3 H, s, 11-H) and 2.25 (3 H, s, 11-H), 3.30 (2 H, m, 8 -H), 3.45 (2 H, 
t, J 6.0 Hz, 10-H) and 3.57 (2 H, t, J6 .2  Hz, 10-H), 6.78 (2 H, AA'BB', d, J 8.8 
Hz, 2,6-H) and 6.81 (2 H, AA'BB’, d, J 8.8  Hz, 2,6-H) and 7.01 (2 H, AA'BB', d, J
8.4 Hz, 3,5-H) and 7.02 (2 H, AA'BB', d, J  8.8 Hz, 3,5-H); 5c (100MHz, D2 O)
16.6 and 17.7 (H -CH 3 ), 29.5 and 30.8 (9-CH2), 39.5 and 41.6 (8 -CH2 ), 58.9 
and 59.2 (IO-CH2 ), 116.4 and 117.2 (3,5-CH), 125.4 and 127.7 (4-quat. C),
128.3 and 128.7 (2 ,6 -CH), 156.1 and 156.6 (1-quat. C) and 164.8 and 165.3 (7- 
quat. C); m/z (El) 208.1210 (M+-HCI. C11H16N2 O2 requires 208.1209); m/z 
(%) 208 (26.5), 177 (15.6), 164 (17.0), 134 (51.8), 109 (100), 99 (28.4), 80
(25.5), 65 (9.2) and 57 (6.4).
A/-(3-Hydroxypropyl)-A/-(4-hydroxyphenyl)propionamidine hydrochloride 104
OH
Ho­ r n
Compound 104 was prepared from oxazine 62 (600 mg, 5.31 mmol) and
4-aminophenol hydrochloride (773 mg, 5.31 mmol) by the method used to 
prepare compound 102. Recrystallisation from isopropanol provided 104 (935 
mg, 3.62 mmol, 68%) as a pale pink powder, mp 131-133 °C (Found: C, 55.74; 
H, 7.33; N, 10.79. C12H19N2 O2CI requires C, 55.71; H, 7.35; N, 10.83%); 
''-max (H2 0 )/nm 223 (e/dm3  mol"1 cm-1 11070); vmax (thin film)/cm ' 1 3238- 
2883s (OH, NH), 1650vs (C=N), 1517s (C=C), 1271m (OH), 1068m (C-O) and 
850w (CH); 5h (400 MHz, D2 O) 0.94 (3 H, t, J 7.6 Hz, 12-H) and 1.23 (3 H, t, J
7.6 Hz, 12-H), 1.64 (2 H, m, 9-H) and 1.83 (2 H, m, 9-H), 2.30 (2 H, q, J 7 .6 Hz, 
11-H) and 2.61 (2 H, q, J 7.6 Hz, 11-H), 3.36 (2 H, m, 8 -H), 3.48 (2 H, t, J 5.9 
Hz, 10-H) and 3.60 (2 H, t, J 6.2 Hz, 10-H), 6.83 (2 H, AA'BB', d, J 8.8 Hz, 2,6- 
H) and 6.86 (2 H, AA'BB', d, J 8.8 Hz, 2,6-H) and 7.05 (2 H, AA'BB', d, J 8.6 Hz,
3,5-H) and 7.07 (2 H, AA'BB', d, J 8.6 Hz, 3,5-H); 8c  (100 MHz, D2 O) 10.1 and
10.6 ( I 2 -CH3 ), 23.5 and 24.3 (9-CH2), 29.5 and 31.0 (11-CH2), 39.5 and 41.5 
(8 -CH2 ), 59.0 and 59.4 (IO-CH2 ), 116.5 and 117.3 (3,5-CH), 125.3 and 127.3 
(4-quat. C), 128.4 and 129.0 (2 ,6 -CH), 156.3 and 156.7 (1-quat. C) and 168.9 
and 169.2 (7-quat. C); m /z (El) 222.1367 (M+-HCI. C12H18N2 O2 requires 
222.1365); m/z (%) 222 (8.2), 204 (9.9), 178 (5.7), 148 (28.4), 136 (7.1), 109 
(100), 108 (14).
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2-Cyano-3-(4-hydroxyphenyl)propenonitrile 121
Compound 121 was prepared in 81% yield on a 4.10 mmol scale by 
general method 2 and gave mp 181-182 °C (CHCI3 ) (lit.,213 180 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
Ethyl 2-Cyano-3-(4-hydroxyphenyl)propenoate 122
Compound 122 was prepared in 58% yield on a 4.09 mmol scale by 
general method 2 and gave mp 170-171 °C ('PrOH) (lit.,249 169 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
2-Cyano-3-(4-hydroxyphenyl)propenamide 123
CONH;
Compound 123 was prepared in 61% yield on a 4.10 mmol scale by 
general method 2 and gave mp 247-248 °C (CHCl3 /MeOH) (lit.,213 250 °C). 
The spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
130
3-Amino-2,4-dicyano-5-(4-hydroxyphenyl)penta-2,4-dienonitrile 124
NH
CN
CN CN
HO'
Compound 124 was prepared in 19% yield on a 4.09 mmol scale by 
general method 2 and gave mp 223-224 °C (MeOH/EtOH) (lit.,213 225 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
2-Cyano-3-(3,4-dihydroxyphenyl)propenonitri!e 125
Compound 125 was prepared in 59% yield on a 7.97 mmol scale by 
general method 1 and gave mp 185 °C (decomp.) (EtOH) (lit.,249 220 °C 
(decomp.)). The spectroscopic data were in agreement with the IR and 1H NMR 
data reported.249
Ethyl 2-cyano-3-(3,4-dihydroxyphenyl)propenonitrile 126
Compound 126 was prepared in 43% yield on a 3.62 mmol scale by 
general method 1 and gave mp 162-165 °C (Et0 H/H2 0 ) (lit.,249 162 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
131
2-Cyano-3-(3,4-dihydroxyphenyl)propenamide 127
c o n h 2
Compound 127 was prepared in 30% yield on a 3.62 mmol scale by 
general method 1 and gave mp 225-226 °C ('PrOH) (lit.,249 221 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
3-Amino-2,4-dicyano-5-(3, 4-dihydroxyphenyl)penta-2,4-dienonitrile 128
m 9
CN
Compound 128 was prepared in 25% yield on a 3.62 mmol scale by 
general method 1 and gave mp 227-229 °C (EtOH) (lit.,249 229 °C). The 
spectroscopic data were in agreement with the IR and 1H NMR data 
reported.249
2-Cyano-3-(3-methoxy-4-hydroxyphenyl)propenonitrile 129
Compound 129 was prepared from vanillin (2.00 g, 13.1 mmol) and 
malononitrile (868 mg, 13.1 mmol) by general method 2 . Recrystallisation from 
isopropanol provided the title compound 129 (2.14 g, 10.7 mmol, 81%) as pale 
yellow needles, mp 130-131 °C (lit.,250 1 33.5-134.5 °C). The spectroscopic data 
were in agreement with the IR and combustion data reported.180-250
New data: /Vmax (MeOH)/nm 246, 371 and 438 (e/dm^ mol-1 cm "1 6060, 
14050 and 5590); 5h (400 MHz, (CD3 )2 SO)) 3.79 (3 H, s, 11-H), 6.97 (1 H, d, J
8.3 Hz, 5-H), 7.47 (1 H, d, J 7.9 Hz, 6 -H), 7.61 (1 H, s, 2-H) and 8.20 (1 H, s, 7-
132
H); 8c  (100 MHz, (CD3 )2 SO)) 55.8 (11-CH3 ), 75.3 (8 -quat.C), 113.3 (5-CH),
114.6 and 115.4 (9,10-CN), 116.4 (6 -CH), 123.4 (1-quat.C), 128.0 (2-CH),
148.2 (4-quat.C), 154.2 (3-quat.C) and 161.0 (7-CH); m/z (El) 200.0587 (M+*. 
C11H8 N2 O2 requires 200.0588); m/z (%) 200 (100), 185 (12.0), 157 (58.5), 
143 (2.8), 129 (16.9), 102 (22.5), 83 (8.5), 75 (7.0) and 51 (5.0).
Ethyl 2-cyano-3-(3-methoxy-4-hydroxyphenyl)propenonitrile 130
Compound 130 was prepared from vanillin (2.00 g, 13.1 mmol) and ethyl 
isocyanoacetate (1.40 mL, 1.49 g, 13.1 mmol) by general method 2. 
Recrystallisation from isopropanol provided the title compound 130 (3.06 g, 
12.39 mmol, 94%) as a pale yellow powder, mp 105-107 °C (lit.,251 107 °C).
New data: Amax (MeOH)/nm 245 and 360 (e/dm^ moH cm-1 8160 and 
19430); vmax (KBr disc)/cnr1 3374m (OH), 2986w (CH), 2941 w (CH), 2220m 
(CN), 1702s (CO), 1573s and 1509s (C=C), 1277s (CH) and 1174w (C-O); 8h 
(400 MHz, (CD3 )2 SO)) 1.29 (3 H, t, J 7.1 Hz, 12-H), 3.82 (3 H, s, 13-H), 4.27 (2 
H, q, J 7.1 Hz, 11 -H), 6.94 (1 H, d, J 8.3 Hz, 5 -H), 7.58 (1 H, dd, J 2.0 and 8.4 
Hz, 6 -H), 7.73 (1 H, d, J  2.0 Hz, 2-H) and 8.18 (1 H, s, 7-H); 8c  (100 MHz, 
(CD3 )2 SO)) 14.3 (12-CH3 ), 55.9 (13-CH3), 62.2 (H -C H 2 ), 97.3 (8 -quat.C),
114.3 (5-CH), 116.3 (6 -CH), 116.9 (9 -CN), 123.2 (1-quat.C), 127.5 (2-CH),
148.1 (4-quat.C), 153.1 (3-quat.C), 155.2 (7-CH) and 162.9 (10-CO); m/z (El) 
247.0847 (M+*. C13H13NO4 requires 247.0850); m/z (%) 247 (100), 219
(27.5), 202 (15.5), 170 (30.3), 158 (7.0), 114 (9.2), 103 (6.3), 76 (5.6) and 51 
(2.0).
2-Cyano-3-(3-methoxy-4-hydroxyphenyl)propenamide 131
o
14 5
o
13 5
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Compound 131 was prepared from vanillin (2.00 g, 13.1 mmol) and 2 - 
cyanoacetamide (1.11 g, 13.1 mmol) by general method 2. Recrystallisation 
from methanol provided the title compound 131 (1.82 g, 8.35 mmol, 64%) as 
yellow crystals, mp 206-207 °C (lit.,252 209 °C). The spectroscopic data were in 
agreement with the IR and combustion data reported.180-252
New data: Xmax (MeOH)/nm 243 and 356 (e/dm3 mol" 1 cm-1 8710 and 
16590); 8h (400 MHz, (CD3 )2 SO)) 3.82 (3 H, s, 12-H), 6.94 (1 H, d, J 8.3 Hz,
5-H), 7.46 (1 H, dd, J 1.5 and 8.3 Hz, 6 -H), 7.66 (1 H, d, J 1.4 Hz, 2-H), 7.68 (2 
H, 2 br. s, 11-H) and 8.07 (1 H, s, 7-H); 8c  (100 MHz, (CD3 )2 SO)) 55.9 (12- 
CH3 ), 101.8 (8 -quat.C), 113.5 (5-CH), 116.3 (6 -CH), 117.8 (9-CN), 123.6 (1- 
quat.C), 126.3 (2-CH), 148.1 (4-quat.C),151.2 (7-CH), 151.8 (3-quat.C) and
164.0 (10-CO); m/z (El) 218.0691 (M+*. C11H10N2 O3 requires 218.0691); m/z 
(%) 218 (100), 202 (11.9), 170 (10.9), 158 (11.9), 114 (10.6), 76 (9.9) and 51 
(6.3).
3-Amino-2,4-dicyano-5-(3-methoxy-4-hydroxyphenyl)penta-2,4-dienonitrile 132
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Compound 132 was prepared from vanillin (2.00 g, 13.14 mmol) and 
malononitrile dimer (1.74 g, 13.14 mmol) by general method 2 . Recrystallisation 
from ethanol provided the title compound 132 (999 mg, 3.76 mmol, 29%) as an 
orange powder, mp 220-221 °C ; Xmax (EtOH)/nm 253 and 372 (e/dm3 mol"1 
cm"1 9350 and 11960); vmax (KBr disc)/cm"1 3396m (OH), 3396-3212m (NH), 
2959w (CH), 2215m (CN), 1574m and 1512s (C=C), 1292s (CH) and 1131m 
(C-O); 8c  000  MHz, (CD3 )2 SO)) 55.9 ( I 5-CH3 ), 97.2 (11-quat.C), 113.3 (5- 
CH), 115.4 (8 -quat.C), 116.1 and 116.2 (9,12,13-CN), 116.4 (6 -CH), 123.4 (1- 
quat.C), 127.0 (2 -CH), 148.2 (4-quat.C), 152.6 (3-quat.C), 153.7 (7-CH) and
166.6 (10-quat.C); m/z (El) 266.0805 (M+#. C14H10N4 O2 requires 266.0806); 
m/z (%) 266 (100), 251 (12.0), 240 (47.2), 235 (19.7), 195 (15.5), 168 (28.9), 
157 (6.3), 141 (14.1), 130 (5.6), 114(12.0), 76 (7.7) and 51 (6.3).
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6.3 EXPERIMENTAL FOR CHAPTER 5
6.3.1 GENERAL PREPARATIVE METHODS 3 TO 6
General method 3
The method of Baker and Howes182 was modified as follows. To a 
stirred solution of hydroxybenzaldehyde (1 equiv.) and malononitrile derivative 
(1 equiv.) in ethanol (ca. 1 mL/mmol), neat piperidine (a few drops) was added. 
The reaction mixture was stirred at room temperature until TLC indicated the 
reaction to be complete whereupon the crude product was filtered, washed with 
cold ethanol and dried under suction. The iminolactone product required careful 
handling as it could not be recrystallised unchanged181-182 and subsequently 
purification was achieved by trituration in cold ethanol.
General method 4
The method of Gazit and co-workers213 was modified as follows. To a 
stirred solution of methoxybenzaldehyde (1 equiv.) and malononitrile derivative 
(1 equiv.) in ethanol (ca. 4 mL/mmol), neat piperidine (a few drops) was added. 
The reaction mixture was heated at reflux until TLC indicated the reaction to be 
complete whereupon the mixture was cooled to room temperature. If 
precipitation of product was not observed dropwise addition of water was 
employed. The precipitated product was then filtered, dried under suction and 
recrystallised from an appropriate solvent
General method 5
General method 5 followed the same experimental protocol outlined for 
general method 4 with the exception of stirring the reaction mixture at room 
temperature rather than heating under reflux.
General method 6
The method of Cabello and workers181 was used. A solution of 
iminolactone in dilute hydrochloric acid (4 M, ca. 15 mL/mmol) was heated at 60 
°C. The reaction's progress was monitored by TLC and on reaching completion, 
the mixture was cooled to room temperature. The precipitated product was 
filtered, dried under suction and recrystallised from an appropriate solvent.
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6.3.2 EXPERIMENTAL DATA
2-lmino-2H-1 -benzopyran-3-carbonitrile 136
7 
6
5 "  4 12
Compound 136 was prepared from salicylaldehyde (0.50 mL, 573 mg, 
4.69 mmol) and malononitrile (310 mg, 4.69 mmol) by general method 3. 
Trituration in cold ethanol provided the title compound 136 (495 mg, 2.91 mmol, 
62%) as a yellow powder, mp 160 °C (decomp.) (lit., 181 mp 160 °C (decomp.)). 
The spectroscopic data were in agreement with the IR and combustion data
reported.181 >182
New data: 8h (200 MHz; (CD3 )2 SO)) 7.12-7.34 (2 H, m, 6 ,8 -H), 7.59- 
7.66 (2 H, m, 5,7-H), 8.40 (1 H, s, 11-H) and 8.89 (1 H, s, 4-H); 5c (50 MHz; 
(CD3 )2 SO)) 104.2 (3-quat. C), 115.1 (9-CN), 117.5 (10-quat. C), 115.6 (8-CH),
124.3 (6 -CH), 129.7 (7-CH), 134.2 (5-CH), 148.0 (4-CH), 151.6 (9-quat. C) and
153.9 (2-quat. C); m/z (CI/NH3 ) 171.0559 (MH+. C10H6 N2 O + H+ requires 
171.0560); m/z (CI/NH3 ) (%) 171 (100), 152 (1.0), 136 (2.5), 113 (4.0), 96
(39.4) and 86 (2.0).
2-lmino-2/-/-1-benzopyran-3-carboxamide 137
CONH;
12 13
Compound 137 was prepared in 75% yield on a 4.92 mmol scale by 
general method 3 and gave mp 175-176 °C (lit.,253 1 78 °C). The spectroscopic 
data were in agreement with the IR and 1H and "*3C NMR data reported.180-254
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8-Methoxy-2-imino-2/-/-1 -benzopyran-3-carbonitrile 142
11
OMe
7
6
Compound 142 was prepared from o-vanillin (600 mg, 3.94 mmol) and 
malononitrile (261 mg, 3.94 mmol) by general method 3. Trituration in cold 
ethanol provided the title compound 142 (660 mg, 3.30 mmol, 84%) as a 
mustard yellow powder, mp 176-177 °C (lit.,219 172-174 °C). The spectroscopic 
data were in agreement with the IR and combustion data reported.219
New data: 5h (400 MHz; (CD3 )2 SO)) 3.88 (3 H, s, 11-H), 7.13 (1 H, dd, 
J  1.4 and 7.8 Hz, 7-H), 7.20 (1 H, t, J 8.0 Hz, 6-H), 7.31 (1 H, dd, J 1.2 and 8.0 
Hz, 5-H), 8.35 (1 H, s, 12-H) and 8.95 (1 H, s, 4-H); 6c (100 MHz; (CD3 )2 SO))
56.4 (11-CH3), 105.1 (3-quat. C), 115.6 (13-CN), 117.1 (7-CH), 118.2 (10-quat. 
C), 121.0 (6-CH), 124.5 (5-CH), 138.0 (9-quat. C), 146.4 (8-quat. C), 147.5 (4- 
CH) and 151.4 (2-quat. C); m/z (El) 200.0585 (M+*. C 11H8 N2 O2 requires 
200.0584); m/z (%) 200 (100), 185 (14.2), 157 (19.9), 129 (14.9), 102 (14.2), 84
(23.8), 79 (14.2) and 63 (13.5).
8-Methoxy-2-imino-2/7-1 -benzopyran-3-carboxamide 143
Compound 143 was prepared from o-vanillin (600 mg, 3.94 mmol) and 2- 
cyanoacetamide (332 mg, 3.94 mmol) by general method 3. Trituration in cold 
ethanol provided the title compound 143 (735 mg, 3.37 mmol, 86%) as a grey 
powder, mp 166-167 °C (lit.,255 195 °C). The spectroscopic data were in 
agreement with the IR and 1H and 13c NMR data reported.254*255
OMe
CONH
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7-Methoxy-2-imino-2/-/-1-benzopyran-3-carbonitrile 144
Compound 144 was prepared from 4-methoxysalicylaldehyde (300 mg, 
1.97 mmol) and malononitrile (130 mg, 1.97 mmol) by general method 3. 
Trituration in cold ethanol provided the title compound 144 (340 mg, 1.70 mmol, 
86%) as a yellow powder, mp 143-145 °C (lit.,182 162-165 °C).
New data: vmax (KBr disc)/cnr1 3436m and 3286m (NH), 3025w and 
2938w (CH), 2222m (CN), 1617s and 1553m (C=C), 1278m (C-O) and 852m 
(CH); 5h (400 MHz; (CD3 )2 SO)) 3.91 (3 H, s, 11-H), 6.81 (1 H, d, J2.1 Hz, 8 - 
H), 6.93 (1 H, dd, J2.4 and 8.6 Hz, 6 -H), 7.57 (1 H, d, J 8.6  Hz, 5-H), 8.34 (1 H, 
s, 12-H) and 8.75 (1 H, s, 4-H); §C 000  MHz; (CD3 )2 SO)) 56.4 (11-CH3 ),
100.5 (3-quat. C), 100.9 (8 -CH), 111.2 (10-quat. C), 111.3 (6 -CH), 116.1 (13- 
CN), 131.1 (5-CH), 147.2 (4-CH), 152.1 (9-quat. C), 156.0 (7-quat. C) and
164.5 (2-quat. C); m/z (El) 200.0587 (M+*. C 11H8 N2 O2 requires 200.0588); 
m/z (%) 200 (100), 173 (68.3), 158 (30.2), 149 (4.3), 130 (5.8), 102 (10.8), 84 
(8 .6 ), 63 (5.8) and 57 (3.6).
6-Methoxy-2-imino-2/-/-1 -benzopyran-3-carbonitrile 49
Compound 49 was prepared from 5-methoxysalicylaldehyde (0.41 ml_, 
500 mg, 3.28 mmol) and malononitrile (217 mg, 3.28 mmol) by general method 
3. Trituration in cold ethanol provided the title compound 49 (405 mg, 2.03 
mmol, 62%) as a yellow powder, mp 184-185 °C. vmax (KBr disc)/cnrr1 3456m 
and 3344m (NH), 2924w (CH), 2218m (CN), 1573m and 1495m (C=C) and 
1211s (C-O); 5h (400 MHz; (CD3 )2 SO)) 3.80 (3 H, s, 11-H), 7.15 (3 H, m, 
5,7,8-H), 8.28 (1 H, s, 12-H) and 8.74 (1 H, s, 4-H); 8c  (100 MHz; (CD3 )2 SO))
55.9 (H -C H 3 ), 104.7 (3-quat. C), 112.2 (7-CH), 115.4 (13-CN), 116.7 (5-CH),
121.0 (8 -CH), 146.9 (4-CH), 148.1 (9-quat. C), 151.9 (6 -quat. C) and 155.3 (2 -
138
quat. C); m/z (El) 200.0595 (M+*. C i 1H8 N2 O2 requires 200.0604); m/z (%) 200 
(100), 185 (22.7), 173 (10.3), 158 (16.5), 130 (6.2), 102 (11.3), 78 (48.3), 63
(45.4) and 61 (7.2).
6-Methoxy-2-imino-2/-/-1-benzopyran-3-carboxamide 145
CONH 
13 14
Compound 145 was prepared from 5-methoxysalicylaldehyde (0.20 mL, 
250 mg, 1.64 mmol) and 2-cyanoacetamide (138 mg, 1.64 mmol) by general 
method 3. Trituration in cold ethanol provided the title compound 145 (266 mg,
1.22 mmol, 74%) as a pale yellow powder, mp 193-194 °C (lit.,218 mp 192-194 
°C). The spectroscopic data were in agreement with the 1H and 1^ c  NMR data 
reported.254
New data: vmax (KBr disc)/cnrr1 3280s (NH, NH2 ), 2950-2759w (CH), 
1681s (CO), 1601m and 1573s (C=C), 1287m (C-O) and 853m (CH); m/z (El) 
218.0690 (M+#. C11H10N2 O3 requires 218.0689); m/z (%) 218 (54.6), 201 
(100), 186 (19.1), 158 (21.3), 148 (3.5), 130 (5.0), 102 (4.3), 79 (48.2), 63 (47.5) 
and 61 (7.1).
5-Methoxy-2-imino-2H-1-benzopyran-3-carbonitrile 146
7
6
CN
OMe
11
Compound 146 was prepared from 5-methoxysalicylaldehyde (600 mg, 
3.94 mmol) and malononitrile (260 mg, 3.94 mmol) by general method 3. 
Trituration in cold ethanol provided the title compound 146 (528 mg, 2.64 mmol, 
67%) as a salmon pink powder, mp 182-183 °C. vmax (KBr disc)/cnrr1 3433w 
and 3276m (NH), 2231m (CN), 1673s and 1608s (C=C), 1272m (C-O) and 785s 
(CH); Sh (400 MHz; (CD3)2SO)) 3.90 (3 H, s, 11-H), 6.73 (1 H, d, J 8A  Hz, 8-
139
H), 7.52 (1 H, t, J 8.4 Hz, 7-H), 8.21 (1 H, s, 12-H) and 8.77 (1 H, s, 4-H); 8c  
(100 MHz; (CD3 )2 SO)) 56.8 (H -CH 3 ), 102.7 (3-quat. C), 106.6 (8 -CH), 107.7 
(11-CN), 108.1 (6-CH), 115.7 (10-quat. C), 135.6 (7-CH), 141.3 (4-CH), 151.7 
(9-quat. C), 154.8 (5-quat. C) and 156.7 (2 -quat. C); m/z (El) 200.0586 (M+*. 
C 11H8 N2 O2 requires 200.0587); m/z (%) 200 (100), 173 (24.1), 158 (13.5), 
135 (18.4), 102 (12.1), 76 (5.0), 63 (2.8) and 52 (2.8).
5-Methoxy-2-imino-2H-1 -benzopy ran-3-carboxamide 147
7
6'
CONH 
13 14
OMe
11
Compound 147 was prepared from 5-methoxysalicylaldehyde (395 mg,
2.60 mmol) and 2-cyanoacetamide (218 mg, 2.60 mmol) by general method 3. 
Trituration in cold ethanol provided the title compound 147 (420 mg, 1.93 mmol, 
74%) as a cream solid, mp 210-212 °C. vmax (KBr disc)/crrr1 3268-3073m 
(NH, NH2 ), 2945w and 2843w (CH), 1672s (CO), 1603s and 1571m (C=C), 
1288m (C-O) and 773m (CH); Sh (400 MHz; (CD3 )2 SO)) 3.96 (3 H, s, 11-H), 
6.78 (1 H, d, J  8.2 Hz, 8 -H), 6.87 (1 H, d, J  8.3 Hz, 6 -H), 7.50 (1 H, t, J8.3 Hz, 
7-H), 7.76 (1 H, s, 4-H), 8.39 (2 H, 2 br. s, 14-H) and 9.51 (1 H, s, 12-H); 5c 
(100 MHz; (CD3 )2 SO)) 56.7 (H-CH 3 ), 106.2 (8 -CH), 107.6 (6 -CH), 108.6 (3- 
quat. C), 119.4 (10-quat. C), 134.2 (7-CH), 135.5 (4-CH), 154.8 (9-quat. C),
155.6 (5-quat. C), 157.1 (2-quat. C) and 163.3 (13-quat. C); m/z (El) 218.0690 
(M+*. C11H10N2 O3 requires 218.0689); m/z {%) 218 (20.6), 201 (30.5), 187
(3.5), 175 (10.6), 149 (14.2), 137 (6.4), 96 (5.7), 79 (97.9), 63 (100) and 61
(14.9).
2-Cyano-3-(2-methoxyphenyl)propenonitrile 150
OMe
NC' CN
140
Compound 150 was prepared in 43% yield on a 5.88 mmol scale by 
general method 5 and gave mp 80-81 °C ('PrOH) (lit.,250 84-85 °C). The 
spectroscopic data were in agreement with the IR and "*H and "I^C NMR data 
reported.222
2-Cyano-3-(2-methoxyphenyl)propenamide 151
OMe
CONH
Compound 151 was prepared from o-anisaldehyde (800 mg, 5.88 mmol) 
and 2-cyanoacetamide (494 mg, 5.88 mmol) by general method 4. 
Recrystallisation from ethyl acetate/methanol provided the title compound 151 
(550 mg, 2.72 mmol, 46%) as pale yellow crystals, mp 157-158 °C (lit.,222 151- 
153 °C).The spectroscopic data were in agreement with the IR and 1H and 13q 
NMR data reported.222
2-Cyano-3-(2,3-dimethoxyphenyl)propenonitrile 152
12 MeO
2^ OMe
9 10
Compound 152 was prepared from 2,3-dimethoxybenzaldehyde (1.0 g,
6.02 mmol) and malononitrile (398 mg, 6.02 mmol) by general method 5. 
Recrystallisation from methanol provided the title compound 152 (881 mg, 4.12 
mmol, 68%) as pale yellow needles, mp 98-100 °C (Found: C, 67.14; H, 4.63; 
N, 13.01. C1 2 H10N2 O2 requires C, 67.29; H, 4.67; N, 13.08%); vmax (KBr 
disc)/crrr1 3048-2841w (CH), 2225m (CN), 1570s and 1481s (C=C), 1281s (C- 
O) and 751m (CH); 8h (400 MHz; (CD3 )2 SO)) 3.86 and 3.87 (two s, 6 H, 11- 
and 12-H), 7.29 (1 H, d, J 8.0 Hz, 4-H), 7.40 (1 H, dd, J  1.2 and 8.0 Hz, 5 -H),
7.60 (I H, dd, J 1.2 and 8.0 Hz, 6-H) and 8.51 (1 H, s, 7-H); 5c (100 MHz, 
(CD3 )2 SO)) 56.4 and 62.0 (11 and I 2 -CH3 ), 83.2 (8 -quat. C), 113.4 and 114.6
141
(9,10-CN), 119.2 (4-CH), 119.6 (5-CH), 125.0 (6-CH), 125.3 (1-quat. C), 149.2 
and 152.9 (2 and 3-quat. C) and 156.7 (7-CH); m/z (El) 214.0743 (M+*. 
C12H10N2 O2 requires 214.0744); m/z (%) 214 (100), 199 (66.0), 184 (4.3), 
171 (18.4), 169 (11.3), 130(15.6), 101 (14.9), 84 (5.7), 75 (5.0) and 51 (3.5).
2-Cyano-3-(2,3-dimethoxyphenyl)propenamide 153
13 MeO
9 10 11
Compound 153 was prepared from 2,3-dimethoxybenzaldehyde (1.0 g,
6.02 mmol) and 2-cyanoacetamide (506 mg, 6.02 mmol) by general method 5. 
Recrystallisation from isopropanol provided the title compound 153 (981 mg, 
4.23 mmol, 70%) as a lemon fluffy solid, mp 164-166 °C (Found: C, 62.02; H, 
5.31; N, 12.04. C12H12N2 O3 requires C, 62.07; H, 5.17; N, 12.07%); vmax 
(KBr disc)/cm"1 3470s and 3142m (NH), 2947w (CH), 2216m (CN), 1750s 
(CO), 1603m and 1576m (C=C), 1277s (C-O) and 745m (CH); 5h (400 MHz; 
(CD3 )2 SO)) 3.81 and 3.85 (6 H, two s, 12 and 13-H), 7.25 (1 H, d, J 8.0 Hz, 4- 
H), 7.29 (1 H, dd, J 1.2 and 8.4 Hz, 5-H), 7.62 (1 H, dd, J 1.2 and 7.6 Hz, 6 -H),
7.91 (2 H, two br. s, 11-H) and 8.34 (1 H, s, 7-H); 5c (100 MHz, (CD3 )2 SO))
56.3 and 61.6 (12 and 13-CH3), 108.3 (8 -quat. C), 116.6 (4-CH), 117.2 (9-CN),
119.8 (5-CH), 124.8 (6 -CH), 126.1 (1-quat. C), 145.9 (7-CH), 148.8 and 152.9 
(2 and 3-quat. C) and 162.9 (10-quat. C); m /z  (El) 232.0849 (M+*. 
C12H12N2 O3 requires 232.0850); m/z (%) 232 (21.3), 201 (100), 186 (7.1), 
174 (9.2), 159 (8.5), 149 (5.3), 102 (4.3), 84 9 (12.1) and 51 (4.3).
2-Cyano-3-(2,4-dimethoxyphenyl)propenonitrile 154
9 10
142
Compound 154 was prepared from 2,4-dimethoxybenzaldehyde (200 
mg, 1.20 mmol) and malononitrile (80 mg, 1.20 mmol) by general method 5. 
Recrystallisation from isopropanol provided the title compound 154 (206 mg, 
0.96 mmol, 80%) as yellow crystals, mp 139-141 °C (lit.,256 142.2-142.6 °C). 
The spectroscopic data were in agreement with the NMR and combustion 
data reported.256
New data: vmax (KBr disc)/cnr1 2924w (CH), 2223m (CN), 1609m and 
1563m (C=C) and 1281s (C-O); 6c  (100 MHz; (C D ^S O )) 56.5 ( I2 -CH3 ), 56.6 
(11-CH3 ), 76.1 (8 -quat. C), 98.6 (3-CH), 108.1 (5-CH), 113.4 (1-quat. C), 114.6 
and 115.6 (9,10-CN), 130.8 (6 -CH), 154.1 (7-CH), 161.7 (4-quat. C) and 167.2 
(2-quat. C); m/z (El) 214.0747 (M+#. C12H10N2 O2 requires 214.0751); m/z (%) 
214 (100), 199 (4.9), 186 (10.7), 171 (9.9), 149 (30.7), 128 (8.9), 121 (21.8), 
101 (8.9), 89 (4.9) and 63 (3.9).
2-Cyano-3-(2,4-dimethoxyphenyl)propenamide 155
NC 8 CONH
9 10 11
Compound 155 was prepared from 2,4-dimethoxybenzaldehyde (200 
mg, 1.20  mmol) and 2 -cyanoacetamide (101 mg, 1.20  mmol) by general 
method 5. Recrystallisation from acetone provided the title compound 155 (140 
mg, 0.60 mmol, 80%) as pale yellow crystals, mp 198-200 °C (Found: C, 62.09; 
H, 5.18; N, 12.08. C12H12N2 O3 requires C, 62.07; H, 5.17; N, 12.07%); v max 
(KBr disc)/crrf1 3461m and 3356m (NH2 ), 2931 w (CH), 2210m (CN), 1667s 
(CO), 1612m and 1570s (C=C) and 1274s (C-O); 5h (400 MHz; (CD3 )2 SO)) 
3.86 (3 H, s, 12-H), 3.89 (3 H, s, 13-H), 6.68 (1 H, s, 3-H), 6.72 (1 H, d, J 8.8 
Hz, 4-H), 7.70 (2 H, 2 br. s, 11-H), 8.10 (1 H, d, J8.0 Hz, 6 -H) and 8.36 (1 H, s,
7-H); 5C (100  MHz, (CD3 )2 SO)) 56.1 ( I 2 -CH3 ), 56.4 (13-CH3), 98.7 (3-CH),
102.4 (8 -quat. C), 106.9 (5-CH), 113.6 (1-quat. C), 117.7 (9-CN), 129.9 (6 -CH),
145.1 (7-CH), 160.8 (2-quat. C), 163.4 (4-quat. C) and 165.0 (10-CO); m/z (El) 
232.0836 (M+#. C12H12N2 O3 requires 232.0825); m/z (%) 232 (61.3), 201 
(100), 186 (6.9), 173 (6.9), 158 (7.9), 149 (5.9), 124 (4.4), 121 (6.9), 109 (5.9), 
102 (4.9), 77 (3.9), 76 (3.9), 63 (2.9) and 51 (1.9).
143
2-Cyano-3-(2,5-dimethoxyphenyl)propenonitrile 156
MeO
9 10
Compound 156 was prepared from 2,5-dimethoxybenzaldehyde (200 
mg, 1.20 mmol) and malononitrile (80 mg, 1.20 mmol) by general method 5. 
Recrystallisation from isopropanol provided the title compound 156 (146 mg,
0.68 mmol, 57%) as bright yellow crystals, mp 105-106°C (lit.,256 107.4-108.2 
°C). The spectroscopic data were in agreement with the IR and "*H NMR data 
reported.256*257
New data: Sc (100 MHz, (CD3 )2 SO)) 55.9 and 56.7 (11.12-CH3), 81.8 
(8-quat. C), 112.7 (4-CH), 113.7 and 114.7 (9,10-CN), 114.0 (3-CH), 120.3 (1- 
quat. C), 123.1 (6-CH), 153.0 and 153.6 (2- and 5-quat. C) and 155.7 (7-CH); 
m/z (El) 214.0740 (M+*. C12H10N2O2 requires 214.0738); m/z (%) 214 (100), 
199 (91.1), 184 (9.4), 171 (10.4), 158 (2.9), 143 (3.5), 128 (7.4), 116 (11.4), 101
(7.9), 89 (4.9), 75 (3.9) and 54 (2.9).
2-Cyano-3-(2,5-dimethoxyphenyl)propenamide 157
MeO'
NC 8 CONH;
9 10 11
Compound 157 was prepared from 2,5-dimethoxybenzaldehyde (100 
mg, 0.60 mmol) and 2-cyanoacetamide (51 mg, 0.60 mmol) by general method 
5. Recrystallisation from ethanol provided the title compound 157 (120 mg, 0.48 
mmol, 81%) as fluorescent yellow crystals, mp 193-194 °C (Found: C, 62.01; H, 
5.14; N, 12.02. C12H10N2 O3 requires C, 62.07; H, 5.17; N, 12.07%); vmax 
(KBr disc)/cm-1 3391m (NH), 2966-2923w (CH), 2213m (CN), 1698s (CO), 
1585m and 1497s (C=C) and 1228s (C-O); 5h (400 MHz; (CD3 )2 SO)) 3.75 (3 
H, s, 12-H), 3.84 (3 H, s, 13-H), 7.12 (1 H, d, J 9.1 Hz, 3-H), 7.17 (1 H, dd, J9.1 
and 2.8 Hz, 4-H), 7.60 (1 H, d, J 2.6 Hz, 6-H), 7.85 (2 H, 2 br. s, 11-H) and 8.38
144
(1 H, s, 7-H); 5c (100 MHz, (CD3 )2 SO)) 55.8 and 56.6 (12.13-CH3), 106.9 (8- 
quat. C), 113.1 and 113.4 (4,6 -CH), 116.9 (9-CN), 120.1 (3-CH), 121.1 (1-quat. 
C), 145.7 (7-CH), 153.0 and 153.1 (2 - and 5-quat. C) and 162.9 (10-CO); m/z 
(El) 232.0841 (M+*. C12H10N2 O3 requires 232.0834); m/z (%) 232 (53.5), 201 
(100), 186 (4.9), 174 (31.7), 159 (8.9), 130 (8 .8 ), 102 (6.9), 76 (5.9) and 63
(3.0).
2-Cyano-3-(2,6-dimethoxyphenyl)propenonitrile 158
Compound 158 was prepared from 2 ,6 -dimethoxybenzaldehyde (450 
mg, 2.71 mmol) and malononitrile (179 mg, 2.71 mmol) by general method 5. 
Recrystallisation from ethanol provided the title compound 158 (502 mg, 2.35 
mmol, 87%) as pale yellow needles, mp 143-144 °C (lit.,257 148 °C). The 
spectroscopic data was in agreement with the combustion data reported.257
New data: vmax (KBr disc)/cm"1 2982-2845w (CH), 2226m (CN), 1598s 
and 1482m (C=C) and 1270m (C-O); 5h (400 MHz; (CD3 )2 SO)) 3.35 (6 H, s,
11,12-H), 6.79 (2 H, d, J 8.5 Hz, 3,5-H), 7.59 (1 H, t, J 8.5 Hz, 4-H) and 8.23 (1 
H, s, 7-H); 5c (100 MHz, (CD3 )2 SO)) 56.2 (11.12-CH3), 87.8 (8 -quat. C), 104.5 
(3,5-CH), 109.7 (1-quat. C), 113.3 and 115.3 (9,10-CN), 136.6 (4-CH), 154.2 (7- 
CH) and 159.3 (2,6-quat. C); m/z (El) 214.0744 (M+*. C12H10N2 O2 requires 
214.0745); m/z (%) 214 (100), 195 (8 .6 ), 186 (12.1), 156 (7.9), 149 (66.4), 128 
(10.7), 91 (12.1), 78 (4.6) and 63 (5.0).
2-Cyano-3-(2,6-dimethoxyphenyl)propenamide 159
MeO
12 NCT3 CN 
9 10
MeO X  
13 NCT 8 CONH2 
9 10 11
145
Compound 159 was prepared from 2 ,6 -dimethoxybenzaldehyde (1.1 g, 
6.62 mmol) and 2-cyanoacetamide (557 mg, 6.62 mmol) by general method 4. 
Recrystallisation from ethanol provided the title compound 159 (940 mg, 4.05 
mmol, 61%) as cream crystals, mp 135-137 °C; vmax (KBr disc)/cm ' 1 3440m, 
3396m and 3177m (NH2 ), 2978-2841w (CH), 2212m (CN), 1692s (CO), 1599s 
and 1477s (C=C) and 1262s (C-O); 8h (400 MHz; (CD3 )2 SO)) 3.84 (6 H, s,
12,13-), 6.76 (2 H, d, J 8.5 Hz, 3,5-H), 7.46 (1 H, t, J 8.4 Hz, 4-H), 7.78 (2 H, 2 
br. s, 11-H) and 8.08 (1 H, s, 7-H); 8c  (100 MHz, (CD3 )2 SO)) 56.0 and 56.1 
(12.13-CH3), 104.4 (3,5-CH), 110.4 (1-quat. C), 116.2 (9-CN), 133.6 (4-CH),
148.6 (7-CH), 158.5 (2 ,6 -quat. C) and 163.1 (10-CO); m/z (El) 232.0847 (M+*. 
C 12H10N2 O3 requires 232.0846); m/z (%) 232 (15.8), 201 (100), 186 (12.9), 
158 (5.0), 149 (4.3), 130 (2.9), 92 (4.0), 77 (2.5) and 63 (1.4).
2-Oxo-2H-1 -benzopyran-3-carbonitrile 174
Compound 174 was prepared from iminolactone 136 (225 mg, 1.32 
mmol) by general method 6 . Recrystallisation from ethanol provided the title 
compound 174 (193 mg, 1.13 mmol, 86%) as cream crystals, mp 184-185 °C 
(lit.,182 mp 184-185 °C (EtOH)). The spectroscopic data were in agreement with 
the IR and combustion data reported.181’182
New data: 8h (400 MHz; (CD3 )2 SO)) 7.49 (2 H, m, 6 ,8 -H), 7.81 (2 H, m, 
5,7-H) and 8.95 (1 H, s, 4-H); 8c  (100 MHz; (CD3 )2 SO)) 102.5 (3-quat. C),
114.9 (11-CN), 117.9 (10-quat. C), 117.1 (8 -CH), 125.8 (6 -CH), 130.3 (5-CH),
135.8 (7-CH), 153.8 (4-CH), 154.4 (9-quat. C) and 157.2 (2-quat. C); m/z (El) 
171.0319 (M+*. C10H5 NO2 requires 171.0317); m/z (%) 171 (100), 144 (7.9), 
143 (75.7), 114 (33.2), 113 (10.0), 89 (12.1), 88 (4.3), 63 (7.9) and 62 (7.1).
146
2-Oxo-2H-1 -benzopyran-3-carboxamide 175
CONH 
11 12
Compound 175 was prepared from iminolactone 137 (390 mg, 2.07 
mmol) by general method 6. Recrystallisation from ethanol provided the title 
compound 175 (350 mg, 1.85 mmol, 89%) as white fluffy needles, mp 264-265 
°C (lit. ,253 258-260 °C). The spectroscopic data were in agreement with the IR 
and 1H NMR data reported.258
New data: 6c (100 MHz; (CD3 )2 SO)) 116.5 (8-CH), 118.8 (3-quat. C),
119.6 (10-quat. C), 125.4 (6-CH), 130.6 (5-CH), 134.4 (7-CH), 148.1 (4-CH),
154.4 (9-quat. C), 160.7 (2-quat. C) and 162.9 (11-quat. C).
8-Methoxy-2-oxo-2H-1 -benzopyran-3-carbonitrile 176
Compound 176 was prepared from iminolactone 142 (200 mg, 1.00 
mmol) by general method 6. Recrystallisation from methanol provided the title 
compound 176 (165 mg, 0.89 mmol, 89%) as yellow fluffy needles, mp 224-225 
°C (lit.,259 222-223 °C). The spectroscopic data were in agreement with the IR 
and combustion data reported.259
New data: 5h (400 MHz; (CD3 )2 SO)) 3.93 (3 H, s, 11-H), 7.33 (1 H, dd, 
J 1.4 and 7.8 Hz, 7-H), 7.40 (1 H, m, 6-H), 7.49 (1 H, dd, J 1.4 and 8.1 Hz, 5-H) 
and 8.92 (1 H, s, 4-H); 6c (100 MHz; (CD3 )2 SO)) 56.6 (H -CH 3 ), 102.7 (3-quat. 
C), 114.9 (12-CN), 117.8 (7-CH), 118.3 (10-quat. C), 121.1 (6-CH), 125.8 (5- 
CH), 143.6 (9-quat. C), 146.8 (8-quat. C), 154.0 (4-CH) and 156.9 (2-quat. C); 
m/z (El) 201.0424 (M+#. C11H7 NO3 requires 201.0422); m/z (%) 201 (100), 
186 (9.9), 158 (22.8), 130 (22.1), 102 (21.0), 76 (9.9) and 52 (7.2).
147
8-Methoxy-2-oxo-2H-1 -benzopyran-3-carboxamide 177
11
OMe
CONH; 
12 13
Compound 177 was prepared from iminolactone 143 (320 mg, 1.47 
mmol) by general method 6 . Recrystallisation from methanol provided the title 
compound 177 (189 mg, 0.86 mmol, 59%) as a pale yellow solid, mp 239-241 
°C (lit.,255 247 °C). The spectroscopic data was in agreement with the 
combustion data reported.255
New data: Vmax (KBr disc)/cm" 1 3460m and 3392m (NH2 ), 3040-2947w 
(CH), 1710s (CO), 1611s and 1591s (C=C), 1281s (C-O) and 799s (CH); 5h 
(400 MHz; (CD3 )2 SO)) 3.94 (3 H, s, 11-H), 7.36 (1 H, m, 6 -H), 7.42 (1 H, d, J 
8.0 Hz, 7-H), 7.50 (1 H, d, J 7.6 Hz, 5-H), 8.00 (2 H, 2 br. s, 13-H) and 8.82 (1 
H, s, 4-H); 5c (100 MHz; (CD3)2 SO)) 56.5 (H -CH 3), 116.4 (7-CH), 119.3 (3- 
quat. C), 119.7 (10-quat. C), 121.5 (5-CH), 125.3 (6 -CH), 143.9 (9-quat. C),
146.6 (8 -quat. C), 148.3 (4-CH), 160.4 (2 -quat C) and 162.8 (12-quat. C); m/z 
(El) 219.0533 (M+*. C11H9 NO4 requires 219.0535); m/z (%) 219 (100), 230
(30.1), 176 (15.6), 148 (9.9), 133 (14.2), 105 (11.3), 90 (7.1), 78 (10.6) and 52
(7.1).
7-Methoxy-2-oxo-2H-1 -benzopyran-3-carbonitrile 178
Compound 178 was prepared from iminolactone 144 (350 mg, 1.75 
mmol) by general method 6. Recrystallisation from methanol/acetone provided 
the title compound 178 (320 mg, 1.59 mmol, 91%) as pale yellow needles, mp 
217-219 °C (lit.,259 218-219 °C). The spectroscopic data were in agreement 
with the IR and combustion data reported.259
New data: 8h (400 MHz; (CD3 )2 SO)) 3.90 (3 H, s, 11-H), 7.05 (1 H, d, J
8.3 Hz, 6-H), 7.10 (1 H, s, 8-H), 7.71 (1 H, d, J 8.6 Hz, 5-H) and 8.8 (1 H, s, 4-
148
H); 8c  (100 MHz; (CD3 )2 SO)) 56.8 (II-C H 3 ), 97.8 (3-quat. C), 101.3 (6 -CH),
111.6 (10-quat. C), 114.2 (8 -CH), 115.4 (12-CN), 131.6 (5-CH), 153.5 (4-CH),
156.9 (9-quat. C), 157.7 (7-quat. C) and 165.7 (2 -quat. C); m/z (El) 201.0425 
(M+*. C11H7 NO3 requires 201.0424); m/z (%) 201 (100), 173 (50.4), 158
(44.0), 148 (14.2), 130 (10.6), 102 (13.5), 79 (11.3), 70 (17.0) and 57 (14.9).
6-Methoxy-2-oxo-2H-1 -benzopyran-3-carbonitrile 179
Compound 179 was prepared from iminolactone 49 (81 mg, 0.40 mmol) 
by general method 6 . Recrystallisation from ethanol provided the title compound 
179 (54 mg, 0.29 mmol, 66%) as brown crystals, mp 223-224°C (lit.,260 226- 
228 °C). The spectroscopic data were in agreement with the IR and combustion 
data reported.260
New data: 5h (400 MHz; (CD3 )2 SO)) 3.82 (3 H, s, 11-H), 7.31 (1 H, d, J
3.2 Hz, 5-H), 7.38 (1 H, dd, J9.2 and 3.2 Hz, 7-H), 7.44 (1 H, d, J 8.8 Hz, 8 -H) 
and 8.85 (1 H, s, 4-H); 5c (100 MHz; (CD3 )2 SO)) 56.2 (H -CH 3 ), 102.7 (3-quat. 
C), 111.7 (5-CH), 115.0 (12-CN), 118.2 (10-quat. C), 118.3 (7-CH), 123.5 (8 - 
CH), 148.9 (9-quat. C), 153.4 (4-CH), 156.4 (6 -quat. C) and 157.3 (2-quat. C); 
m/z (El) 201.0426 (M+*. C11H7 NO3 requires 201.0426); m/z (%) 201 (100), 
186 (25.2), 158 (35.3), 143 (3.6), 130 (13.7), 102 (12.2), 77 (7.9), 63 (8 .6) and 
57 (2.9).
6-Methoxy-2-oxo-2H-1 -benzopyran-3-carboxamide 180
MeO CONH;
12 13
Compound 180 was prepared from iminolactone 145 (230 mg, 1.06 
mmol) by general method 6 . Recrystallisation from methanol provided the title 
compound 180 (224 mg, 1.02 mmol, 96%) as pale yellow crystals, mp 228-230
°C (Found: C, 60.19; H, 3.90; N, 6.19. C 11H9 NO4 requires C, 60.27; H, 4.11; 
N, 6.39%); vmax (KBr disc)/cnr1 3419m and 3258w (NH2 ), 1716s (CO), 1623m 
and 1570s (C=C), 1278m (C-O) and 829m (CH); 8h (400 MHz; (CD3 )2 SO)) 
3.83 (3 H, s, 11-H), 7.35 (1 H, dd, J3.0and 9.1 Hz, 7-H), 7.45 (1 H, d, J9.1 Hz,
8 -H), 7.54 (1 H, d, J 3.0 Hz, 5-H), 8.01 (2 H, 2 br. s, 13-H) and 8.85 (1 H, s, 4- 
H); 5c (100 MHz; (CD3 )2 SO)) 56.2 (H -CH 3 ), 112.2  (7-CH), 117.6 (8 -CH),
119.2 (3-quat. C), 119.7 (10-quat. C), 122.3 (5 -CH), 148.0 (4-CH), 148.9 (9- 
quat. C), 156.3 (6 -quat. C), 160.8 (2 -quat. C) and 162.9 (12 -quat. C); m/z (El) 
219.0532 (M+#. C11H9 NO4 requires 219.0533); m/z (%) 219 (100), 203 (23.1), 
176(12.1), 161 (14.2), 133(13.5), 119 (6.4), 78 (6.5) and 63 (3.6).
5-Methoxy-2-oxo-2/-/-1 -benzopyran-3-carbonitrile 181
7
6' CN
OMe
11
Compound 181 was prepared from iminolactone 146 (200 mg, 1.00 
mmol) by general method 6 . Recrystallisation from ethanol provided the title 
compound 181 (177 mg, 0.96 mmol, 96%) as tan crystals, mp 196-197 °C. 
vmax (KBr disc)/cnr1 3060-2849w (CH), 2234m (CN), 1727s (CO), 1604s and 
1480s (C=C), 1266s (C-O) and 785m (CH); 5h (400 MHz; (CD3 )2 SO)) 3.95 (3 
H, s, 11-H), 7.02 (2 H, d, J8 .4  Hz, 6 ,8 -H), 7.73 (1 H, t, J 8.4 Hz, 7-H) and 8.82 
(1 H, s, 4-H); 8c  (100 MHz; (CD3 )2 SO)) 57.1 (H -C H 3 ), 100.4 (3-quat. C),
107.3 (8 -CH), 108.4 (12-CN), 109.0 (7-CH), 115.0 (10-quat. C), 137.2 (6 -CH),
148.1 (4-CH), 155.1 (9-quat. C), 157.1 (5-quat. C) and 157.2 (2 -quat. C); m/z 
(El) 201.0426 (M+*. C11H7 NO3 requires 201.0427); m/z (%) 201 (100), 173
(24.1), 158 (27.7), 130 (14.2), 102 (13.5), 76 (6.4) and 57 (7.1).
5-Methoxy-2-oxo-2/-/-1 -benzopyran-3-carboxamide 182
7
6 CONH 
12 13OMe
11
150
Compound 182 was prepared from iminolactone 147 (200 mg, 0.92 
mmol) by general method 6 . Recrystallisation from ethanol provided the title 
compound 182 (165 mg, 0.75 mmol, 82%) as white crystals, mp 266-267 °C 
(Found: C, 60.09; H, 4.08; N, 6.21. C11H9 NO4 requires C, 60.27; H, 4.11; N, 
6 .39%); vmax (KBr disc)/crrr1 3406m and 3160m (NH2 ), 1720s (CO), 1610s 
and 1567s (C=C), 1259m (C-O) and 791s (CH); 5h (400 MHz; (CD3 )2 SO)) 3.98 
(3 H, s, 11-H), 6.70 (1 H, t, J8.4 Hz, 7-H), 7.02 (1 H, d, J8 .3  Hz, 8 -H), 7.05 (1 
H, d, J 8.4 Hz, 6 -H), 7.97 (2 H, 2 br. s, 13-H) and 8.89 (1 H, s, 4-H); 6c  (100 
MHz; (CD3 )2 SO)) 56.9 (H -C H 3 ), 106.8 (8 -CH), 108.6 (6 -CH), 109.1 (3-quat. 
C), 117.5 (10-quat. C), 135.8 (7-CH), 142.4 (4-CH), 155.3 (9-quat. C), 157.3 (5- 
quat. C), 160.6 (2-quat. C) and 162.8 (12 -quat. C); m/z (El) 219.0532 (M+*. 
C 11H9 NO4 requires 219.0533); m/z (%) 219 (100), 203 (67.6), 201 (18.5), 173
(13.5), 134 (16.4), 105 (6.4), 78 (7.8) and 51 (3.6).
2-Formyl-3-methoxythiophene 190
OMe 7
4
5
1 O
To a stirred solution of 3-methoxythiophene (0.87 mL, 1.0 g, 8.67 mmol) 
in tetrahydrofuran (10 mL), at rt, was gradually added n-butyllithium (1.6 M in 
hexanes, 5.47 mL, 8.76 mmol). Following this, the reaction mixture was gently 
heated at reflux for 3.5 h. On cooling to 0 °C, a solution of N , N- 
dimethylformamide (0.70 mL, 656 mg, 8.98 mmol) in tetrahydrofuran (10 mL) 
was added dropwise and stirring continued at 0 °C for 1 h. The mixture was 
then warmed to rt and the reaction progress monitored by TLC. After stirring at 
rt for a further 15 h the reaction was quenched by pouring the mixture into water 
(50 mL) and the product was extracted with ethyl acetate (3 x 30 mL). The 
organic extracts were combined, washed with brine (2 x 30 mL), dried over 
anhydrous magnesium sulfate and concentrated in vacuo. Purification by 
column chromatography, eluant hexane-ethyl acetate (1:1), and subsequent 
recrystallisation from isopropanol provided the title compound 190 (717 mg,
5.05 mmol, 58%) as yellow needles, mp 80-82 °C (lit.,261 82 °C).
New data: Found C, 50.73; H, 4.14. C6 H6SO2 requires C, 50.70; H, 
4.23%); vmax (KBr disc)/cm"1 3102m and 3089m (CH), 1643vs (CO), 1538s 
(C=C) and 1215s and 1078s (C-O); 5h (400 MHz; CDCI3 ) 3.92 (3 H, s, 7-H),
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6.80 (1 H, d, J  5.2 Hz, 4-H), 7.58 (1 H, d, J  5.2 Hz, 5-H) and 9.91 (1 H, s, 6 -H); 
8C (100  MHz; CDCI3 ) 59.2  (7 -CH3 ), 116.2 (4-CH), 121.5 (2 - quat. C), 135.6 (5- 
CH), 165.5 (3-quat. C) and 181.7 (6 -CH); m/z (El) 142.0089 (M+*. C6 H6 SO2 
requires 142.0090); m/z (%) 142 (100), 124 (30.4), 111 (25.7), 96 (22.1), 84 
(84.3), 70 (7.1) and 51 (21.4).
2-Cyano-3-[2-(3-methoxythienyl)]propenamide 192
OMe 11
1^1 6 
nc^ x o n h 2 
8 9 10
To a stirred solution of compound 190 (150 mg, 1.06 mmol) and 2 - 
cyanoacetamide (89 mg, 1.06 mmol) in ethanol (10 mL), at rt, neat piperidine (2 
drops) was added. Stirring was maintained at rt for 6 h whereupon dropwise 
addition of water to the filtrate caused the product to precipitate from the 
solution. The product was filtered, dried under suction and recrystallised from 
isopropanol to provide the title compound 192 (158 mg, 0.76 mmol, 72%) as 
yellow crystals, mp 201-203 °C (Found: C, 51.84; H, 3.79; N, 13.31. 
C9 H8 N2 O2S requires C, 51.92; H, 3.85; N, 13.46%); Vmax (KBr disc)/cnrr1 
3467s (NH2 ), 3140-3079m (CH3 ), 2198m (CN), 1704s (CO), 1565vs and 1521s 
(C=C), 1361s and 1313s (CH3 ), 1052m (C-O) and 764m (CH); 8h (400 MHz; 
CDCI3 ) 4.00 (3 H, s, 11-H), 7.23 (1 H, d, J5 .6  Hz, 4-H), 7.63 (2 H, 2 br. s, 10- 
H), 8.10 (1 H, d, J 5.6 Hz, 5-H) and 8.27 (1 H, s, 6 -H); 5c (100 MHz; CDCI3 )
59.7 (H -C H 3 ), 97.5 (7-quat. C), 113.5 (8 -CN), 116.7 (4-CH), 117.8 (2 -quat. C),
135.5 (5-CH), 139.9 (6 -CH), 163.3 (3-quat. C) and 164.6 (9-quat. C); m/z (El) 
208.0307 (M+#. C9 H8 N2 O2 S requires 208.0307); m/z (%) 208 (78.0), 177 
(100), 175(11.3), 150(16.3), 121 (12.1), 109(16.7), 83 (39.7) and 63(18.4).
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2-Cyano-3-[2-(3-methoxythienyl)]propenonitrile 193
O M e 1 0
5
4
l ( r  CN
8 9
The method of Henrio and co-workers241 was used. To a stirred solution 
of compound 190 (250 mg, 1.76 mmol) in ethanol (5 mL), at rt, was added a 
solution of malononitrile (116 mg, 1.76 mmol) in ethanol (5 mL). The mixture 
was then heated at reflux for 15.5 h. On cooling to 0 °C the precipitated product 
was filtered, dried under suction and recrystallised from ethanol to provide the 
title compound 193 (226 mg, 1.19 mmol, 68%) as yellow needles, mp 142-143 
°C (Found: C, 56.67; H, 3.13; N, 14.65. C9 H6 N2 OS requires C, 56.84; H, 3.16 
; N, 14.74%); vmax (KBr disc)/cm-1 3100-2945m (CH3 ), 2219s (CN), 1569vs 
and 1512vs (C=C), 1332s and 1242s (CH3 ) and 1070s (C-O); 8h (400 MHz; 
CDCI3 ) 3.96 (3 H, s, 10-H), 6.83 (1 H, d, J5.6 Hz, 4-H), 7.72 (1 H, dd, J5.6 and
0.8 Hz, 5-H) and 7.95 (1 H, d, J 0.8 Hz, 6 -H); 8c  (100 MHz; CDCI3) 58.3 (10- 
CH3 ), 71.6 (7-quat. C), 113.0 (2-quat. C), 113.7 (4-CH), 113.8 and 113.9 (8,9- 
CN), 136.1 (5-CH), 146.5 (6 -CH) and 164.5 (3-quat. C); m/z (El) 190.0200 
(M+V C9 H6 N2 OS requires 190.0199); m/z (%) 190 (100), 175 (43.8), 147
(20.6), 121 (37.0), 94 (15.7), 83 (7.1) and 45 (17.8).
2-Formyl-3-hydroxythiophene 195
To a stirred solution of compound 190 (200 mg, 1.41 mmol) in 
dichloromethane (10 mL), at -78 °C, was added boron tribromide (1 M in DCM,
4.22 mL, 4.22 mmol). After stirring at -78 °C for 5 h, the reaction mixture was 
allowed to slowly warm to rt and stirring was continued overnight. The reaction 
was quenched by pouring the mixture into ice/water (50 mL) and the product 
was extracted with ethyl acetate (3 x 30 mL). The combined organic extracts 
were washed with aqueous sodium hydroxide (2 M, 3 x 15 mL) and the
OH 7
o
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resulting aqueous layers were combined, acidified to ca. pH 3 then extracted 
with ethyl acetate (3 x 50 mL). The organic extracts were dried over anhydrous 
magnesium sulfate, concentrated in vacuo. Purification by column 
chromatography, eluant hexane-ethyl acetate (1:1), provided the title compound 
195 (0.83 mmol, 106 mg, 59%) as a pale pink powder, mp 88-90 °C (lit.,262 88 -
89.5 °C). The spectroscopic data were in agreement with the 1H NMR and 
combustion data reported.262
New data: vmax (KBr disc)/crrr1 3100-2593m (OH, H-bonded), 1613s 
(CO), 1449s and 1411s (C=C), 1312s (OH) and 1021s (C-O); 5c (100 MHz; 
CDCI3 ) 114.6 (2 -quat. C), 118.6 (4-CH), 135.4 (5-CH), 165.3 (3-quat. C) and
184.7 (6 -CH); m/z (El) 142.0089 (M+*. C6 H6 SO2 requires 142.0090); m/z (%) 
142(100), 124 (30.4), 111 (25.7), 96 (22.1), 84 (84.3), 70 (7.1) and 51 (21.4).
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